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ABSTRACT:
AN EVALUATION OF THE USE OF A CLINICAL RESEARCH DATA WAREHOUSE
AND I2B2 INFRASTRUCTURE TO FACILITATE REPLICATION OF RESEARCH
Bret J. Gardner, PhD
University of Nebraska, 2018
Supervisor: James C. McClay, MD, MS
Replication of clinical research is requisite for forming effective clinical decisions
and guidelines. While rerunning a clinical trial may be unethical and prohibitively
expensive, the adoption of EHRs and the infrastructure for distributed research networks
provide access to clinical data for observational and retrospective studies. Herein I
deomonstrate a means of using these tools to validate existing results and extend the
findings to novel populations. I describe the process of evaluating published risk models
as well as local data and infrastructure to assess the replicability of the study. I use an
example of a risk model unable to be replicated as well as a study of in-hospital mortality
risk I replicated using UNMC’s clinical research data warehouse.
In these examples and other studies we have participated in, some elements are
commonly missing or under-developed. One such missing element is a consistent and
computable phenotype for pregnancy status based on data recorded in the EHR. I
survey local clinical data and identify a number of variables correlated with pregnancy as
well as demonstrate the data required to identify the temporal bounds of a pregnancy
episode. Next, another common obstacle to replicating risk models is the necessity of
linking to alternative data sources while maintaining data in a de-identified database. I
demonstrate a pipeline for linking clinical data to socioeconomic variables and indices

v

obtained from the American Community Survey (ACS). While these data are locationbased, I provide a method for storing them in a HIPAA compliant fashion so as not to
identify a patient’s location.
While full and efficient replication of all clinical studies is still a future goal, the
demonstration of replication as well as beginning the development of a computable
phenotype for pregnancy and the incorporation of location based data in a de-identified
data warehouse demonstrate how the EHR data and a research infrastructure may be
used to facilitate this effort.
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INTRODUCTION
Overview
Consistently improving clinical care relies on validated evidence applicable to the
current patient. While any number of experimental designs or anecdotal evidence may
purport to resolve the mystery, scientifically, the randomized controlled clinical trial is
considered the gold standard for answering clinical questions 1 . Despite the need for
high-quality evidence to shape clinical practice, Francis Collins (the director of the
National Institutes of Health (NIH)) et al. note only 11% of practice recommendations
issued by cardiologist specialty societies “were based on ‘level A’ evidence, that is,
evidence based on multiple well-done randomized trials” 2 . Due to challenges of
conducting clinical trials, insufficient data may be published. In addition, published data
is not always well-validated. Finally, the results of replicated studies may not be
extendable to a novel population. For these reasons, demonstrating an efficient method
for reliably replicating and extending research remains paramount.
While these challenges exist, recent advances in technology and policy may
facilitate the accrual and application of actionable data in the clinical setting. First,
increased adoption of electronic health records (EHRs) provides an alternative source of
clinical data for research. Next, the growing number and established infrastructure of
distributed research networks (DRNs) have the potential to enable pragmatic trials and
observational studies for comparative effectiveness research (CER) at a greater rate
than was previously possible. Finally, these tools may be harnessed to allow not only
novel research, but, replication and extension of previously published results. While
exhibiting great potential, each of these tools also has inherent weaknesses. One
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significant obstacle is heterogeneity between datasets being combined within distributed
networks 3 . A second obstacle is consistent identification of a study population across
institutions. These concerns must be accounted for and addressed in any effort to
produce clinical data.
In this introduction, I review various factors contributing to the insufficiency and
lack of applicability of reliable clinical data. I also explore the benefits and challenges of
the use of EHRs and DRNs for clinical research. Finally, I address how these tools may
be harnessed to facilitate replication research to validate previously published results
and enhance the applicability of clinical data.

Data Challenges Impacting Improving Clinical Decisions
Challenges to Conducting Clinical Trials
As noted above, there is a dearth of high-quality and applicable evidence for
creating and updating clinical guidelines. This may in part be due to the barriers to
conducting clinical research. These challenges exist at all elements of the research
process, from planning a study to implementing changes based on results. Challenges
may be grouped into categories of trial administration and cost, recruitment, and
publication. All of these categories must be fully addressed for a trial to succeed.
Resource and Time Requirements for Trial Administration
Trial administration requires investment of a great deal of resources in terms of
time, personnel, and money. Eligibility screening usually occurs before consent and
entails reviewing medical records, often necessitating obtaining additional information
from other institutions and providers 4 . Penberthy et al. reviewed cancer trials over an
18-month period and discovered that three to thirteen patients were screened for each
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patient actually enrolled at a cost of $129 to $336 per enrolled patient 4 . Additionally,
they noted that more than 50% of the screening took 30 or more minutes per patient 4 .
While resource intensive, eligibility screening represents only one small element of a
clinical trial.
Many additional costs exist in conducting clinical trials. In 2010, of the $46.4
billion spent by Pharmaceutical Research and Manufacturers of America (PhRMA)
member companies on R&D, $32.5 billion went toward clinical trials 5 . Xu et al. estimate
that it costs over $800 million to develop a new drug 6 . Costs for reimbursing patients,
paying for time to navigate the complex web of the Institutional Review Board (IRB)
approval process, and translating questionnaires or other documents are just a few of
the many expenses likely to be incurred when conducting a clinical trial. Emanuel et al.
concluded that on average, 200 hours were required per patient for pharmaceutical
industry-sponsored trials. 32% of these hours were for non-clinical activities such as
those noted above. They concluded that, “on average, excluding overhead expenses, it
cost slightly more than $6,094 [. . .] per enrolled subject for an industry-sponsored trial,
including $1,999 devoted to nonclinical costs” 7 . Berndt and Cockburn explain that, “the
growing complexity of clinical trials and of the underlying science suggests that more
time, more highly trained personnel, and more sophisticated equipment may be required
to conduct a typical study 5 . The U.S. Bureau of Labor Statistics estimated that the input
costs for conducting clinical trials rose 8% per year between 1989 and 2011, nearly
double the inflation rate in the NIH Biomedical R&D Price Index during the same period 5
. With today’s extremely competitive funding environment, such costs may be
insurmountable for a single researcher or research team.
Recruitment

4

The next set of challenges in conducting effective trials deals with recruitment.
The population recruited must be large enough for statistical analysis, representative of
the population results will be applied to, and reachable by the researchers conducting
the trial. Califf et al. note that 62% of interventional trials registered on ClinicalTrials.gov
between 2007 and 2010 had fewer than 100 participants 8 . Additionally, they described
that the majority (66%) of registered trials were single-center 8 . Bernardez-Pereira et al.
studied over 7,000 cardiovascular clinical trials from 2000 through 2013 and concluded
low recruitment represented the primary cause of early termination 9 .
Connected to low recruitment numbers is the difficulty of generalizing the results
of clinical trials. Researchers estimate that only 2% to 3% of adult cancer patients are
enrolled in clinical trials in the United States 10 . Furthermore, minorities are often
underrepresented relative to the portion of cancer patients composed of any given
minority 11 . For instance, Blacks have a higher incidence and mortality rate for most
cancers compared to Whites, nearly double for Black males relative to White males for
prostate cancer 11 . However, from 1998 to 2001 the total number of Black patients
enrolled in National Cancer Institute sponsored clinical trials increased by only 38 while
the total number of participants increased by more than 6,500 11 . Such
underrepresentation makes it difficult if not impossible to extend results of carefully
constructed clinical trials to all cancer patients. Additionally, potential population specific
polymorphisms effecting pharmacokinetics or pharmacodynamics may not be
recognized 11 . With such a small percentage of patients being enrolled in trials, and this
small cohort not always being an accurate representation of the entire patient
population, it is difficult for generalize results from these studies.
With the cost and resource requirements to conduct clinical trials compounded by
the challenge to recruit a patient population representative of the target population,
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alternate strategies must be employed to effectively acquire and validate high-quality
clinical data.
Extant Data Not Validated
Overview
Despite these challenges, researchers persist and clinical data continues to be
published. ClinicalTrials.gov reports in 2000, fewer than 4,000 trials were registered. By
2015 this number has exceeded 180,000 (http://ClinicalTrials.gov). This rise in the
number of registered trials likely represents both a total increase in the number of trials
being conducted as well as an increased proportion of trials registering. Policy changes
may influence the proportion registering. In September 2005 the International Committee
of Medical Journal Editors (ICMJE) required registration as a condition of publication. In
December 2007 the Food and Drug Administration Amendments Act of 2007 (FDAAA)
was passed by congress, expanding the types of trials to be registered, increasing trial
registration information to include summary results and adverse events, and imposed
potential penalties for non-compliance including civil monetary penalties or withholding
of NIH grant funding

12

.

Despite this increase in clinical trials, data concerns remain. Recent emphasis
has been given to encouraging improved data management for accessibility and reuse
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. However, many studies go unpublished or are published after a great delay (median of
21 months between completion of trial and publication in a journal) 14 . Few studies are
replicated or independently validated. This is due in part to publication bias, increased
emphasis on patient privacy, the aforementioned challenges to conducting clinical
research, and a culture favoring rapid output of novel results.
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While clinical data has been accumulating for millennia, with the challenges to
conducting original research, much of these data have not been validated 15, 16 . This
trend continues for studies relying on data extracted from the EHR 17 . In a systematic
review of risk prediction models based on EHR data, only 26 of 107 studies performed
validation across sites 18 . In addition to some studies without evidence of attempting to
be validated, examples abound of observational studies contradicting previous studies or
of being rejected by randomized trials performed later 19 . Some instances of such
contradictory results include studies of the relation between hormone replacement
therapy (HRT) and cardiovascular risk

20, 21

, bisphosphanate use and cancer risk

22, 23

,

and fracture risk accompanying use of statins 24-26 . Wagenmakers et al put the situation
in perspective stating “findings that do not replicate are worse than fairy tales”

27

. In light

of these many contradictory findings, accepting any single study becomes questionable.
With the potential for contradictory results, working toward replication is
paramount. In this section, I explain the importance of reproducibility in science, review
disparate definitions of reproducible research, explore the impact of the paucity of
reproducible results, examine obstacles to replication studies stemming from publication
practices as well as local infrastructure challenges, and describe some of the existing
guidelines in various fields for moving toward reproducible research. While efforts are
underway in many fields to enable and encourage reproducibility, this paradigm shift will
take time.
Importance of Reproducibility in Science
Reproducibility has been referred to as the cornerstone and Supreme Court of
science, and as the best and possibly the only believable evidence for reliability of an
effect 28 . Wagenmakers et al state “findings that do not replicate are worse than fairy
tales” 27 . Cacioppo continues, “Reproducibility is a minimum necessary condition for a
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finding to be believable and informative” 29 . Despite the essential nature of replication,
across all domains of science, many studies are not validated 30, 31 . Reliably replicating
results with consideration of resource limitations is essential for evidence based
medicine.
Mixed Results from Historic Replication Efforts
Lack of validation may be the result of there being no attempts made to replicate
a study or the failure of attempts to replicate published results. In some cases,
replication is not attempted or published. As noted earlier, a systematic review of risk
prediction models based on EHR data revealed only 26 of 107 studies performed
validation across sites 18 . Even when replication is attempted, lack of reproducibility has
not been seen to correlate with journal impact factor, the number of publications about a
specific finding, or the number of collaborators on the publication 32 . In one review, only
one-third to one-half of studies in high-ranking psychology journals demonstrated
replicable results 16 . In the pharmaceutical industry, target validation is often attempted
before advancing a potential drug to phase II trials. In an industry sponsored study,
despite basing this validation on published material, key data were only reproduced in
25% of cases 32 . This low rate held true even when cell lines or assay formats were
modified. The results which were reproducible were demonstrable irrespective of
modifying the experiment environment, while the majority of results were not
reproducible whatever the experimental conditions. A similar set of experiments revealed
only 11% of pre-clinical oncology results could be replicated 33 . These contradictory
results may stem from errors or multiplicity in the original study, errors in the attempted
replication, insufficient information in the publication to facilitate replication, insufficient
infrastructure or data at an independent site to replicate the study, or a study
demonstrating an effect that may exhibit reproducibility but not replicability. The inability
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to replicate a study calls into question the published results and makes it challenging to
have confidence in clinical guidelines stemming from this work.
Definitions
In order to promote and adopt practices toward reproducible research, a clear
definition of reproducibility is essential. Despite being a priority in computer science 34-37 ,
bioinformatics 38 , biostatistics 39 , epidemiology 40 , and clinical trials 41 , as well as being
promoted by the NIH 42 , no common, agreed upon and accepted definition of
reproducibility is currently in use across scientific disciplines 30, 43 .
Historically, Claerbou defined reproducible research within computer science as
providing sufficient code and original data to allow the reader of the publication to be
able to view the entire process from raw data collection to publication of results

44

. Other

researchers, however, define reproducibility as “the provision of sufficient
methodological detail about a study so it could, in theory or in actuality, be exactly
repeated by investigators” 43 . Further confusing matters, the terms reproducibility,
replication, duplication, and generalization are often used interchangeably or
inconsistently in publications.
For the remainder of this work, I will adhere to definitions recommended to the
National Science Foundation (NSF) 29 (Table 1). Herein, reproducibility “refers to the
ability of a researcher to duplicate the results of a prior study using the same materials
and procedures as were used by the original investigator”

29

. While replicability is “the

ability of a researcher to duplicate the results of a prior study if the same procedures are
followed but new data are collected” 29 . Goodman et al help clarify the distinctions
between reproducibility and replicability. They synonymize reproducibility with “methods
reproducibility” 30 . In essence, this consists of the original researcher providing raw data
and all source code and software to a novel investigator. The novel investigator may
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then use the same data and same programs to attempt to generate the same results.
Contrarily, replicability is explained as “results reproducibility”. In this case, the original
researcher provides a detailed protocol and clear explanation of results to a novel
investigator. The novel investigator may then conduct as similar an experiment as
possible with new data collection in a new environment to see if the same results are
produced. Thus reproducibility serves to validate the methods and replication offers a
second witness of the observed effect.

10

Table 1. Definitions of Reproducibility and Replication. *30 , **29

11

Obstacles to Replication – Publication and Local Infrastructure
Many challenges exist hindering researchers’ ability to replicate studies. These
challenges occur both in the current publication environment as well as in the local
infrastructure researchers work in. The current publication environment suffers from
publication bias, has no systematic means of publishing sufficient data and protocols,
and has no consistent metric to assess the replicability or reproducibility of a study. The
peer review process is not able to detect all errors 45 , and rejected manuscripts are often
published in another location 46, 47 . While irreplicable results are rarely the result of
fraudulence 48 , obstacles continue to impede the publication of replicable work.
Publication Bias:
Many studies over the past decades demonstrate a bias in published journals
toward studies showing positive results 14, 49-51 . This “publication bias” as well as delay in
publication (median of 21 months between completion of trial and publication in a
journal) limits clinician access to complete data, may lead to duplicated research,
publication of spurious results, and limits improvements to the quality of medical care
implemented 14, 52, 53 . In addition, this publication practice may lead to the “file-drawer”
problem where significant, negative results are tucked away privately and Type I errors
are published 54 . Future clinical guidelines and clinical trials will thus be based on
incorrect conclusions. Publication bias may also promote multiplicity 30 . Multiplicity is the
practice of testing many hypotheses, multiple associations, innumerable models,
endpoints not defined a priori, hypothesizing after the results are known (HARKing), and
often failing to publish this winding protocol which eventually led to a significant result
63

55-

. Many negative results lost in file drawers may replicate well if they were published.

Type I errors have a low likelihood of replicating no matter how carefully a protocol is
observed. Effects called significant after irregular statistical analyses will likely fail to be
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dubbed significant when a single, standard analysis is performed on novel data 64 .
These issues are exacerbated by some of the aforementioned challenges in clinical
research. For instance, a small sample size leads to low statistical power and may
hamper a researcher’s ability to demonstrate statistical significance with traditional
analyses.
Data and Protocol Sharing:
In addition to publication bias leading to the dissemination of non-replicable
studies, the current publication environment has no systematic means of sharing
detailed protocols and raw data for EHR based studies 65 . This is due both to current
systems as well as culture. Currently, biomedical journals have no unified approach for
authors to submit code or software used to extract, transform, or analyze data.
Additionally, no uniform repository or approach exists for making raw data available.
Culturally and legally, if such a repository were made available, patient privacy for EHR
based studies may preclude sharing of data from any point in the pipeline. Researchers
desiring to replicate or reproduce prior studies are haltered by this lack of consistent
sharing of code or data.
Next, researchers are further limited due to inconsistent publication of written
descriptions of protocols. While clinical research may involve extremely detailed
phenotypes and inclusion and exclusion criteria to define the cohort of interest, studies
have demonstrated the practice of incomplete protocol or phenotype publication. In a
review of research studies using UK EHR data, only 5.1% published the entire set of
terms sufficient to implement the EHR-derived phenotype 66 . Even if listed, EHR-based
phenotypes are usually published as human-readable, complex documents rather than
machine-readable programs 67 . Also, these complex documents of innumerable terms
often still lack sufficient context, such as noting if the diagnosis being queried was the
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primary cause of admission 43 . In a separate review, only one of 400 biomedical studies
published a complete protocol 68 . With the diversity of proprietary formats for EHR data
collection and storage, research pipelines involving data extraction, pre-processing, and
manipulation are similarly diverse. However, associated programmatic code is rarely
published 43 . The combination of a lack of a systematic approach to sharing
programmatic code or data coupled with a culture of publishing incomplete protocols
leads to published studies that will not be replicable. To facilitate reproducibility, many
studies developing risk models report model coefficients 18 . There is no systematic
approach to this practice and the calculation of such coefficients may remain a black
box. Independent researchers are left to interpret the limited methods and may not be
able to conduct similar analyses or identify a similar population.
Cultural Limitations:
Finally, in addition to publication bias and lack of infrastructure or culture for
publishing sufficient methods and data for reproducible research, there is no systematic
metric in place to assess the replicability of a published study or reward authors for
adhering to replication practices. Journals could incentivize publication of raw data and
programmatic code, note if authors pre-registered hypotheses, indicate if all co-authors
have reviewed and have access to the raw data, or otherwise note via reviewer
feedback if the publication provides sufficient information for replicability 69 .
Policy Changes Increasing Replicability of Published Studies
Recently, approaches have been proposed for overcoming the aforementioned
obstacles to replication. First, clinical research has had safeguards in place for some
time to protect patients and maintain a high level of scientific integrity. These safeguards
are not as developed or mandated in pre-clinical or basic science research. When
human subjects are involved, a detailed protocol, including justifications for sample size
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and planned analysis, must be submitted to and reviewed and approved by a local IRB.
Being required to state hypotheses and analysis approach before any patient data
collection will prevent at least some multiplicity. Modifications are possible and
wandering statistical analysis may still occur prior to final publication of the results,
however, the checkpoints currently in place promote replicable studies. Reporting of
some of these details is outlined in the revised CONSORT (Consolidated Standards of
Reporting Trials) guidelines 70 . Herein researchers should ensure they report on the 22
points of a standardized checklist as well as clearly outline the experimental design in a
flowsheet detailing enrollment, intervention allocation, follow-up and analysis. In this
way, other researchers may evaluate the scientific merit and reliability of the results
being published.
Next, the FAIR (Findable, Accessible, Interoperable, Reusable) Data Principles 13
set forth by a diverse set of stakeholders from academia, industry, publishers and
funding agencies, outline the desiderata of reproducible and replicable science. While
not prescribing specific structure or location for data sharing, these principles provide
clear definitions and represent the cultural recognition of the need for revisions. The
authors clearly relate the interoperability and openness of data to scientific advancement
and make plain the necessity of having data and protocols both human and machine
readable. Furthermore, example repositories for diverse data types are noted as starting
points for seamless data sharing. As these principles are adopted and as a greater
infrastructure is developed for standard data sharing in each scientific domain,
replication will be enabled to a much greater degree.
Next, in 2014, Francis Collins announced plans the NIH was implementing
toward reproducibility and replication in science 42 . These plans were designed to
provide better training toward replicable science as well as provide forums for scientific
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discussion and repositories for raw data. For researchers, a training module was to be
developed emphasizing reproducibility and good experimental design. For reviewers of
grant applications, a systematic checklist was proposed. This checklist would include an
evaluation of the planned analyses, a review of the antecedent work the current grant is
based on, and may necessitate replicating previous studies if their results were
questionable. The NIH plan further called for a Data Discovery Index (DDI) where
researchers could locate and access unpublished, primary data. With this repository, the
new researcher could then cite the data source if used thereby giving credit for original
data collection. Finally, Collins proposed the development of PubMed Commons, a
forum for open discourse about scientific articles. Collaborations, clarifications,
questions, and criticisms for published work could be documented at this site. These
plans may help shift the paradigm of researchers and other stakeholders, elevating the
importance of publishing replicable results and rewarding the replication of findings.
Additional guidelines are being set forth from a variety of disciplines. In 2007 the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
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guidelines outlined what should be included for an accurate and complete report of
observational studies. As clinically captured data have become more available and
abundant, further recommendations were made in the REporting of studies Conducted
using Observational Routinely collected health Data (RECORD) statement 72 . This 13
point checklist outlines recommendations for reporting on the type of study, provenance
of data, data cleaning and analysis, any data linkages, and the location and time of the
study as well as a description of the participants, results, generalizability, and
accessibility of protocol and code. These guidelines are available to researchers, editors,
and other stakeholders. They provide examples of good reporting, though, no consistent
standard is prescribed.
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With these cultural and policy advances toward increased replicability of
published results, an effective means of conducting clinical research and replicating
published results must be developed. With the challenges described above, it is not
feasible, and may not be ethical, to replicate clinical trials at novel sites. However,
validating and extending existing results is critical to improve patient care. The increased
use of electronic health records in conjunction with the growing number and
infrastructure of distributed research networks may provide a framework for collecting
clinical data and independently replicating clinical results.

Potential Solutions for Making More Data Actionable
Increased Adoption of Electronic Health Records
Historically, paper charts were the repository for patient information. These bulky
files included quickly scrawled clinical impression and were stored at the site of care. In
recent years, electronic health records have replaced this archaic system. For instance,
in 2001, only 18% of office-based physicians utilized any type of EHR 73 . Stimulated by
President Bush’s 2004 Executive Order 13335, which created the position of National
Coordinator for Health Information Technology, and incentivized through the Health
Information Technology for Economic and Clinical Health (HITECH) Act of 2009, in 2013
at least 78% of office-based physicians had implemented an EHR 73, 74 . Private acute
care hospitals saw similar increases in EHR adoption, rising from 9% in 2008 to 59% in
2013 and 75% in 2014 75, 76 .
Clinical Benefits of Electronic Health Records
Electronic capture and storage of patient data is not merely a new approach to
record keeping, rather, EHRs offer benefits toward interoperability, patient safety, and
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efficiency. Interoperability across the healthcare community is becoming a national goal.
In 2015 Karen B. DeSalvo, MD, MPH, MSc, the National Coordinator (ONC) for Health
Information Technology, published “A Shared Nationwide Interoperability Roadmap”
outlining critical actions both the public and private sector of healthcare must adopt to
enable an interoperable ecosystem of health IT within a decade 77 . As vendors and the
healthcare community adhere to the ONC standards in the creation and use of EHRs,
the ability to share clinical information across institutions and care settings will come to
fruition.
As interoperability is achieved, advances in patient safety are enabled. With
standards employed, clinical decision support (CDS) systems may be centrally
developed and tested and then applied across diverse EHRs. These CDS systems
evaluate drug-drug interactions, may alert the health care team to abnormal or extreme
lab values or vital signs, and may recommend the most efficacious therapy for the
current condition. Historically these were developed ad hoc or required onerous
adaptation at each site. Adhering to interoperability standards further advances patient
safety as clinicians may more readily obtain a complete patient history. Rather than
bulky charts being lost or requiring excessive time to sift through faxed copies, EHRs
allow electronic transfer of this critical, clinical information. In the past, the “curly braces”
problem has prohibited efficient sharing of data across sites
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resolved as sites follow ONC guidelines. Clinicians may then have access to a more
complete patient history to allow them to make the best therapeutic choice. In the future,
patient safety may also be enhanced as interoperable EHRs are used for clinical
research. Access to patient information across sites will enable pragmatic trials and
retrospective studies to be conducted leading to greater clinical evidence. In each of
these ways, interoperable EHRs move health care toward a safer patient experience.
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Finally, adoption of EHRs enhances efficiency. While a handwritten chart exists
in only a single physical location, EHRs allow patient information to be accessed and
updated irrespective of geographic location. A single copy of a paper chart may be
reviewed by only a single individual at any one time. EHRs allow all members of the
health care team to review information simultaneously. Reviewing paper charts may
necessitate examining many pages of scrawled notes. EHRs allow for electronic
searching, data summary, calculations, and other heuristics to be employed quickly.
Efficiency is increased with the use of EHRs as geographic limitations are removed,
multiple individuals are able to collaborate simultaneously, and technological advances
for data interpretation and searching are employed.
Clinical Research Benefits of Electronic Health Records
Overview
While the re-use of EHR data is rife with challenges, use of EHRs for
comparative effectiveness research may decrease the cost of time and resources spent
on eligibility screening and recruitment, allow study of a more representative population,
incorporate more diverse data elements, and increase efficacy of trials that are
underway. Payne et al. conducted a survey of IT use in clinical translational research
and noted specific benefits of utilizing EHRs 79 . These researchers note that the data
contained in EHRs may be used at many steps of the clinical trial process, including
hypothesis formation, recruitment, analysis, and especially data collection 79 . Similar to
records for clinical care, historically, data collection for clinical trials has depended on
paper forms, with data extrapolated and codified manually 79 . These paper forms must
then be transcribed into databases for analysis, a process introducing further opportunity
for errors 79 . The increased use of time and resources as well as the introduction of
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greater potential for human errors are paramount. Payne et al. report that harnessing
EHR technology has significantly decreased time-consuming and redundant data entry
and simultaneously demonstrated increases in data quality 79 .
Eligibility Screening
Furthermore, recent work has shown with high fidelity electronic records,
eligibility screening may be largely automated. Ni et al. demonstrated this principle and
noted a 92% reduction in workload and a 450% increase in trial screening efficiency 80 .
While the use of EHRs aids in screening, efforts to establish automated screening must
be made at each participating site with unique EHRs.
Patient Population
In addition, data from operational EHRs compliments information gathered from
well-controlled clinical trials. First, EHRs include data on an entire patient population, not
a highly selected cohort. Data is collected on this population continuously rather than
only at a few time points during a year. In contrast to the very limited population with
strict adherence to study protocol, EHRs offer data on a very broad population that
reflects actual care and patient conformance to prescribed therapy 81 . Also, within a trial
only a small subset of data elements are collected and analyzed. In contrast, within an
EHR data is diverse, not focused on a single disease or known risk factors. In this way,
EHRs provide an abundance of data elements for the formulation of novel hypotheses
and foundation for analyses. While not the same, with careful consideration, data
gathered from an EHR may be valid to answer clinical research questions.
Finally, as EHRs are used for research, translating results into decision support
or deploying risk calculators in clinics is much simpler than historic methods
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that EHRs may be used for secondary purposes of data acquisition and maintenance for
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clinical research with meaningful impact on diminishing time and expense of conducting
trials. However, EHR data is not collected for research – potentially leading to problems
with quality, completeness and comprehensiveness of these data.
Concerns with Secondary Use of EHR Data for Clinical Research –
Whether on paper or electronically, data is recorded in the medical record by
many members of the health care team, by equipment, and in some instances by
patients. While the volume of data abound, there are concerns with use of these data
directly for clinical research. Data captured in the EHR are recorded for clinical and
billing use. As such, these data may be inaccurate, incomplete, transformed locally,
lacking necessary granularity, or irreconcilable with approved research protocols
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Each of these potential limitations must be taken into consideration prior to drawing
conclusions from analysis of these data.
Inaccurate Data:
Numerous studies evaluating data from diverse EHR vendors and locations have
demonstrated spurious data recorded for patient care 82 . Extracted data may include
pregnant males, treatments apparently prior to birth or following death, and patients
being emergently intubated only to be released a short time later 83, 84 . Without quality
analysis in place, inappropriate conclusions may be drawn from secondary use of EHR
data.
Incomplete Data:
Incomplete data exists at various levels. First, a patient rarely receives all
medical care throughout his/her life at a single institution. Whether traveling, moving, or
changes in management of local institutions, a patient is likely to have clinical data
maintained at a plethora of medical centers and clinics. Nasir et al have shown 19.1% of
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readmissions for heart failure patients were to a different hospital than the original 85 .
Similarly, Bourgeois et al found 31% of patients in Massachusetts visited two or more
hospitals over a five-year period 86 . This fragmentation means no single clinic will be
able to access a complete medical picture for the patient. In addition, as data are
recorded for clinical care, only necessary studies are conducted and pertinent findings
recorded. While vital signs may be recorded at nearly every visit, complete visual
examination findings may not be found during a visit for a appendectomy, even if the
patient is suffering from diabetic retinopathy at the time. This may lead to censoring, a
property where events outside the dates of observation are absent or ambiguous 87 . The
date of recorded diagnosis in the EHR is rarely the date of onset of the disease
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EHRs are inherently limited on data from healthy individuals and biased toward those
needing medical care. Finally, as hospital and clinical environments differ between
institutions, the normal labs and findings regularly recorded will differ in like manner.
Various elements may be routine at one institution and routinely absent at a neighboring
medical center. Managing missing variables and accepting the absence of some findings
is requisite for research involving EHR data.
Transformed Data:
Data in the EHR is recorded for clinical care and later processed for
administrative and billing purposes. In many instances, all of the data is not available to
the researcher. Claims data may be given in lieu of full access to source data. As data is
processed, data quality for research may decline. First, studies have shown 88
prognostic indicators, patient reports, and disease burden are not well represented in
billing data. In addition, unintentional errors may creep in through the administrative
process. These may be due to coding errors, inexperience, insufficient clinician
oversight, upcoding to maximize payment, underreporting quality measures, and poor
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verbal or written communication 89 . Beyond these errors, standard coding has limitations
and perils for research. Semantic drift may occur over time wherein certain diagnostic or
other codes and vocabulary change, making longitudinal studies difficult to interpret 90 .
In addition, relying solely on diagnostic codes may drastically underrepresent the study
population of interest 91 . Extensive data are often retained in clinical, pathology,
radiology, or other notes requiring sophisticated natural language processing (NLP)
techniques to extract them with unknown efficacy 92 . Which data are available and the
processing of these data within the EHR must be considered when planning and
conducting any research study relying on such patient information.
Data Provenance:
Data stored in the EHR may originate from a variety of sources, including any
member of the health care team, equipment or instruments, the laboratory, pathology
reports, radiology reports, and the patient himself. In some instances, multiple sources
may provide insight into a single issue. Administration of a medication is a prime
example 82 . A patient may report what medication he is taking and what was
administered during his stay. These data will be stored in the medication reconciliation
form. There are orders for medications, dispensing records from the pharmacy, and the
medication administration record. Each of these elements is stored in the EHR and none
of these elements is definitive to the question of what medication was physically given to
the patient. Selecting any one of these as a proxy for the fact of interest has implications
that must be reconciled.
Data Lacking Sufficient Granularity:
While data recorded in the EHR is extensive and varied, research protocols may require
data elements not present. In a review of 98 outcomes studies utilizing EHR data, 55%
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of these studies supplemented EHR data with non-EHR data 93 . In addition, as noted
earlier, some data made available to researchers represent only a summary of the
patient’s condition 82 . A plethora of clinical findings and laboratory values may contribute
to the diagnosis made by a clinician. The final ICD code may be all the researcher has
available. Individual elements contributing to the diagnosis are masked from the
researcher and may inhibit drawing meaningful conclusions from EHR data.
Increased Developments of Distributed Research Networks
Overview
As described above, with considerations of the limitations and potential bias
introduced by re-using clinically collected data, EHRs may prove a valuable tool for
comparative effectiveness research. This resource may be bolstered as it is used in
conjunction with distributed research networks (DRNs). While EHRs contain a diversity
of data, these data are still limited to a single clinic or academic institution. Studying rare
diseases or small effects may remain outside the potential for a single researcher. DRNs
offer an opportunity for collaboration, data sharing, and federated queries to maximize
sample size and generalizability of the results. Many of the challenges to clinical
research noted earlier may be addressed through DRNs. A variety of DRNs have
developed in recent history Observational Medical Outcomes Partnership (OMOP)
launched in 2008 94 , Sentinel System (FDA drug monitoring system with 28
collaborators) launched in 2008 95 . I will focus on the National-Patient Centered Clinical
Research Network (PCORnet) to describe the potential benefits for comparative
effectiveness research.
Example of a Distributed Research Network – PCORnet
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Collins et al. describe “PCORnet aims to build a national research network,
linked by a common data platform and embedded in clinical care delivery systems. This
network will enable studies, and in particular randomized trials, that have been
impractical to conduct to date—and do so with economies of scale” 2 . These leaders
summarize the potential benefits of a massive network of linked EHRs stating, “a
network of electronic medical records representing over 100 million covered lives will
make large-scale observational and interventional trials faster to launch, more
representative of diverse real world populations, and capable of providing much-needed
answers to comparative effectiveness research questions with greater accuracy” 2 .
Additionally, they note that PCORnet will facilitate conducting these effective trials at
“affordable cost” 2 . With the tremendous promise PCORnet offers, as with any
intervention or prescribed behavioral change in medicine, evaluating its efficacy is
essential.
The Greater Plains Collaborative
In 2013, the Patient-Centered Outcomes Research Institute (PCORI) funded 11
clinical data research networks (CDRNs) and 18 patient-powered research networks
(PPRNs) that compose PCORnet 96, 97 . Fleurence et al. describe the commitments for
each CDRN including building a large patient cohort with comprehensive clinical data,
developing necessary policies to ensure patient privacy and data security while allowing
for data sharing and participation in multi-network randomized trials and observational
studies, and developing policies for data standardization 97 . This system of multicenter
research allows many advantages, including “greater sample size and power, the ability
to study effects of practice pattern and treatment variation, the inclusion of diverse
populations, and the possibility of supporting analyses that assess heterogeneity of
treatment effect” 97-99 . Efficient multi-site analyses are facilitated by the creation of a
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common data model (CDM) that allows for queries to be shared rather than large
amounts of patient data being transferred. Developing the infrastructure for this research
has been ongoing (Phase I). Recently, PCORI awarded Phase II funding to ensure
sustainability and continued progress for three additional years.
The Greater Plains Collaborative (GPC) is one of these 11 CDRNs. The GPC
encompasses over 10 million patients from over 20 hospitals, 700 clinical locations, and
8,000 providers for all levels of care 100 . The patients included embody a diverse mix of
rural populations and urban communities, including often underrepresented minorities.
The GPC institutions are committed at the highest levels to this collaborative work. As
evidence of this commitment, the GPC has established a master data-sharing
agreement as well as reciprocal IRB agreements to allow collaborative research queries
to be run and facilitate multi-site studies. Additionally, the GPC contains a robust
collaborative team of informaticists. Teams from each participating site have worked to
load data into the vendor neutral informatics for integrating biology and the bedside
(i2b2) data warehouse. Data sources are diverse and range across commercial EHRs
including Epic and Cerner, tumor registries from the North American Association of
Central Cancer Registries (NAACCR), the Social Security Administration’s Data Master
File for mortality, Health Information Exchange data such as NeHII and the Indiana
Health Information Exchange and patient-reported outcomes via Research Electronic
Data Capture (REDCap) surveys 100 . While the availability of such data has great
potential for research, Waitman et al. note that application of such data to determining
clinical effectiveness has not been convincingly demonstrated to date 100 .
i2b2
As noted above, the GPC is utilizing Informatics for Integrating Biology and the
Bedside (i2b2) to achieve its goals of collaborative clinical research. I2b2 is operational
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at more than 60 academic medical centers, HMOs, and private companies. This
software resides in the public domain (http://www.i2b2.org) and allows for immense
individual adaptation and development while maintaining interoperability with a common
messaging protocol that allows communication through web services and XML 101 . The
goal of i2b2 is “to provide clinical investigators broadly with the software tools necessary
to collect and manage project-related clinical research data in the genomics age as a
cohesive entity, a software suite to construct and manage the modern clinical research
chart” 101 . This suite allows integration of a variety of data types and allows queries to be
created at one site and shared with many locations to probe locally secure data.
The University of Nebraska Medical Center (UNMC) clinical research data
warehouse (CRDW) is an IRB approved environment built on i2b2. Patient-centric data
is extracted from affiliated health care organization electronic health records (EHR),
combined with national registries, mapped to Office of the National Coordinator (ONC)
designated terminology standards and fully de-identified.
With data extraction and curation efforts at a plethora of sites, PCORnet seeks to
bridge the gap to this secondary use of clinically captured data by tapping into this
torrent of information from the EHR. A variety of standard and proprietary coding
systems are used to organize this massive dataset. While information about medications
prescribed, hospital admissions and diagnoses, family history, allergies, complications,
and even genomic information may be stored, querying this data in a meaningful way for
clinical research is often prohibitively cumbersome. Querying large patient sets spanning
multiple institutions has historically been onerous due in part to differences in local
coding and representation of facts. With the CDM and an infrastructure for querying it as
well as widespread use of i2b2, federated queries for large patient sets are becoming a
reality.
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Persistent Challenges
While this pooling of data under a common umbrella may appear to be the
panacea for obstacles encompassing clinical research, recent studies from other
collaborative groups demonstrate heterogeneous data sets may yield disparate results
despite application of identical methods 3, 102 . Heterogeneity of treatment effect and
patient differences may be masked as observational studies amalgamate large
populations 103, 104 . Significant, yet opposite, effects from distinct populations
participating in the network may average out to no effect or an effect in one direction.
Overhage et al. demonstrated the efficacy of using the Observational Medical Outcomes
Partnership (OMOP) common data model across multiple sites and maintaining data
integrity to investigate safety surveillance, however, they made no inquiry as to individual
site result variations 105 .
One critical, and often overlooked element of the design process, is the selection
of an appropriate data source to query. Selection of a data source may often be made
on the basis of convenience or accessibility rather than on any standard guidelines or
rationale 19 . While attaining necessary statistical power and having data elements
needed to ask the desired questions are critical elements of a well-designed
observational study, recent studies demonstrate that the choice of database plays a
major role and that applying the same study methods to different datasets may yield
disparate results 3 .
As with the use of EHRs for clinical research, adopting federated queries in a
DRN has challenges that must be considered. The impact of heterogeneity of data and
the effect of transforming data to a common data model require further investigation.
Despite these potential issues, the infrastructure and participants in a DRN offer
valuable solutions to many of the challenges I have described regarding comparative
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effectiveness research. Sample sizes may be dramatically increased. Costs for largescale trials may diminish drastically. The population and the data captured as data are
populated from the EHR will be real-world rather than a potentially biased trial
environment. With the ability to conduct trials, it will be critical to ensure the validity of
both novel results as well as previously published material.

Leveraging EHRs and DRNs to Replicate and Extend Clinical Research
Addressing Challenges to Replication Research
Use of EHR data for observational and retrospective studies provides a potential
alternative to fully duplicating clinical trials to assess the original hypothesis 106, 107 .
Tannen et al demonstrated the potential to use observational studies from operational
EHRs to successfully replicate the findings of a series of cardiovascular clinical trials
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Observational studies are increasing in popularity. During the 1990s, nearly 80,000
observational studies were published. In the following decade, this number rose to
263,557 108 . Overhage et al note that well designed observational studies may yield
effect estimates comparable to those reported in randomized controlled trials (RCTs) 19 .
However, not all studies are well designed and may produce spurious or conflicting
results. Young boldly states “Any claim coming from an observational study is most likely
wrong” 108 . While this may be hyperbole, as with any scientific claim, the results of
observational studies or clinical trials should be replicated to enhance validity.
Remaining Gaps in this Process
With the availability of clinical data extractable from widespread EHRs coupled
with the infrastructure and collaborations made possible with growing distributed
research networks, replication of studies may be accomplished more efficiently. The
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challenges of excessive cost and time requirements, the difficulty in enrolling a
sufficiently large and sufficiently diverse study population, the obstacle of data collection
and storage, and the hurdles of selecting an appropriate data source and maintaining
patient privacy may in large measure be met through these new tools. As these
challenges are overcome, efficiently replicating a study becomes feasible.
As described earlier, the NIH and multiple scientific journals are calling for
cultural and policy changes toward reproducibility and replicability in science, including
clinical research. As repositories are developed to make data and protocols available
and as providing these data becomes expected rather than the exception, replication of
studies may increase. Despite these changes, no metric for evaluating an articles
replicability nor a metric for assessing a local infrastructure have come to light.
In this dissertation, I first evaluate UNMC’s CRDW infrastructure as a potential
tool to rapidly replicate risk models. I explore the limitations resulting from incomplete
protocol publication as well as the requirements for data volume and variety at the
replication site. With the identification of missing data in terms of a computable
phenotype for pregnancy and variables related to a patient’s socioeconomic status, I
explore the development of such a phenotype and demonstrate the integration of extraEHR variables into the CRDW. In this way, I demonstrate and approach and
considerations researchers seeking to replicate studies may use as well as provide a
means for incorporating census data with clinical data in a queryable fashion. While this
dissertation cannot address all outstanding obstacles and concerns relevant to
conducting replication research, this work does demonstrate replication and provides
additional resources to assist other researchers in this effort.
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CHAPTER 1 – ATTEMPTED REPLICATION OF A READMISSION
RISK MODEL FOR HEART FAILURE PATIENTS
Introduction
Clinical research results are being published at an unprecedented rate. A
majority of these studies, however, involve relatively few patients and are completed at a
single institution 8 . With minorities often underrepresented and such a small sample of
the disease population enrolled, widespread application of results in clinical practice may
not be warranted 10, 11 . One means to validate conclusions and extend the results to a
more general population is replication of studies at novel sites. While conducting a
second clinical trial to address the same hypothesis may be infeasible and potentially
unethical, an observational study may provide reliable results using a fraction of the
resources. Observational studies have been shown to be an effective means to
reproduce results initially documented via clinical trials 106, 107 . Successfully replicating a
study requires elements to be in place at the new site as well as sufficient
documentation to be provided in the publication of the original study. The new site must
have sufficient data for the population in question and a means of interrogating these
data. The published study must detail the phenotype of the disease population in a way
that can be reproduced at novel sites. Any risk models or calculations must be clearly
explained if they are to be replicated.
In this and the following chapter, I describe initial evaluations of two studies and
of UNMC’s infrastructure in terms of the ability to replicate what was published from
other sites. I describe the local site and publication requirements, the selection of the
study, and review my results at attempted replication.
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Site Requirements
Data Volume
As described earlier, small sample size is the leading cause of early termination
of clinical trials. For studies running to completion, small sample size limits statistical
power and the conclusions which can be drawn from the study. A researcher may miss a
novel effect or may over-analyze in an attempt to find significance, both resulting in
publication of false findings. Data extraction from the entire population recorded in an
EHR may mitigate this problem. Rather than attempting to enroll dozens or even
hundreds of patients, researchers have a pool of thousands or hundreds of thousands of
patients to identify eligible patients from. All eligible patients may be enrolled in an
observational study. In the case of rare conditions or diseases, extending the study to an
entire distributed research network may see a ten-fold increase in the number of
patients. In this way, even for rare diseases, it is likely a sufficient sample size may be
identified to aid in drawing statistically sound conclusions.
Diverse Population
While a sufficiently large sample size is critical for drawing meaningful
conclusions, it is critical that the study population is representative of the target
population. The availability of diverse data within an EHR as well as increased diversity
across a distributed research network, make it possible to have a representative study
population, similar to what is described in the study being replicated. If the site
attempting to replicate clinical studies only has limited date from a small registry, an
appropriate study population may not be available.
Data Variety
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Beyond having a sufficiently large and diverse sample, replicating clinical
research may require a diverse set of data domains. Having a single domain, such as
diagnostic codes, is useful for identifying information about disease incidence or
prevalence. However, having only this information precludes further analysis in terms of
disease progression, susceptibility, or outcomes. For these types of studies, additional
data domains may be required. From the EHR, diagnostic history, laboratory data,
medication orders and dispensing history, demographic information, procedures, and
family history are often available. Some studies may involve extra-EHR data elements
such as socioeconomic status, location information, or patient-reported outcomes from
surveys. In order to attempt to replicate a study, all data elements from the original study
must be available at the independent site. Missing data elements or data domains will
limit the extent to which researchers can replicate prior results.
Infrastructure to Interrogate Data
With a data repository in place, to effectively replicate a study, researchers need
an efficient means of interrogating the data, locally, or across a distributed research
network. If individual data elements must have custom ETLs produced and custom SQL
queries written, there will be a great deal of duplicated effort across studies and costs for
developer time and infrastructure building may exceed the benefits of attempting to
replicate a previous study’s findings. With a clinical data research warehouse (CRDW)
established, containing the majority of common data elements for most studies, a query
platform may put in place to make data available to researchers. Across PCORnet, SAS
queries are shared for this purpose (see appendix A for local instructions for running
federated queries). Dozens of academic medical centers and other institutions have
deployed i2b2 for local and federated queries. With minimal addition, these platforms
allow researchers for diverse clinical studies to rapidly query existing data. Having this
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infrastructure in place allows observational or retrospective studies to be accomplished
with a fraction of the resources of conducting a new clinical trial.
Publication Requirements
Phenotype Description
While having a local infrastructure with sufficient data volume, data variety, and a
querying mechanism in place is essential to be able to replicate studies, results and
methods must be published in a replicable manner. A clear description of inclusion and
exclusion criteria composing a phenotype is critical. Results may vary unnecessarily
from the original study if a clear phenotype is absent. It is insufficient to simply state all
patients with a disease of interest are included. Describing how this disease was defined
for the study is essential. For instance, a diabetic study may include patients based on
ICD diagnostic codes alone, may require one or multiple hemoglobin A1C (HbA1C)
measures within a certain time frame, may be based on medication history, or some
combination of any of these criteria. Each of these criteria should be provided in a
human readable and machine parsable and interoperable format, possibly in the
supplemental material to a published study. Without these clear descriptions, a
replication attempt may study a very different population relative to what was originally
documented.
Transparent Statistical Analysis
Finally, with the data and infrastructure in place and a study publishing a clear
description of inclusion and exclusion criteria, it is also critical that the published work
clearly document the statistical analysis and computations performed. Researchers have
a vast arsenal of statistical means at their disposal, each of which may be appropriate in
some situations. Understanding the original hypothesis, significance level, and any
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model computation is requisite for a researcher attempting to replicate the study. A risk
model whose components remain in a black box may not be replicable. If coefficients
and how they were obtained is clear, a similar approach to developing a replicate is
possible. If a winding path of statistical analysis with multiple endpoints and subsets of
the population were employed and not published, replication may be infeasiable,
Study Selection
With the criteria described above, I evaluated a series of published risk models to
attempt to replicate. This chapter focuses on efforts with one of these studies. While
UNMC has a CRDW with an i2b2 infrastructure for querying a diverse set of clinical data,
some studies required extra-EHR data or published insufficient information to enable an
attempt at replication 109 .
This initial evaluation centered on a study of 30-day hospital readmission for
heart failure patients 109 . Readmission to a hospital within 30 days of discharge is a
pervasive problem. With 19.6% of Medicare beneficiaries being readmitted to a hospital
within 30 days of discharge the cost is estimated to be between $17.4 and $26 billion per
annum 110, 111 . Section 3025 of the Affordable Care Act established the Hospital
Readmissions Reduction Program (HRRP), which financially penalizes hospitals with
excess readmissions (subpart 1 of 42 CFR part 412 (§412.150 through §412.154).
Effective strategies to reduce unplanned readmissions are complex, resource intensive,
and often short-lived 111, 112 .
Identifying patients prior to discharge at the greatest risk for readmission may
focus finite resources. Heart failure (HF) represents the primary cause of hospitalizations
in patients over age 65 and is among the leading causes for preventable readmissions
within 30 days 113, 114 . Understanding if the results published by this study are valid and
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extendable to the population at UNMC is a necessary precursor to implementing any
future change in clinical workflow or policy.
A number of models have been proposed and used to predict risk for 30-day
readmission for heart-failure patients. For this assessment of coverage of UNMC’s
CRDW I selected Amarasingham’s 2010 model for a number of reasons. First, this
model encompasses much of preceding models 115 . Next, Amarasingham et al
demonstrated the validity of their model in comparison to a CMS model and the Acute
Decompensated Heart Failure Registry (ADHERE) model 109 . Finally, Amarasingham et
al designed this model to utilize data commonly available in a basic EHR within the first
24 hours of hospital admission, making it likely UNMC’s CRDW would contain much of
the needed information. Additionally, this may facilitate future efforts of real-time
application of the model within the EHR.
My initial hypothesis was the infrastructure established around UNMC’s CRDW is
sufficient to replicate a study that developed a risk model for readmission in heart failure
patients. To address this hypothesis, I surveyed the necessary data elements from the
study and produced the necessary queries to obtain sufficient data on the heart failure
population at UNMC.

Methods –
Infrastructure
Overview
The clinical data research warehouse (CRDW) at the University of Nebraska
Medical Center (UNMC) is a composite of de-identified data from a variety of sources
(Figure 1). The development and use of this registry of patient data was approved by the
institutional review board (IRB) at UNMC (IRB # 132-14-EP). Extracted patient-centric
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data are transformed to adhere to vocabulary standards recommended by the office of
the national coordinator (ONC) and loaded into informatics for integrating biology and
the bedside (i2b2). Data are further transformed to conform to the National PatientCentered Clinical Research Network (PCORnet) common data model (CDM) to allow
participation in this national network 96, 97 .
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Figure 1. Overview of UNMC’s CRDW. Data originate from both local and national
sources. These data are extracted, transformed to ONC recommended vocabulary
standards, and merged into a single data warehouse queryable by i2b2 and SAS.
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Data Sources
Data for the clinical research are extracted from enterprise specific as well as
national data sources. The bulk of data originate in Epic One Chart (Epic Systems
Corporation, 1979 Milky Way, Verona, WI 53593), the electronic health record (EHR) at
Nebraska Medicine. Local tissue biobank data and information from clinical research
stored in Research Electronic Data Capture (REDCap) may also be incorporated to
provide a more complete patient picture. These data are supplemented with information
from the national level, including data from the Social Security Death Index (SSDI
www.ntis.gov/products/ssa-dmf.aspx), the North American Association of Central Cancer
Registries (NAACCR www.naaccr.org), and from the United States Census
(www.census.gov).
UNMC’s CRDW has de-identified information for more than 2 million patients.
The majority of this data were recorded since 2012 when Nebraska Medicine adopted an
Epic EHR. However, some data, especially demographic and laboratory information, has
coverage originating many years earlier. For more than half a million patients, relatively
complete medical information exists for the past several years in this database.
De-Identification:
All data stored in UNMC’s CRDW is fully de-identified according to guidelines
associated with the Health Insurance Portability and Accountability Act (HIPAA) Privacy
Rule 116 . Protected health information (PHI), including patient names, addresses, e-mail
addresses, phone numbers, social security numbers (SSN), fax numbers, health
insurance beneficiary numbers, account numbers, medical record numbers,
certificate/license numbers, vehicle identification numbers, and other unique identifying
numbers are excluded from the data warehouse. All dates, including birth dates,
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encounter dates, death dates, and diagnoses or procedure dates, are obfuscated. On a
per patient basis, dates are shifted by a random number from -1 to -30. Date shifting is
consistent across all of a single patient’s encounters and characteristics. Geographical
identifiers are obfuscated to ensure the covered population is greater than 20,000
individuals. To accomplish this, zip codes are truncated after two or three digits.
Standardization
As data are extracted from disparate and often proprietary formats, we dedicated
considerable effort to transform elements to ONC recommended vocabulary standards
77, 117

. Where feasible, standards were adopted or recommended to facilitate

interoperability. Per ONC guidelines, encounter diagnoses were mapped to international
classification of disease (ICD) versions 9 and 10, demographic data such as race and
ethnicity conform to Office of Management and Budget (OMB) standards, laboratory
information are represented via Logical Observation Identifiers Names and Codes
(LOINC www.loinc.org), medication information is presented with appropriate National
Drug Codes (NDC) and RxNorm codes, and clinical findings are reported as
Systematized Nomenclature of Medicine – Clinical Terms (SNOMED-CT) terms (See the
Interoperability Standard Advisory from the Office of the National Coordinator for Health
IT 118 for further details of datatypes and standards).
Informatics for Integrating Biology and the Bedside (i2b2)
The CRDW is built on the Informatics for Integrating Biology and the Bedside
(i2b2) research environment. This is an NIH-funded National Center for Biomedical
Computing (NCBC) devoted to translational research (http://www.i2b2.org). In particular,
it is a scalable, open-source informatics framework and architecture that can be used to
host a research data warehouse 119 . Developed within the Partner’s Health Care, i2b2 is
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now deployed at more than 60 academic medical centers across the country. This webbased service allows authorized users to query de-identified patient data for exploratory
analysis and cohort identification. With a common messaging protocol, queries may be
developed locally, tested on a single date warehouse, and then shared across large
networks to interrogate data covering many more patients. In this way, the query, rather
than patient data, is shared between institutions.

Model Replication
Defining the Study Population
Eligible patients (table 2) have a documented diagnosis of heart failure based on
ICD 9 code 109, 120 and were admitted to a Nebraska Medicine hospital at least once from
May 2012 to December 2015. Visits for rehabilitation (DRG 462) were excluded.
Additionally, admissions where the patient expired or left against medical advice (ICD10
CM Z53.21, ICD9CM: V64.2) were not considered as index hospitalizations 110 . A 30day readmission was defined as an admission to the hospital for any cause within 30
days of the most recent discharge from an acute care hospital.
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Table 2. Eligibility Criteria for Inclusion in the Amarasingham Model. All patients were
admitted to a Nebraska Medicine Hospital between May 2012 and December 2015.
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Assessing Coverage
For assessing the coverage of data, we considered all inpatient encounters for
eligible patients during the date range specified. Patient counts were generated using
i2b2 queries.
Variable Definitions
Age was defined by the age at the initial visit. Laboratory values were defined by
relevant LOINC codes. These were not defined by the original authors. History of
depression or anxiety was defined by the following ICD-9-CD codes: 293.83, 293.84,
297.1, 297.9, 300.0, 300.00, 300.01, 300.02, 300.09, 300.11, 300.23, 300.29, 300.4,
300.9, 301.6, 301.83, 301.9, 306.1, 306.4, 308.0, 308.3, 308.9, 309.0, 309.24, 309.28,
309.29, 309.9, 311, and 312.20. Appendix B contains a printed version of a sample i2b2
query’s generated SQL for identifying the variables from the original risk model.
Obtaining Missing Data Elements
Clinicians and laboratory technicians were consulted to determine if missing data
elements were routinely ordered or recorded at Nebraska Medicine. Following the
pattern for previous data extracts, data elements were identified in Clarity data tables,
and extracted, transformed to align with ONC standards where applicable, and loaded
into the star schema supporting i2b2. In addition to loading new facts, metadata was
created as necessary to allow querying in the web client. As part of this metadata
creation and updates, metadata xml was created for many existing labs in order to allow
the user to query lab values rather than just the presence or absence of results. Finally,
quality assessment on new and existing data was performed to ensure proper loading
and mapping. This was done by sampling patients and encounters and reviewing
pertinent records from Clarity.
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Results
Data Coverage
The CRDW at UNMC has excellent overall coverage of the variables in the
Amarasingham risk model (34/40, 85%) (Table 3). All variables in the demographics and
laboratory values are covered. Vital signs will be fully covered if the Tabak mortality
score is calculated and recorded. Socioeconomic status and health system interactions
had the poorest coverage (50% and 66%, respectively).
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Table 3. Amarasingham Model Data Coverage in UNMC’s CRDW. The majority (34/40)
variables were represented in UNMC’s CRDW.
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Discussion
Conclusions
I rejected my hypothesis that the current CRDW at UNMC was sufficient to fully
replicate this risk model for readmission in heart failure patients. Inability to replicate the
study stemmed both from insufficient information being published and from lack of
sufficient data variety being available and incorporated into the CRDW.
First, the authors failed to publish how the risk model coefficients were calculated
for application of their scoring. Attempts to reach the author for clarification went
unanswered. In addition, standard LOINC codes for laboratory values were not
published necessitating the replication effort to include attempting to identify appropriate
laboratory tests. Without these data, full replication is impossible.
In addition to insufficiencies in the published study, limitations in data variety in
the CRDW prevented full replication of the risk model. Socioeconomic status required
linking EHR data to U.S. Census data which had not been completed at UNMC. Multiple
variables, including number of home address changes, payer information, and missed
scheduled visits may be extracted from the EHR in the future. Finally, arrival time at the
ED was excluded as this work was completed in a de-identified database.
While data elements present in the de-identified CRDW did not allow for full
replication of this risk model, this assessment helps prioritize efforts to load additional
clinical data elements into the CRDW.
Limitations
Data for this study come only from Nebraska Medicine and do not reflect
readmissions to other hospitals. Nasir et al indicate same-hospital readmission rate is
not a reliable indicator of all-hospital readmission rates. They showed only 80.9% of
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readmissions for heart failure patients were to the index hospital 85 . However, samehospital data may be a useful benchmark for internal quality improvement. Readmission
data for all hospitals in the area may be available through NeHII and may be used in
future studies.
Future Research
Future research may focus on validating the existing model and investigating
new variables to include. Additionally, the queries used in this research effort may be
shared with other sites using i2b2 to expand the study cohort. Further research can be
formed with similar methods for other patient cohorts who are commonly readmitted
(COPD, Pneumonia, AMI, TKA/THA, and septicemia patients). Eventually, this predictive
model may be applied in real-time to identify patients at risk for readmission before they
leave the hospital or as they present to the ED.
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CHAPTER 2 – ATTEMPTED REPLICATION OF AN IN-HOSPITAL
MORTALITY RISK MODEL
Introduction
As the heart failure study proved irreplicable, I selected another risk model
addressing in-hospital mortality. Tabak’s 2014 model for mortality risk has demonstrated
validity relative to published models and was designed to use data commonly available
in an EHR in the first 24 hours of a patient visit

121

. This risk model is based on age,

gender, and 23 laboratory findings.

Methods
Infrastructure
See chapter one for a full description of the development and contents of the
UNMC CRDW. Data coverage and encounter data were collected via i2b2 queries and
SQL scripts targeting the de-identified database (Appendix C).
Assessing Coverage
For assessing the coverage of our current data, we considered all encounters
with any discharge disposition recorded (Logical Observation Identifiers Names and
Codes (LOINC) 75528-0 and 75527-2) for a three-year period (de-identified 5/1/2012 –
5/1/2015). Patient counts to assess data coverage were generated using i2b2 queries
using pertinent LOINC and Current Procedure Terminology, 4th Version (CPT-4) codes.
Defining the Study Population
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Data were analyzed for patients discharged from a Nebraska Medicine hospital
between 1/1/2013 and 12/31/2017 (de-identified date range). Patients with a discharge
were defined by having a discharge disposition recorded based on LOINC code 75528-0
and a vital status recorded at discharge based on LOINC code 75527-2. Those patients
with missing data or a status of unknown, no information, or other recorded were
excluded. Only inpatient encounters were considered. Encounters with a length of stay
less than 24 hours were excluded.
Outcome variable
The outcome variable for this study was inpatient mortality. Inpatient mortality
was defined by a vital status at discharge of “Expired” (LOINC 75527-2 code “E”) or a
discharge disposition of expired (LOINC 75528-0). Encounters with unknown, other, or
no information recorded for vital status at discharge were excluded.
Statistical Analysis
Using the coefficients provided by Tabak et al, a risk score was calculated for all
encounters in the cohort. This score was used as the predictor variable with inpatient
mortality as the dependent variable to fit a logistic regression model.
Missing Values
For missing lab values, we followed Tabak et al’s procedure of assigning a score
based on the reference range for the missing variable 121 . For each lab, if multiple values
exist, the earliest recorded value in the encounter is used.
Creating a Receiver Operator Characteristic (ROC) curve and computing the area
under the curve (AUC)
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With missing values imputed as described above, a risk score was calculated for
each encounter as the sum of scores for each data element. For each risk score, the
number of expired and living patients at discharge was identified and the sensitivity and
specificity for each score as a cutoff was computed. Next, for each risk score the true
positive rate (sensitivity) and the false positive rate (1 – specificity) were tabulated.
Based on this table, an ROC curve was plotted and the area under the curve was
calculated (concordance (c)-statistic). Analyses performed with R (R Core Team (2016).
R: A language and environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.org/.).
Logistic Regression and Comparing c-statistics
Using functions available in R packages (glm) we fit a logistic regression to our
data. We compared the coefficients generated from these data to those reported by
Tabak et al. To assess the predictive power of our model, we computed the c-statistic for
the logistic regression. We then compared this c-statistic to that published by Tabak et al
121

. A c-statistic of 0.5 indicates a predictive model no better than chance. As the c-

statistic increases toward 1.0, the discriminatory power of the model is greater. The cstatistic defines the probability that a patient selected from the outcome group will have a
risk score greater than a patient selected from the group without the outcome of interest.

Results
Data Coverage
All variables employed by the Tabak risk model were present in the CRDW at
UNMC (25/25, 100%) (see table 4). The Demographics variables had the best coverage,
with over 99% of encounters having this data available. Serum chemistry variables
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demonstrated good coverage with between 57% and 80% of all encounters having
recorded values. Arterial blood gas labs and cardiac markers demonstrated the lowest
coverage. Less than 16% of encounters had arterial blood gas values. Three of the six
hematology and coagulation variables were represented in over 80% of the encounters
while the other three variables had less than 40% of encounters with results (see table
4).
Encounter Characteristics
For the specified date range, 79,039 distinct adult patients were identified having
a total of 136,084 distinct, inpatient encounters lasting longer than 24 hours. The number
and percentage of these encounters with each of the risk score variables is displayed in
table **5. For these encounters, 3,047 (2.24%) resulted in a discharge disposition of
expired. The average total score for encounters where the patient expired was 77.0 (SD
23.0) while the average total score for encounters where the patient was discharged
alive was 34.8 (SD 21.0) (Figure 2).
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Table 4. Number of Encounters Recording Variables from the Tabak Mortality Risk
Model
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Figure 2. Comparison of Tabak Total Score for Patients Discharged Relative to Expired
Patients.
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Receiver Operator Curve
Using the total score with Tabak’s reported coefficients as the predictor, a
receiver operator characteristic curve was computed (Figure 3a). As it is up and to the
left, the curve demonstrates the high predictive value of the model. The area under the
curve (AUC) is 0.94. As the dataset is highly unbalanced, we also created a precisionrecall (PR) curve (Figure 3b).
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Figure 3. Receiver Operator Characteristic (ROC) curve and Precision-Recall (PR)
Curve based on Tabak mortality score. ROC (A) and PR (B) Curves based on scores
calculated from 136,084 inpatient encounters for adults at Nebraska Medicine between
January 2013 and December 2017. Area under the ROC curve (AUC) is 0.94.
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Logistic Regression
Using the ranges assigned by Tabak et al for age, gender, and each laboratory
test, we used multiple logistic regression to compute new coefficients for a risk model
score (Table 5). Recomputed coefficients demonstrated medium correlation to the
coefficients reported in the original study (Spearman rho = 0.709, p < 0.001) (Figure 4).
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Variable

Discharges,
n (%)

Mortality
, n (%)

Coeff.

Std.
Error

P

30-34

9,026 (6.6)

53 (0.6)

0.24

0.19

0.212

35-39

7,316 (5.4)

56 (0.8)

0.38

0.19

0.046

40-44

7,117 (5.2)

70 (1)

0.34

0.18

45-49

8,284 (6.1)

134 (1.6)

0.68

50-54

11,197 (8.2)

198 (1.8)

0.79

55-59

13,545 (10)

286 (2.2)

60-64
65-69

13,857
(10.2)
12,970 (9.5)

70-74

Tabak
Coeff.

Diff.

0.21

0.03

*

0.67

-0.29

0.057

.

0.83

-0.49

0.16

< 0.001

***

1.12

-0.44

0.15

< 0.001

***

1.28

-0.49

0.89

0.14

< 0.001

***

1.47

-0.58

374 (2.8)

1.14

0.14

< 0.001

***

1.64

-0.50

387 (3.1)

1.24

0.14

< 0.001

***

1.8

-0.56

10,600 (7.8)

360 (3.5)

1.44

0.14

< 0.001

***

1.96

-0.52

75-79

8,946 (6.6)

308 (3.6)

1.57

0.14

< 0.001

***

2.11

-0.54

80-84

7,403 (5.4)

313 (4.4)

1.81

0.14

< 0.001

***

2.32

-0.51

85-89

7,624 (5.6)

317 (4.3)

1.93

0.14

< 0.001

***

2.51

-0.58

>89

448 (0.3)

3.77

0.18

< 0.001

***

2.78

0.99

Male

61,124
(44.9)
7,222 (5.3)

0.12

0.04

0.007

**

0.14

-0.02

1.17

0.07

< 0.001

***

0.89

0.28

6,298 (4.6)

113
(33.7)
1,673
(2.8)
795
(12.4)
374 (6.3)

0.72

0.08

< 0.001

***

0.47

0.25

9,305 (6.8)

453 (5.1)

0.63

0.07

< 0.001

***

0.26

0.37

12,842 (9.4)

431 (3.5)

0.44

0.07

< 0.001

***

0.08

0.36

8,997 (6.6)

349 (4)

0.31

0.07

< 0.001

***

0.14

0.17

AST 41 - 60 U/L

7,401 (5.4)

397 (5.7)

0.46

0.07

< 0.001

***

0.28

0.18

AST 61 - 100
U/L
AST > 100 U/L

5,149 (3.8)

310 (6.4)

0.41

0.08

< 0.001

***

0.37

0.04

6,553 (4.8)

578 (9.7)

0.60

0.07

< 0.001

***

0.6

0.00

Total Bilirubin
1.5 - 2 mg/dL

4,552 (3.3)

249 (5.8)

0.25

0.08

0.003

**

0.07

0.18

Total Bilirubin
> 2.0 mg/dL

6,414 (4.7)

571 (9.8)

0.36

0.07

< 0.001

***

0.29

0.07

Calcium <= 7.9
mg/dL L
Calcium 8 - 8.4
mg/dL
Calcium > 10.1
mg/dL
Creatinine > 2.0
mg/dL
pro BNP 8001 18000

7,523 (5.5)

590 (8.5)

-0.03

0.07

0.635

0.26

-0.29

16,221
(11.9)
3,727 (2.7)

583 (3.7)

-0.08

0.06

0.145

0.09

-0.17

132 (3.7)

0.40

0.11

< 0.001

***

0.22

0.18

13,715
(10.1)
12 (0)

800 (6.2)

-0.12

0.07

0.072

.

0.09

-0.21

2 (20)

2.16

0.83

0.009

**

0.35

1.81

Albumin <= 2.4
g/dL 4
Albumin 2.5 2.7 g/dL
Albumin 2.8 - 3
g/dL
Albumin 3.1 3.3 g/dL
AST 31 - 40 U/L

Sig.
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pro BNP >
18000
BNP 1201 2400
BNP > 240

9 (0)

0 (0)

-9.18

99.82

0.927

0.68

-9.86

1,594 (1.2)

144 (9.9)

0.21

0.11

0.057

.

0.11

0.10

733 (0.5)

89 (13.8)

0.58

0.14

< 0.001

***

0.28

0.30

Glucose <= 70
mg/dL
Glucose 136 165 mg/dL
Glucose > 165
mg/dL
K <= 3.2 mEq/L

1,754 (1.3)

113 (6.9)

0.45

0.13

< 0.001

***

0.43

0.02

16,248
(11.9)
19,837
(14.6)
8,065 (5.9)

525 (3.3)

0.26

0.06

< 0.001

***

0.16

0.10

781 (4.1)

0.28

0.05

< 0.001

***

0.32

-0.04

255 (3.3)

0.09

0.08

0.242

0.19

-0.10

K 5 - 5.3 mEq/L

3,812 (2.8)

212 (5.9)

0.05

0.09

0.572

0.1

-0.05

K > 5.3 mEq/L

3,564 (2.6)

287 (8.8)

0.11

0.08

0.206

0.21

-0.10

Na <= 130

8,503 (6.2)

445 (5.5)

0.12

0.07

0.066

0.28

-0.16

Na 131 - 135

836 (3.1)

0.07

0.05

0.162

0.09

-0.02

Na 144 - 145

27,553
(20.2)
1,876 (1.4)

96 (5.4)

0.40

0.13

0.002

**

0.27

0.13

Na > 145

995 (0.7)

0.69

0.13

< 0.001

***

0.61

0.08

Alk Phos 116 220 U/L
Alk Phos 221 630 U/L
Alk Phos > 630
U/L
BUN 26 - 30
mg/dL
BUN 31 - 40
mg/dL
BUN 41 - 55
mg/dL
BUN > 55
mg/dL
pH Arterial <=
7.2
pH Arterial 7.21
- 7.3
pH Arterial 7.31
- 7.35
pH Arterial >
7.48
PO2 <= 50

14,430
(10.6)
4,109 (3)

114
(12.9)
576 (4.2)

0.01

0.06

0.898

0.11

-0.10

238 (6.1)

0.04

0.09

0.675

0.34

-0.30

636 (0.5)

59 (10.2)

0.31

0.17

0.068

.

0.54

-0.23

7,032 (5.2)

319 (4.8)

0.33

0.07

< 0.001

***

0.24

0.09

7,783 (5.7)

386 (5.2)

0.15

0.07

0.035

*

0.37

-0.22

5,692 (4.2)

344 (6.4)

0.23

0.08

0.005

**

0.53

-0.30

5,630 (4.1)

452 (8.7)

0.36

0.09

< 0.001

***

0.68

-0.32

1,401 (1)

1.72

0.09

< 0.001

***

1.38

0.34

1.27

0.07

< 0.001

***

0.87

0.40

1.11

0.07

< 0.001

***

0.66

0.45

0.58

0.10

< 0.001

***

0.5

0.08

479 (0.4)

384
(37.8)
466
(18.8)
376
(12.6)
180
(13.7)
81 (20.4)

0.90

0.15

< 0.001

***

0.79

0.11

PO2 50.1 - 55

486 (0.4)

81 (20)

0.91

0.15

< 0.001

***

0.57

0.34

PO2 > 140

7,781 (5.7)

639 (8.9)

0.34

0.06

< 0.001

***

0.78

-0.44

pCO2 Arterial
<= 35
pCO2 Arterial
>50
PTT <= 22

6,758 (5)

881 (15)

0.97

0.06

< 0.001

***

0.56

0.41

3,513 (2.6)

533
(17.9)
43 (7)

0.86

0.08

< 0.001

***

0.46

0.40

0.72

0.19

< 0.001

***

0.22

0.50

2,942 (2.2)
3,355 (2.5)
1,497 (1.1)

653 (0.5)

.
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PTT 45.1 - 55

1,324 (1)

0.33

0.11

0.003

**

0.21

0.12

0.61

0.10

< 0.001

***

0.28

0.33

12,828 (9.4)

148
(12.6)
225
(17.2)
664 (5.5)

PTT > 55

1,532 (1.1)

PT INR 1.11 1.4
PT INR 1.41 - 2

0.22

0.06

< 0.001

***

0.23

-0.01

6,000 (4.4)

471 (8.5)

0.41

0.07

< 0.001

***

0.44

-0.03

PT INR 2.1 - 5

5,942 (4.4)

456 (8.3)

0.68

0.07

< 0.001

***

0.34

0.34

PT INR > 5

765 (0.6)

81 (11.8)

0.68

0.15

< 0.001

***

0.51

0.17

Bands 7 - 13%

5,126 (3.8)

451 (9.6)

0.85

0.07

< 0.001

***

0.37

0.48

Bands 14 -32%

6,641 (4.9)

0.80

0.06

< 0.001

***

0.59

0.21

Bands > 32%

2,565 (1.9)

0.87

0.08

< 0.001

***

0.79

0.08

Hemoglobin <=
10 g/dL
Hemoglobin >
18 g/dL
Platelets <=
115*109/L
Platelets 115.1
– 150*109/L

24,558 (18)

0.20

0.05

< 0.001

***

0.16

0.04

477 (0.4)

644
(10.7)
309
(13.7)
1,107
(4.7)
24 (5.3)

0.18

0.25

0.474

0.25

-0.07

10,019 (7.4)

667 (7.1)

0.34

0.06

< 0.001

0.63

-0.29

11,084 (8.1)

352 (3.3)

0.07

0.07

0.284

0.13

-0.06

Platelets >
420*109/L
WBC <=
4.3*1,000/mm3
WBC 11 14.1*1,000/mm
3
WBC 14.2 19.8
*1,000/mm3
WBC >
19.8*1,000/mm
3
Troponin I 0.050.1 or CPK MB
3-5 ng/mL
Troponin I 0.110.2 or CPK MB
6-10 ng/mL
Troponin I 0.210.3 or CPK MB
11-34 ng/mL
Troponin I >0.3
or CPK MB >34
ng/mL
Total

5,249 (3.9)

131 (2.6)

-0.19

0.11

0.077

.

0.13

-0.32

25,421
(18.7)
14,674
(10.8)

480 (1.9)

-0.11

0.06

0.059

.

0.27

-0.38

453 (3.2)

0.30

0.06

< 0.001

***

0.28

0.02

9,182 (6.7)

417 (4.8)

0.33

0.07

< 0.001

***

0.47

-0.14

3,380 (2.5)

282 (9.1)

0.32

0.08

< 0.001

***

0.78

-0.46

5,542 (4.1)

435 (8.5)

0.62

0.06

< 0.001

***

0.15

0.47

1,709 (1.3)

193
(12.7)

0.86

0.10

< 0.001

***

0.29

0.57

744 (0.5)

99 (15.3)

0.94

0.14

< 0.001

***

0.54

0.40

2,810 (2.1)

392
(16.2)

0.98

0.07

< 0.001

***

0.82

0.16

136,084
(100)

3,047
(2.3)

***

Table 5. Logistic Regression Coefficients for Variables in Tabak Mortality Score. AST =
Aspartate Aminotransferase, Pro-BNP = pro-B-type natriuretic peptide, BNP = B-type
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natriuretic peptide, K = Potassium, Na = Sodium, Alk Phos = Alkaline Phosphatase, BUN
Blood Urea Nitrogen, PTT = Prothrombin Time, Prothrombin Time International
Normalized Ratio, WBC = White Blood Cells, CPK MB = Creatinine Kinase Muscle
Brain.
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Figure 4. Correlation of Newly Calculated and Tabak Model Coefficients. Labeled points
had a difference with magnitude greater than 0.75.
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Discussion
Conclusions
Sufficient data volume and variety were included in UNMC’s CRDW to enable
replication of the readmission risk model. Replication was further facilitated as the
authors published clear methods on how they computed the coefficients for the risk
model. In addition, the original article clearly defined the characteristics of the
encounters to be included in the analysis. With the infrastructure in place and sufficient
details published, we successfully replicated this risk model and extended the results to
a novel population. This lends further credence to the original work and supports use of
the model for further studies or applications within CDS.
A few points comparing newly calculated coefficients to the originally published
values stand out. The Pro-BNP values demonstrate a large discrepancy between this
replication effort and the original study. This is most likely due to the very low encounter
counts recording this laboratory value (21 total encounters with abnormal values
recorded). The apparent protective effect of a grossly elevated pro-BNP is most likely an
artifact of zero of the nine encounters resulting in an expired patient. Further analysis of
this model may benefit from excluding this variable as it has such a low encounter count.
The coefficient for age > 89 being slightly different from the original study is likely also
due to a low encounter count for this category coupled with a slightly higher incidence of
mortality for this category. Further study may require a threshold for a minimum
encounter count for a variable to be included in the analysis.
Limitations
This study was limited as data were obtained solely from Nebraska Medicine
affiliated hospitals. The study being replicated collected data from 70 hospitals and
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accumulated nearly ten times the number of encounters to include. Artifacts due to the
local environment and workflows may introduce bias in our analysis. In addition, the
demographics included in our study sample may not be representative of the entire
United States and may not be applicable in all areas.
Future Research
With successful replication of this readmission risk model, applying this
replication methodology to additional risk models is possible. The pattern of evaluating
the publication and assessing the coverage of the CRDW infrastructure provides a
means to potentially replicate any clinical research.
In addition, with the validation and extension of the risk model described in this
chapter, further analyses on subsets of the population are possible. Refining the risk
model for specific diseases as well as considering additional variables with high
predictive power are possible.
Finally, incorporating this risk model score into the CRDW and eventually into
CDS is possible. Within i2b2, the score can be calculated and stored on a per encounter
basis. Metadata may be developed to allow researchers to use this score within clinical
queries. As the efficacy of the risk model are further demonstrated, incorporating this risk
score upstream within the EHR becomes possible.
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CHAPTER 3 – DEVELOPING A COMPUTABLE PHENOTYPE FOR
PREGNANCY
Introduction
Distributed research networks relying on data extracted from the EHR offer a
variety of benefits for comparative effectiveness research (CER) and conducting
pragmatic trials. Data are collected for millions of patients including diverse
demographics and clinical environments and are representative of actual care 97-99.
Federated queries allow patient screening and subsequent data collection with a fraction
of previously required resources. However, to be effective, queries must be applicable
across all sites. Each query represents a computable phenotype, i.e. a set of
characteristics and clinical features more commonly observed in patients with a disease
or condition than individuals in the general population 122. Some elements of these
phenotypes recur as building blocks for queries in other studies. For instance, many
queries seek to identify a population with diabetes. Some of these may focus on
individuals of a certain age, only inpatients, or only those with specified comorbidities. In
each instance, the base population of those with diabetes must be defined. For many
diseases, professional societies have put forth detailed guidelines that can be adopted to
construct interoperable computable phenotypes.
One common condition for which a computable phenotype has not been welldefined is pregnancy. While the EHR is replete with data on this condition and being
pregnant is very often an inclusion or exclusion criteria for clinical research, no standard
EHR definition has been put forth to consistently identify a pregnant population

123

Defining this element has often been done ad hoc with limited success 124 . Some

.
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challenges to creating a common definition include the variety of measures and findings
that may indicate a pregnancy, the diverse location in the EHR these elements may be
stored, inconsistent coding across sites, and the varying levels of care sought during
pregnancy.
In this chapter, I describe the process of identifying variables commonly available
in basic EHRs to inform future development of a computable phenotype for pregnancy.
Our approach was to analyze a validated pregnant population and compare features to
an age-matched control population to identify candidate variables. In future work, these
will be incorporated into the development of a multiple logistic regression model that may
be validated against a test population and shared with other sites.

Methods
Data Source
As described in chapter 1, all data were extracted from the electronic health
record at Nebraska Medicine. These data were transformed to adhere to ONC
recommended standard terminologies, fully de-identified, and loaded into an i2b2
infrastructure to allow querying. In the course of this study, additional variables were
added to the ETL processes and additional metadata was added to i2b2 to facilitate
querying these new data elements. For instance, flowsheet rows regarding fetal
measurements were added to the extract. Also, metadata was created to allow for
identifying positive and negative pregnancy tests rather than simply the presence or
absence of these test.

Candidate Variable Identification
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Identifying candidate variables associated with pregnancy was both a stepwise
and an iterative process. An initial population with high confidence of pregnancy was
identified. This population was used to assess a plethora of variables for inclusion.
Clinician review by James R. Campbell, MD (Professor, Internal Medicine Division of
General Medicine-Academic) and Teresa Berg, MD (Director - Maternal-Fetal Medicine;
Director, Prenatal Diagnostic Center; McGoogan Professor of Obstetrics and
Gynecology) pared down the candidate variable list. Based on this analysis, additional
variables were extracted from the EHR and the i2b2 metadata was created or refined as
necessary to allow querying. Finally, Pearson chi square analysis demonstrated
association between identified variables and pregnancy. All elements of this study were
approved by the UNMC IRB (#601-17-EP).
Initial Pregnant Population
Within the EHR at Nebraska Medicine, during routine care clinicians may indicate
if an encounter is part of an episode. Episodes may be related to surgery,
anticoagulation, pregnancy, delivery, or a number of other longitudinal situations. In
consultation with domain experts (Campbell and Berg) and in conjunction with a limited
chart review, I discovered the flag of pregnancy episode had a high specificity and
limited sensitivity for identifying currently pregnant patients. The initial pregnant
population was limited to those females ages 15-50 years old with an encounter flagged
as part of a pregnancy episode during 2015 or 2016.
Variable Frequency Analysis
For the population identified as described above, all extracted data elements
recorded during encounters within the pregnancy episode were identified. These data
included vital signs, visit diagnoses, procedures, medications ordered or dispensed,
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demographic information, laboratory values, clinical findings, location of visit, and
diagnostic related group (DRG) information. The total number and percentage of
patients with each fact was identified.
Clinician Review
In consultation with doctors Cambpell and Berg, this survey of variables was
grouped and pared down. The initial survey identified each separate diagnostic code and
multiple variations of the same laboratory test. The clinicians eliminated non-specific
facts (such as common labs for all patients regardless of pregnancy status) as well as
grouped similar diagnostic codes at a higher level (i.e. rather than considering Z34.00:
“Encounter for supervision of normal first pregnancy, unspecified trimester”, Z34.01:
“Encounter for supervision of normal first pregnancy, first trimester”, Z34.02: “Encounter
for supervision of normal first pregnancy, second trimester”, and Z34.03: “Encounter for
supervision of normal first pregnancy, third trimester” independently, the facts were
grouped to become “ENC DX: Supervision of pregnancy - ICD10CM:Z33-34”).
Updating Data Extraction and i2b2 Metadata
This survey of data and clinician review identified two types of gaps in what was
previously extracted for obstetric data. First, certain flowsheet rows were missing. Next,
the i2b2 metadata allowed for queries to determine if a laboratory test was performed
while not allowing querying of the results of the test. To resolve the first concern, the
ETL from the research copy of the clinical data research warehouse was updated to
include flowsheet information relative to fetal ultrasounds and measurements. In
addition, episode data was not originally extracted from the EHR into the CRDW. For
these novel data elements, i2b2 metadata was also created to allow for querying.
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Next, the analysis demonstrated the metadata previously deployed was
insufficient to query laboratory values for various pregnancy tests. For these instances,
metadata XML was developed to query the lab values. This necessitated interpreting
numeric values as well as free text in some instances to identify each laboratory value
as positive, negative, or unknown.
Statistical Analysis
With this enhanced list of candidate variables, contingency tables were created
to compare the pregnant cohort to a control population using Pearson Chi-Square tests
for significance for each refined variable. The control group consisted of female patients
ages 15-50 years old without a pregnancy episode noted during 2015-2016 who had at
least one face to face encounter at a Nebraska Medicine affiliated hospital or clinic
during this time frame. Patient counts for each population for each variable were
identified using i2b2 queries.
Refining the Pregnant Cohort and Control Population for Model Development
Identifying Pregnancy Beginning and End Dates
With candidate variables identified, a verified cohort of all pregnant patients
during the date window of interest was required (Figure 5). This needed to include
patients with and without pregnancy episodes noted in the EHR. The bounds of a
pregnancy were calculated from information extracted from the EHR. The end date for a
pregnancy was identified first by the delivery date noted in the obstetric history. If this
date was not available, the date of a delivery encounter was used. If this was not
identified, the start date of a delivery episode was used to denote the end date of a
pregnancy. If none of these were available, the estimated delivery date recorded for the
pregnancy episode was used. The start date for a pregnancy was calculated based on
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the end date as recorded above. If available, the end date minus the gestational age
recorded at delivery was used. When not available, the estimated delivery date – 280
days identified the start of the pregnancy.
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Figure 5. Initial Pregnant Cohort and Control Group Identification Algorithm.
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Control Population
Using i2b2, we identified all females ages 15-50 who were seen at Nebraska
Medicine for any care during 2015-2016. We excluded patients with a pregnancy
episode identified during these years. For both the control and pregnant cohort, patients
were required to reside within 50 miles of UNMC. Patients outside of 50 miles often only
came to UNMC for specialty care or emergent conditions. During these encounters,
pregnancy was noted. However, obstetric care and associated records were maintained
elsewhere and not available for inclusion in this analysis. All patients were required to
have at least one face to face encounter during the study window.

Results
Variable Identification
Table 6 and Figure 6 provide demographic details about the initial pregnancy
episode and control population used to refine the list of potential variables. In both
instances, the majority of the population was White and the mean age was
approximately 30 years old. Table 7 summarizes the curated list of variables associated
with pregnancy. The reported p-values in this table are the results from the Pearson ChiSquare analyses.
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Pregnant
Control
(n = 5,439) (n = 74,949)

Age (years)
Minimum Age
Maximum Age
Median ± SD

15
47
28 ± 5.61

Race (count (% ))
White or Caucasian
Black or African American
Asian
Other / Unknown

15
50
31.5 ± 9.00

Pregnant
(n=5,439)

Control
(n=74,949)

3,523 (64.8)
909 (16.7)
136 (2.5)
871 (16.0)

55,486 (74.0)
7,163 (9.6)
1,975 (2.6)
10,325 (13.8)

Table 6. Demographics of
Pregnant Cohort and Nonpregnant Control
Populations.

Race of Pregnant and Control Groups
80%

% OF POPULATION

70%
60%
50%
40%
30%

Pregnant

20%

Control

10%
0%
White or
Caucasian

Black or African
American

Asian

Other /
Unknown

RACE

Figure 6. Race of Pregnant Cohort and Non-pregnant Control Population.
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Pregnant Control
p-value
(n=5,439) (n=74,949)
Encounter Diagnoses

Variable

Description

ICD10CM:Z33-34
ICD10CM:O60-O94
ICD10CM:O009-O29,
O98,O99
ICD10CM:O31-O41

Supervision of pregnancy
Complications of delivery

4,408 (81.0) 1,127 (1.5)
1,463 (26.9) 374 (0.5)

<0.001
<0.001

Disorders during pregnancy 3,915 (72.0) 1,564 (2.1)

<0.001

Pregnancy complications

<0.001

1,308 (24.0)

330 (0.4)

Procedures
CPT4:76801-76828

Obstetric ultrasound

4,064 (74.7) 1,285 (1.7)

<0.001

3,513 (64.6) 2,402 (3.2)

<0.001

Lab Tests
LOINC:882-1

ABO and Rh group [Type]
B-hCG in serum by
immunoassay (Positive)
B-hCG in serum by
immunoassay (Negative)
hCG in urine (Positive)
hCG in urine (Negative)
hCG in serum/plasma
(Positive)
hCG in serum/plasma
(Negative)

LOINC:20415-6
LOINC:20415-6
LOINC:2106-3
LOINC:2106-3
LOINC:2118-8
LOINC:2118-8

879 (16.2)

724 (1.0)

<0.001

129 (2.4)

659 (0.9)

<0.001

178 (3.3)
353 (6.5)

120 (0.2)
6,455 (8.6)

<0.001
<0.001

45 (0.8)

74 (0.1)

<0.001

124 (2.3)

2,089 (2.8)

0.03036

3,434 (63.1) 1,293 (1.7)
3,434 (63.1) 1,293 (1.7)
110 (2.0)
26 (0.0)

<0.001
<0.001
<0.001

Problem List Entry
SNOMEDCT:173300003
SNOMEDCT:77386006
SNOMEDCT:16356006

Disorder of pregnancy
Patient currently pregnant
Multiple pregnancy

OB Clinical Encounter and Measures
OB Clinical Encounter at
UNMC
LOINC:11881-0
LOINC:55283-6
LOINC:57088-7

Visit to obstetric clinic
Uterus fundal height tape
measure
Fetal heart rate (Positive)
Fetal movement - reported
(Positive)

3,993 (73.4) 9,949 (13.3)

<0.001

3,373 (62.0)

337 (0.4)

<0.001

3,552 (65.3)

348 (0.5)

<0.001

3,194 (58.7)

309 (0.4)

<0.001

Table 7. Comparison of Frequency of Finding in Pregnant vs. Non-pregnant Populations.
P-value obtained from Pearson Chi-square test.
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Discussion
Conclusions
This survey of the EHR identified a series of variables highly associated with
pregnancy. None of these variables taken independently was highly sensitive. Variations
in clinical workflow, physician preference, and charting practice within an institution, and
likely exacerbated across multiple institutions, may account for differences in data
elements being recorded during pregnancy. From initial chart review, some of these
variables demonstrated high specificity.
Limitations
A number of considerations must be made when evaluating these data. First, this
survey of the EHR was limited to the environment in a single academic medical center
with a single EHR. Workflows and technical bias may be introduced as a similar review
is conducted at other institutions using disparate, proprietary EHRs. I attempted to
mitigate the potential of overfitting to UNMC’s environment by identifying a variety of
variables from several data domains likely to be recorded in the majority of basic EHRs. I
did not simply rely on a single diagnosis or a specific procedure. Rather, data came from
procedures, clinical findings, diagnoses, laboratory tests, and obstetric measures. In
addition, interoperability and replicability are enhanced as I relied on ONC
recommended standard vocabularies to define these variables. With the exception of
visiting a UNMC obstetric clinic, all other variables were defined using accepted
terminologies.
This review, as well as future creation of a predictive model, was also limited as
there is no current and consistent gold standard for identifying a pregnant patient. I used
episode data as a specific surrogate for such a standard, however, I noted sensitivity

74

was lacking. As thousands of patients deliver each year at a Nebraska Medicine
hospital, performing a chart review on all patients to be included in the study as well as
matched controls becomes a major undertaking. Failure to review all charts may lead to
bias as certain individuals are false positives or false negatives as well as having
difficulty in identifying meaningful dates for a pregnancy. I attempted to address this
challenge by accepting all pregnancy and delivery episodes as being pregnant. As this is
a multistep process for a clinician to indicate, the likelihood of false positives is reduced.
In addition, I began to refine the population for chart review by identifying patients with
high likelihood of pregnancy (i.e. those with multiple, specific findings from the variable
list). In this way, future chart review would be limited to those with a lower suspicion of
pregnancy as well as matched controls.
Finally, there is the potential for bias as I relied on clinician input to refine the list
of variables. Each clinician has a unique background which may affect how she
considers characteristics of pregnancy. I limited the potential for bias in two ways. First, I
conducted a survey of all recorded facts for patients during the time of interest and
examined those with greatest frequency. Any common data elements recorded during
pregnancy should be captured in this way. Secondly, I relied on multiple clinicians to
review and refine the list of variables. Each could add to or comment on the list to refine
it effectively. Bias may be further mitigated as these variables are shared with other
domain experts, especially outside this institution, to gain greater perspectives toward
general applicability.
Future Research
The methods and results reported in this chapter represent initial stages of a
larger effort to develop a computable phenotype for pregnancy status. This initial survey
demonstrated variables exist in a basic EHR that are associated with pregnant status.
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Immediate next steps will be to continue chart review to identify well-characterized
pregnant patients with definitive start and end dates for the pregnancy. Chart reviews will
also be required to validate a matched control population for comparison. With these
populations identified, each variable will be given an effective time period for which it is
an indicator of pregnancy. For instance, a positive urine pregnancy test may indicate a
pregnancy six weeks prior to and up to 34 weeks following the date the event was
recorded.
With a pregnant cohort and age-matched control identified as well as variables
with date ranges associated, a multiple logistic regression approach will be taken to
identify a predictive model. The population will be divided into a training and a test
group, each with a portion of pregnant and control patients. Random sampling at various
time points during the years of interest will be used to fit the model based on the training
group. Each patient will have a well-defined period of pregnancy and non-pregnancy.
Once refined, this predictive model will be evaluated against the test subset of patients.
The effectiveness of the model will be evaluated with a receiver operator
characterization curve and its sensitivity and specificity will be noted.
With a well-characterized model, interoperability and extendability will be
evaluated. Using the infrastructure and collaboration within the GPC, the variables and
model will be shared throughout the distributed research network. This will begin with a
survey of sites to determine how many of the 14 variables are currently recorded and
extracted from local EHRs. If sufficient data coverage exists, and with IRB approval, a
sampling of patients and subsequent chart review will be used to evaluate the
applicability and effectiveness of the model.
With this further refinement, the eventual goals are to publish the model in a
fashion it may be re-used for clinical research, including pragmatic trials and
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observational studies. Further evaluation of the model across larger networks may
further refine it. Once widely validated, incorporating the predictive model into the EHR
will be planned. Using this model in clinical decision support to identify potentially
pregnant patients prior to procedures, medication administration, or imaging will
enhance patient safety.
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CHAPTER 4 – INCORPORATING A LOCATION-BASED
SOCIOECONOMIC INDEX INTO A DE-IDENTIFIED I2B2 CLINICAL
DATA WAREHOUSE
Introduction
Clinical research data warehouses are often populated with de-identified patient
data extracted from an electronic health record (EHR)

125

. With the continuing

advancement and adoption of EHRs, the amount of information available for reuse in
clinical research continues to rise 73-76 . However, for complete patient characterization,
these data need to be linked to other sources 93 . For instance, while a patient’s race,
gender, and smoking status are often well-documented in the EHR, other elements of
socioeconomic status are often unstructured or absent from the clinical record and
unavailable for incorporation into a research data warehouse. These non-clinical
elements describing a patient’s social, economic, and environmental determinants of
health (healthypeople.gov) are a major contributing factor in readmission, morbidity, and
mortality 126 .
With the paucity of data in the EHR related to socioeconomic status, researchers
have relied on insurance type as a proxy for this measure 127 . Data elements related to a
patient’s neighborhood socioeconomic status (NSES) may reliably be obtained from
extra-EHR sources such as American Community Survey (ACS) data from the U.S.
census. Neighborhood resources have robust effects on health 128-131 , because of their
correlation with individual socioeconomic status and as an independent source of
influence. The demographic composition of residential areas also has important links to
health behaviors and health outcomes 132-135 . Linking measures of the local residential
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context to clinical data from the EHR can provide insights into these socioeconomic and
demographic correlates of health for researchers.
Using Geographic Information System (GIS) software, a patient’s physical
address can be linked to a variety of location-based datasets such as the EPA’s Air
Quality System 136 or the ACS (https://www.census.gov/programs-surveys/acs/). While
efforts are being made to integrate these elements directly into the EHR, to date, no
EHR has demonstrated widespread integration of such “community vital signs” 137 .
Implementing this linkage for clinical research with an EHR-agnostic approach
introduces additional challenges related to patient privacy and data standardization. The
Health Information Portability and Accountability Act (HIPAA) privacy rule, the Health
Information Technology for Economic and Clinical Health Act of 2009, and the Federal
Policy for the Protection of Human Subjects are designed to safeguard protected health
information (PHI), including street address and geocodes 138 . These safeguards may
prohibit researchers from sharing the information required for geocoding with an
academic or business partner third party, hampering the ability to link clinical and NSES
data within an institutional review board (IRB) approved process. Additionally, data that
would identify a patient’s location with too much granularity may not be displayed in a
de-identified data warehouse. For instance, HIPAA requires zip codes be obfuscated if
the population is below 20,000 for that area. Many details are available from the ACS for
significantly smaller populations, requiring obfuscation before being made available in a
de-identified system.
One approach to maximize sample population while maintaining patient privacy
is to participate in a distributed research network (DRN). The National Patient-Centered
Clinical Research Network (PCORnet) and its participating Clinical Data Research
Networks (CDRNs) illustrate how patient data may be stored locally and federated
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queries may be shared across the network

2, 97, 100

. However, interoperability of research

queries across a CDRN is challenging as variability may be introduced into a
collaborative study if geocoding is performed independently at each site with disparate
methods 139-141 . This variability may affect analysis and conclusions in health care
studies 142 . As clinical and socioeconomic data are linked, successful collaboration and
data analysis is dependent on a means of querying these data from each site for a
variety of studies.
In this chapter, we provide a model for combining socioeconomic and clinical
data while maintaining patient privacy and allowing rapid querying in a de-identified data
warehouse. We describe an algorithm for extracting socioeconomic status data from the
American Community Survey (ACS), geocoding patient data without involving a third
party, and combining these data within an Informatics for Integrating Biology & the
Bedside (i2b2 - www.i2b2.org) framework for interrogation. Due to the volume and
variety of data within the ACS, we extracted only elements to calculate a validated
socioeconomic index 126 . We demonstrate this data extraction and incorporation into the
research infrastructure using an example of evaluating the impact of NSES on
emergency department (ED) utilization. The approach we describe may be fully
deployed at other sites and will allow for collaborative research and federated queries
while keeping PHI secure 143

Methods
Clinical Data
Patient data were extracted from a research copy of the EHR data warehouse at
the University of Nebraska Medical Center (UNMC). This system contains data
originating from multiple hospitals and clinics in urban, suburban, and rural Nebraska.
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Clinical and demographic data are extracted, standardized based on Office of the
National Coordinator (ONC) recommended vocabularies, and transformed for use within
an Informatics for Integrating Biology & the Bedside (i2b2) clinical data warehouse

118, 119

. Data are transformed and staged on an identified server and then de-identified and
made accessible to researchers via i2b2 in a fully de-identified database on a separate
server (Figure 7). This data extraction and use in a de-identified data warehouse was
approved by the institutional review board (IRB) at UNMC (IRB #132-14-EP).
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Figure 7. Integrating Census Data into a De-identified Data Warehouse and Querying
with i2b2
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Geocoding Process
Current and historic patient address information was extracted from the EHR and
stored on a secure server. TIGER/Line Shapefiles and other location-based files needed
for geocoding were obtained via FTP from the United States Census Bureau and loaded
onto the server alongside patient address data. These files were for year 2017 and for
the states of Nebraska and Iowa. Using these data, PostGIS version 2.4
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geocoding

software running on PostgreSQL version 10.1 was used to identify the longitude and
latitude for each patient address. Subsequently, the U.S. census block group for each
successfully geocoded address was determined via PostGIS. For this study, we
geocoded only patient addresses for Nebraska and Iowa. In the extraction, we
eliminated P.O. Box addresses and those addresses with null or invalid street addresses
(Figure 8). Invalid street addresses were defined as those consisting of all alpha or all
numeric characters, a single character, or containing variants of the words unknown or
invalid.
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Figure 8. Identifying patients with a well-geocoded address
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We compared demographic data for the geo-coded population relative to those
patients we excluded from analysis. Rural versus urban location was based on United
States Department of Agriculture (USDA) Rural Urban Commuting Area (RUCA) codes
mapped to zip codes (https://ruralhealth.und.edu/ruca , https://www.ers.usda.gov/dataproducts/rural-urban-commuting-area-codes/documentation/). Financial class for the
patient was defined as the primary insurance category listed on the patient’s account in
the EHR. Age was calculated from the date of the data extract (December 2017).
Census Variable Extraction and Socioeconomic Index Calculation
Based on the index and variables described by Bird et al, a set of equivalent
variables which could be computed from the U.S. Census Bureau’s annual American
Community Survey (ACS) were identified 126 . Table 8 identifies the Bird variables from
the 2000 decennial census and the field and computation employed from the 2011-2015
five-year estimates from the ACS. Using the U.S. Census Bureau API, ACS estimates
for each variable for each block group in the U.S. were extracted and stored locally.
These raw estimates were transformed and normalized for all Nebraska and Iowa block
groups to have a mean of 0 and a standard deviation of 1 as described by Bird

126

. The

Bird NSES is computed as the sum of the standardized values for each of the six
variables, where the standardized values are multiplied by -1 for variables where a
higher positive value indicates lower socioeconomic status. This method results in higher
Bird index values corresponding to a higher socioeconomic status. If any of the six
variables were unavailable from the ACS for a specific block group, the Bird index was
not computed for that block group. Standardized values for the six variables as well as
the Bird index were stored for all block groups within Nebraska and Iowa.
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Table 8. Description of Variables to compute neighborhood socioeconomic status
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Identifying Patient NSES and i2b2 Fact Creation
Patient addresses from Nebraska and Iowa were linked to census block groups.
Patient identifiers were linked to the Bird index and standardized ACS variables
associated with their block group. Data were de-identified and loaded into the database
on the de-identified server used by i2b2. De-identification included using a randomly
generated patient number, shifting all dates for each patient randomly by -1 to -365
days, and excluding any HIPAA identifiers. For each block group, we ensured the level
of granularity of the reported NSES index was only sufficient to match at least seven
block groups. This ensures the patient remains anonymized in a population of at least
20,000 people. For each patient, seven records were inserted into the database: the Bird
NSES index and the six standardized variables necessary for its computation.
Metadata Creation and i2b2 Querying
The demographics portion of the i2b2 ontology cell was updated to support
interrogation of ACS based facts (Figure 9). A folder for neighborhood socioeconomic
status was added with subfolders for the Bird NSES index and the six, standardized
variables of interest. ACS variables were identified with the field label as well as a brief
description to ensure they are both standardized and human readable. Metadata XML
was included to allow users to specify ranges or values of interest for each of the
variables.
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Figure 9. Integration of ACS Metadata into the Demographics Hierarchy of an i2b2 Client
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Example Use Case: Emergency Department Utilization
All patients with a computed Bird socioeconomic status index who were seen in
any Nebraska Medicine affiliated hospital or clinic between January 2013 and December
2017 were identified. An odds ratio was computed comparing the number of patients
with zero emergency department (ED) visits to those patients with one or more ED visits
during 2013 to 2017. These patients were stratified on the basis of above average or
below average Bird index. ED visits included encounters with any resulting discharge
disposition, including hospital admission or expiration. In addition, for patients with an
ED encounter and two or more total face to face encounters within the target date range,
an ED frequency metric was computed. For each patient, the total number of ED
encounters was divided by the time between the earliest and latest face to face
encounter of any type. A one-tailed student’s t-test with alpha of 0.05 was used to
compare this metric between the high and low NSES populations (R Core Team (2016).
R: A language and environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.org/.). Results

Results
Geocoding
We geocoded only patients with a Nebraska or Iowa address, representing the
majority (507,586 / 534,735 (94.9%)) of Nebraska Medicine patients. Patients were
excluded from analysis if: 1. The patient address failed to geocode or have a block group
assigned (1,330), 2. The patient street address was unknown or invalid (28,893), or, 3.
The geo-rating assigned by PostGIS was greater than 10 indicating a low confidence in
the geo-code assignment (81,179). The final geo-coded population consisted of 396,913

89

patients who have had an encounter at Nebraska Medicine, a well-geo-coded address,
and a block group assigned (Figure 8).
Figure 10 illustrates the comparison of the included versus the excluded
population for analysis. The percentage of the excluded population living in a rural zip
code was 23.7% compared to only 9.8% of the included population. The racial
composition of the included and excluded populations were very similar with each
demonstrating a majority white (78.9% and 80.8%, included and excluded populations,
respectively) with a lower percentage of black (9.5% and 7.6%) and other races (11.7%
and 11.6%) in the both populations. The populations demonstrated little difference in
gender proportion (54.7% and 52.7% female, inclusion and exclusion population,
respectively). The included population had a higher percentage of private / commercial
insurance (48.09% vs. 45.44%) while having a slightly lower Medicare percentage
(16.5% vs. 20.1%). The included population had a lower age relative to the excluded
population (age years (SD)) (42.1 (23.6) vs. 44.6 (24.0)).
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Figure 10. Comparison of Geo-coded and Excluded Patient Population
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Neighborhood Socioeconomic Status Variables
For the six variables we computed from the ACS data, values were present for at
least 98% of block groups in Nebraska and Iowa. We were able to compute a Bird index
for 4,208 of 4,263 (98.7%) of all block groups in these states.
ED Utilization
Using the i2b2 data warehouse, 360,947 patients were identified as being seen
in any Nebraska Medicine hospital or clinic between January 2013 and December 2017
who also had an assigned Bird index. Of these 214,325 (59.38%) had above average
index values and 146,622 (40.62%) had below average values. For patients with a below
average index value for their neighborhood, 60,309 (41.13%) had at least one visit to an
emergency department during the study period for any reason. During the same period,
59,550 (27.78%) of patients with an above average index had an emergency department
encounter (Figure 11). Patients living in an area with a below average index have 1.82
times the odds of visiting the emergency department compared to patients with living in
neighborhoods with a higher index (95% CI 1.79-1.84).
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Figure 11. ED Utilization Stratified by NSES
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For patients with at least two total face-to-face encounters and at least one
emergency department visit between 2013 and 2017, there were 39,697 patients
residing in areas with high NSES and 39,535 patients in areas with below average
NSES. Figure 12 displays the distribution of ED utilization rates for each of these
populations. The average number of visits to the ED per year were 2.11 for patients with
an above average NSES and 2.40 for patients with below average NSES. A student’s t
test demonstrated that patients with below average NSES had a mean emergency
department visit rate of at least 0.2 visits per year higher than those with above average
NSES (alpha=0.01, p < 0.001).
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Figure 12. ED Utilization Rate Stratified by NSES
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Discussion
Conclusions
With evidence of the impact of environmental factors on health, facilitating
comparative effectiveness clinical research incorporating social determinants of health is
paramount 145 . Advances in geoinformatics make it possible to link patient locationto
data provided by the U.S. Census Bureau. We demonstrated an approach to link social
determinants of health data from the American Community Survey to clinical data in a
de-identified data warehouse. All elements of this approach may be completed at
individual sites, avoiding the need to send PHI to a third party. When sites utilize the
same geocoding and linkage process, collaborations are possible without introducing
unnecessary variability between sites. Institutions who implement this approach using
i2b2 may share federated queries across networks such as PCORnet and the GPC, to
increase the patient sample size for analysis 146 . Facilitating this research will inform
efforts to incorporate location-based census data directly into the EHR and future clinical
decision support (CDS) at the point of care.
This study is an example using only a single socioeconomic index. While many
indexes have been published to estimate socioeconomic status, we selected Bird’s
model as it is well-validated and fully reproducible using data elements from the ACS 147151

. Future work includes incorporating other well-validated models based on extant ACS

data using the process described in this manuscript. These may readily be incorporated
into the database within the ontology cell of i2b2. We demonstrated the efficacy of
querying these data with a use case based on evidence from prior studies. We noted
both a higher proportion and more frequent per patient utilization of the ED for patients
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living within areas of lower NSES relative to patients from areas of above average
NSES.
Limitations
This study is limited by only including patients from Nebraska and Iowa.
Additionally, the clinical data utilized does not encompass all hospitals and clinics
patients may visit. Integrating health information exchange data would enhance the
clinical picture and facilitate studies investigating readmission.
This study is also limited by the quality of data available in the EHR. For
instance, 28,893 / 508,315 (5.68%) of all addresses were unable to be geocoded as they
were recorded as some variant of unknown, were null, or were P.O. Boxes rather than a
physical address of a residence. In addition, there is varying quality of confidence in the
results returned by the geocoding software with 81,179 / 508,315 (15.97%) having a
geo-rating with low confidence (PostGIS geo-rating > 10). As addresses are non-uniform
and may contain errors, some may not geocode accurately. By excluding patients and
potentially mismapping a small portion of the patient population, the potential for bias is
introduced. While race and gender showed no significant difference between the
included and excluded populations, as is evidenced in other studies, rural locations had
a lower percentage of successful geocoding 152 . Differences in these populations were
also seen for age (included population slightly younger) and financial class (Medicare
patients more likely to be excluded). Recognizing these population differences is
essential as they may impact analyses when future studies rely on these data

153

. While

the geocoding for this study did not reach 100% completeness or 100% accuracy,
results were comparable with other first-pass geocoding efforts 152, 154-159 . A refinement
of the geocoding process may reduce this bias and increase confidence of results
relying on the generated data. Perfecting geocoding is beyond the scope of the current
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demonstration. An enhanced geocoding process could readily be integrated into this
model for incorporating census data into a de-identified data warehouse.
Future Research
To demonstrate reproducibility and extend the results demonstrated in this paper,
collaborations to implement this data integration approach will occur in existing
distributed research networks (Greater Plains Collaborative (GPC) and The National
Patient-Centered Clinical Research Network (PCORnet)). Within the GPC, sites have
implemented de-identified data warehouses on an i2b2 platform. Across PCORnet, each
participant transforms clinical data to adhere to the common data model (CDM). While
the i2b2 querying approach will not be able to be demonstrated throughout PCORnet,
the CDM and established federated query protocols will allow collaboration.
Future efforts will also address incorporating additional socioeconomic indices
and ACS variables into the de-identified clinical data warehouse 148, 150, 160 . As part of this
effort, a standard approach to identifying these indices and component variables within
an i2b2 ontology will be proposed for interoperability. Integration of additional indices will
allow both the comparison of the efficacy of indices in a variety of contexts as well as the
application of validated indices within many disease phenotypes.
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DISCUSSION
Summary
Overview
In this dissertation I have demonstrated an approach to assessing the utility of a
clinical research data warehouse for effectively and efficiently replicating clinical
research. With the gaps identified in this assessment, I also performed preliminary work
toward developing a computable and shareable phenotype for pregnancy status based
on EHR data. Finally, I developed and deployed a methodology for linking EHR data to
socioeconomic data contained within the U.S. Census within an i2b2 infrastructure.
While replication of all studies remains a future goal, the results described in this
dissertation represent progress toward this end and provide areas of consideration as
institutions establish clinical data research warehouses or participate in distributed
research networks.
Assessing Risk Models and Infrastructure for Replication
First, using two risk models based largely on data from basic EHRs, I assessed
their replicability with the infrastructure established at UNMC. While I surveyed a variety
of risk models, those included in this dissertation clearly demonstrated significant points
in the replication process. First, these models were clinically meaningful and based on
EHR data. While not always the case, these two models each provided meaningful
results for a clinically significant concern (readmission in heart failure patients and risk of
in-hospital mortality). If the initial results are not clinically significant, attempting to
replicate the model may be superfluous. This may be due to being statistically significant
but not clinically meaningful (i.e. less than a one-point systolic blood pressure difference)
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which may be detectable with very large sample sizes, or, due to being relevant to only a
very specific subset of the population that may not be represented at all sites (i.e. a very
rare disease or an effect linked to geographic region). Next, each model was largely
based on data likely to be found in a basic EHR. Other models may be based on data
from surveys, disease registries, or public records. While replication of these models
may be possible, this would require incorporation of novel data sets for each model
rather than clinical data that may be re-used for a plethora of models. The
generalizability and replicability of risk models relying on extra-EHR data is hampered by
the resource cost of instantiating these data.
Next, beyond the clinical significance and the reliance on EHR data, to assess
the utility of UNMC’s CRDW to replicate risk models, I surveyed the specific data
elements the risk model was built on. Each of the risk models in this dissertation were
designed to largely use data collected on the majority of patients within the first 24 hours
of hospital admission. UNMC’s CRDW demonstrated excellent coverage of
demographics data and a large portion of encounters had laboratory data as well. One
element limiting the replicability of the heart failure risk model was the inclusion of
additional data elements, such as socioeconomic status based on census data, number
of address changes in recent history, and the number of missed visits. While visit and
address information are recorded in the EHR, these may not be commonly extracted into
a clinical research data warehouse. Developing ETLs for specific data elements requires
an investment of time and resources. Prioritizing these extracts to the data elements
used most frequently is essential. In addition, extra-EHR data, such as that found in the
U.S. Census may be linked to EHR data, however, as demonstrated later in the
dissertation, significant resource investment is required. One contribution of these efforts
toward replication was the prioritization of future data extracts into UNMC’s data
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warehouse. Assessing specific data elements is essential to evaluating a site’s ability to
replicate a study.
An essential element of this data survey is the definition of each data element.
For a significant amount of clinical data, the ONC has recommended standard
vocabularies for use in recording and describing data. If employed and well-documented,
these standards facilitate interoperability of healthcare data as well as enhance
replicability of published research. For the two risk models described in this work, neither
fully described all clinical elements with these recommended vocabularies.
Amarisingham et al had a well-defined phenotype for the heart failure patients based on
ICD-9 CM codes. However, in both studies, only the laboratory name was given rather
than a series of LOINC codes. This necessitated the replication effort to include a lookup
of a significant number of laboratory codes and may represent a departure from the
original studies. In neither case was the phenotype or inclusion criteria published in a
machine parseable form. My work involved manually parsing the descriptive text and
interpreting definitions for each data element. To enhance replicability to make this effort
more efficient, authors may publish a human readable description in conjunction with a
fully machine-readable document using standard terminologies.
In addition to ensuring data elements are present in the data warehouse,
ensuring data volume is sufficient for the study is critical. I assessed data volume for
each model by developing and executing a series of queries in i2b2. This provided
simple patient counts for each variable of interest. Some data may be extracted but exist
at a very low rate. For instance, while all laboratory elements for the heart failure model
were extracted from the EHR, no patients in this cohort had a pro-BNP recorded. For a
rare disease, it is possible an insufficient number of patients may exist at a single
institution necessitating collaboration across a network. This was not a concern for the
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two models described in this dissertation as the i2b2 queries demonstrated a large
patient population for the common cohorts of heart failure and hospital admission.
Ensuring both data variety and data volume are important elements in ensuring a site
has the capability of replicating published research.
Along with assessing the clinical relevance and potential generalizability of a risk
model and surveying the specific data elements required in the model, an evaluation of
the statistical methods the authors used is critical when determining if a model may be
replicated. While Amarasingham’s risk model for readmission in heart failure patients
may have demonstrated significance, neither the publication nor attempts to reach the
author were sufficient to elicit a replicable set of methods. While data limitations
precluded replication of this model, even if all data were present, the absence of clear
methods prevents replication of the work. At best, I could demonstrate correlation
between the same set of variables and readmission rate. It would be guesswork to
determine if the variable had relative contributions as described by the authors. Whereas
the methods for the first model remained somewhat a black box, Tabak’s mortality risk
model had well-described analyses and model development. Prior to investing significant
resources toward extracting additional data elements or linking to external data sources,
it is essential to ensure the analyses are well-described and well-designed.
To summarize, any attempt toward replicating a published risk model with clinical
data requires assessment both of the published work and of the infrastructure at the new
site. In this dissertation I demonstrated these processes with two separate models. In
each instance, I ensured the model had clinically significant results, was applicable to
the population at this site, and published sufficient methods to allow me to perform
similar analyses and model development. In addition, I surveyed data available within
the clinical research data warehouse to ensure volume and variety sufficient to model
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the methods in the original work. Neither paper published fully defined criteria using
standard terminologies. One model failed to publish a complete description of the
methods. This model also employed extra-EHR data not available within UNMC’s data
warehouse at the time of the replication attempt. My overall assessment indicated one of
the two studies may be replicable at UNMC. The other study may have valid results,
however, due to infrastructure limitations and publication omissions, replication is not
possible.
Replication Attempt of Risk Model
With the model assessment in place, an attempt to replicate Tabak’s mortality
model was possible. In order to replicate this study, definitions of data elements needed
to be interpreted, local data needed to be queried, and analysis of the data as described
by the original study was required.
As described above and documented in Appendix C, I translated the narrative
description of laboratory values and inclusion criteria into LOINC codes to interrogate the
clinical data at UNMC. Multiple LOINC codes were possible for the majority of laboratory
tests described. Through i2b2 queries I answered which codes were used in the EHR
and populated in the data warehouse. In consultation with James R. Campbell, MD, a
clinician and the institution’s terminologist, I ensured the codes I selected were
comprehensive and accurate. Once defined, these codes are shareable to any other site
desiring to replicate this or a similar study.
With standard codes in place, clinical data needed to be queried. While feasibility
counts for the study were obtained using i2b2 queries, data extraction required SQL
scripts to be written. Scripts were designed to identify the inpatient encounters of
interest, extract raw values for each of the necessary laboratory values, and calculate a
total score for each patient encounter. These scripts rely on standard terminologies and
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the i2b2 star schema data structure. They may readily be shared and adapted to other
sties who have implemented i2b2. In this way, this work may be re-used to facilitate
future replication.
Finally, with standard definitions in place and re-usable SQL scripts developed to
extract the data, the methods described in the study were replicated. Using R, a
precision recall as well as a receiver operator characteristic curve were created to
assess the predictive value of the total calculated score. This demonstrated similar
predictive power to what was described by the original study. In addition, multiple logistic
regression analysis was used to develop a new risk model using the same variables.
This model demonstrated similar predictive power to the original model.
Through the assessment described above, I demonstrated that a replication
attempt using the Tabak mortality risk model was possible. With the data extraction and
statistical analysis performed in R, I demonstrated replication of the study. The published
results were validated by this work and extended to a novel population. Future
replication at other sites is possible as standard definitions are now in place and data
extraction and analysis code is available for re-use.
Creating a Computable Phenotype for Pregnancy
In this dissertation I described initial steps toward creating a computable
phenotype for pregnancy status based on data commonly recorded within an EHR in the
course of typical care. Based on a number of queries from participation in a distributed
research network which had variable or poor definitions of pregnancy, the need for a
consistent and interoperable phenotype was recognized. While fully-defining, validating,
and sharing such a phenotype will take a greater investment of resources and input from
a variety of experts, this dissertation demonstrates a series of variables for incorporation
into a fully-defined phenotype. Through frequency analysis, expert input, and statistical
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analysis, a number of data elements were seen to correlate with being pregnant. This
dissertation provides definitions for these data elements using standard terminologies
(LOINC, SNOMED-CT, CPT, and ICD*) to enable interoperability of the definition. This
work also demonstrates how these variables may be extracted from the EHR as well as
how to identify temporal bounds for pregnancy from the EHR.
Incorporating Location-Based Data into the i2b2 Infrastructure
As with the necessity to develop a computable phenotype for pregnancy, the
need for a means of incorporating queryable location-based data into the clinical
research data warehouse stemmed from working with other studies. As described
above, Amarasingham’s risk model for readmission in heart failure patients requires
socioeconomic variables available within the U.S. Census. While many studies rely on
these data, the novel contribution of the results presented herein is a demonstration of a
replicable means of incorporating these data into an i2b2 infrastructure in a de-identified
data warehouse.
Geocoding has greatly advanced in recent years and there are countless
approaches to translating addresses into longitude and latitude and later linking this to
census data. One important element of the approach taken in this dissertation is the
geocoding was all done in house. Patient data remained on a secure server, never
requiring a third party or any data transfer which may increase the risk of exposing PHI.
While enhancements to geocoding are beyond the scope of this dissertation,
demonstrating an approach to securely geocode patient data in an IRB approved
manner was critical. Of note, alternative geocoding processes may readily be
implemented into the pipeline described in this dissertation.
Beyond demonstrating a secure approach to geocoding patient addresses, this
dissertation demonstrates a method for maintaining HIPAA compliance while exposing
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patient neighborhood socioeconomic status. HIPAA geographic requirements mandate
de-identification ensures that a patient’s geographic location may not be identified to a
catchment area with fewer than 20,000 people. We de-identified the data in a number of
ways. First, rather than publishing raw data from the ACS, standardized data and
summary indices were displayed in the i2b2 environment for researchers. As we publish
our methods and as other researchers could potentially work back to which blockgroup a
standardized variable originated in, we also truncated these published variables to
ensure a sufficient number of blockgroups are identified with any given published result.
In this way, only a group of blockgroups could ever be identified for a single patient,
ensuring at least 20,000 people were located in this geographic region.
To demonstrate the validity of this approach, we replicated a well-published
result of ED utilization. Using i2b2 queries for feasibility queries and SQL scripts for data
extraction, we demonstrated increased ED utilization based on residence in an area with
below average socioeconomic status. While this result is not novel, our work serves to
validate the result on a novel population. Furthermore, our results demonstrate the
efficacy of our approach to incorporating socioeconomic variables in a fully-deidentified
i2b2 data warehouse. Our approach is both efficacious and replicable.

Assessment of Hypothesis
The methods and results presented in this dissertation formed to evaluate the
hypothesis that the data and infrastructure of UNMC’s clinical research data warehouse
were sufficient to allow for replication of risk models and other clinical studies. As was
demonstrated early on, this hypothesis was rejected and required modifications. Early
work demonstrated inability to replicate studies was due to two major categories. First,
insufficiency of extracted data types in the CRDW, and, second, insufficiency of
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published methods and analyses to allow any site to replicate the study. The first
category led to the work toward developing a shareable, computable phenotype for
pregnancy and the process of incorporating socioeconomic variables from the census
into the data warehouse.
From the results described in this dissertation, a refined hypothesis that may
undergo continued testing is the CRDW infrastructure is sufficient to allow replication of
studies publishing clear methods and analyses. Some studies may require investment of
resources to extract additional clinical variables or link to extra-EHR data sources. The
assessment pattern described herein allows rapid identification of the replicability of a
study and identification of any missing variables requiring ETL development. In this way,
if a study may be replicable, additional data elements can be prioritized in the extraction
workflow.

Generalizability of the Results
The results documented in this dissertation are not without limitations. This work
was done in a clinical data research warehouse based on EHR data with some
transformations. These data were standardized to ONC recommended vocabularies,
either within the EHR or after extraction. In addition, these data were de-identified during
extraction, precluding incorporation of some identifying variables per HIPAA guidelines.
Finally, these data were stored in a form to foster interoperability via i2b2 as well as the
PCORnet CDM. The standardization made the data survey for required elements much
simpler. The methods described herein to assess the utility of a CRDW for replication of
a study may be more challenging to employ without standard vocabularies in place.
The results of replicating the risk model for in-hospital mortality are expected to
be highly generalizable. With the methods available, the specific variables well-defined,
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and the model validated on two independent hospital environments, other sites with a
typical hospital census should find high utility in the model. Generalizability could be
further validated by evaluating the mode’s performance across the GPC or all of
PCORnet’s DRNs.
The methods and results reported regarding incorporating location-based data
into a de-identified clinical data warehouse should also be generalizable. The ED
utilization result was validated in a novel population with novel calculation of
socioeconomic status. As with the risk models reported on, further validation and
generalizability may be achieved if this hypothesis were tested across a DRN rather than
at a single site. The methods to incorporate and use these data were designed to be
portable and reproducible. Ideally, other sites could implement this workflow and have
queryable variables in a de-identified i2b2 data warehouse.

Future Work
The results and methods presented in this dissertation facilitate both immediate
next steps for research and long-term expansions of these concepts. Future research is
possible focusing on three distinct areas. First, further validating the risk models
described herein as well as additional risk models. Next, continuing the development of
a computable phenotype for pregnancy status and sharing this phenotype. Finally,
incorporating and utilizing additional location-based variables from the ACS into the deidentified i2b2 data warehouse.
Future Research Replicating Risk Models and Observational Studies
In-hospital Mortality Model
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First, the risk model for in-hospital mortality may be further validated and used as
a test case for replication research across a distributed research network. I
demonstrated a means of assessing the replicability of a study at a single site. I also
validated this previously published risk model. With similar methods, an assessment of
the replicability of this model across the GPC is possible. Shared i2b2 queries or SQL
may be minimally modified to survey other sites to ensure data volume and variety are
queryable relative to this risk model. Independent models could be constructed at each
site, or, with IRB approval, de-identified encounter level data could be analyzed at a
central site to test the validity of the model on a larger population covering much of the
Midwest. While greater adaptation would be required, SAS scripts or SQL could be
made to query the PCORnet CDM. If a data survey indicated the necessary information
is currently populated in the CDM, any participating site across the country could
execute the queries and the model could be replicated at dozens of sites.
Potential Problem of Heterogeneity
Attempting to replicate risk models and observational studies across diverse
distributed research networks offers advantages of large sample size and a more
diverse study cohort. However, as described earlier, there is evidence this may introduce
bias due to the heterogeneity of the databases and environments being combined. One
area of necessary future research beyond the scope of this dissertation is to determine if
bias is introduced from pooling diverse data sets. If so, does this significantly affect the
outcomes of federated queries? Will pooling the data across many sites mask individual
variations in results, or, does conforming to the common data model allow the same
results to be observed with greater statistical significance?
Higgins et al. proposed a means to increase the efficacy of meta-analyses, taking
into account the potential heterogeneity of studies being included 161 . While this is
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certainly valuable and will add credence to the conclusions of meta-analyses, further
efforts to provide a means to validate the results of collaborative studies from various
medical centers is needed to ensure individual variation is not simply being averaged
and true results lost. Madigan et al performed such a study in the OMOP DRN.
Attempting to replicate that analysis across the GPC or across PCORnet will provide
valuable data about potential bias. The results of such an analysis will have significant
impact on future use of data from large networks.
Additional Study Replication
The work presented in this dissertation represented a survey of a series of risk
models and efforts to replicate only two of them. Countless risk models and
observational studies have been published while very few have been replicated or
validated. Applying the principles outlined in this dissertation will facilitate a researcher’s
effort to determine if a study is replicable and what resource investment is required to
allow replication at any site or across a network. This process may be followed for
specific populations, such as those with a given disease, or for a variety of risk models
ranging from mortality to other outcomes. Such replication studies will direct resource
utilization in incorporating further data into research data warehouses as well as identify
valid risk models that may be incorporated into an operational EHR for CDS.
Future Research Developing a Computable Phenotype for Pregnancy Status
Temporal Variable Definitions
The results described in this dissertation represent the foundation for future
research in developing a computable phenotype for pregnancy status. An important
initial next step is to define the temporal relevance of the variables described. One
challenging element of identifying pregnancy status is its transient nature. Recognizing a
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patient was pregnant two years ago has very little baring on her current pregnancy
status. In like manner, a positive pregnancy test from many months ago may be
meaningless for the patient today. Each of the variables described in this dissertation will
need to have a temporal window associated with it. From the date of the finding, how far
along can the pregnancy be and how much longer would the pregnancy be expected to
last? In this way, rather than a single point in time, each variable will have a window
wherein pregnancy is more likely.
Multiple Logistic Regression Modelling
With the variables defined temporally, a multiple logistic modelling approach may
be taken to create a predictive model. The patients identified in this dissertation with
well-defined temporal bounds on pregnancy episodes may be randomly divided into a
training and a test group. Age-matched non-pregnant controls may also be included.
Further chart review may be required to ensure pregnancy status of both groups.
Sampling may occur at various time points during the year of interest. At each time point,
the pregnancy status of each patient will be identified and the predictive model
computed. With a model in place, it can be evaluated using the test population.
Evaluation and Validation at Novel Sites
With a predictive model developed at UNMC, efforts may be made to replicate
and validate this model at additional sites. The first step in this process will be to survey
other sites to ascertain what proportion of the variables identified are commonly
available. ETLs for obtaining these data may also be shared as necessary. If sites are
able to extract the necessary data elements, the predictive model may be shared and
assessed against novel patient populations. IRB approval for chart reviews at each site
may be necessary to validate the results. The data survey and model testing may be
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done across the GPC where federated queries are supported. To enable testing this
model within PCORnet, an evaluation of the variables in light of the CDM would be
necessary. If the CDM has enough data variety to encompass all elements of the model,
federated queries could be generated and shared with participating sites. Validation
across many sites would allow for refinement of the model and development of a
shareable computable phenotype suitable for consistent incorporation into future studies.
Future Research Incorporating Location-based Data into the i2b2 Infrastructure
Incorporating Additional Variables in a Standardized Fashion
As described in this dissertation, some risk models incorporate data extracted
from sources beyond the EHR. I demonstrated a means of coupling ACS data with
clinical data within a de-identified i2b2 infrastructure. Further work is required to
instantiate additional variables in a standardized fashion. The approach of extraction of
data, linking to patient data, and de-identification may be applied to any single ACS
variable or combination of variables to compute indices for socioeconomic status. To
facilitate interoperability a standard ontology may be developed to identify which ACS
variable is being incorporated. While the ACS has an identifiable code for each data
broad element (percent unemployment), each variable within the ACS is often reported
for different subsets of the population (i.e. percent unemployment for males, percent
unemployment for females). For this reason, it is insufficient to identify the variable in the
database with only the ACS identifier as this may represent dozens of values.
Developing a standard approach is further hampered as ACS values may be used to
compute novel values more meaningful for research. Additionally, as demonstrated
herein, these computed values may be combined to calculate indices or standardized for
a population of interest. Input from terminologists, epidemiologists, and clinical
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researchers may guide the development of a standard ontology for incorporating ACS
variables into a clinical data research warehouse.
Linking Address Changes with Appropriate Socioeconomic Data
Along with a standard approach to incorporating additional ACS variables,
developing an approach to deal with address changes and updated ACS data is
imperative. The ACS is updated on an annual basis and reports data for a five-year
period at the block group level. Patients may move one or more times within the
catchment area of an academic medical center. The relation between socioeconomic
variables and clinical outcomes may be identified more accurately if patients are
assigned to the appropriate date range of data for their location during that period. This
is a two-fold effort. First, a patient’s location may be stored as a fact with a start date and
an end date. Any changes in location should be mapped to a new block group with
potential changes in socioeconomic status variables. Next, the temporal nature of a
patient’s location should be linked to the appropriate ACS data set. This is important as
areas change over time and as block group boundaries change over time. Mapping a
patient’s location to the most accurate data will facilitate drawing meaningful clinical
conclusions.
Utilizing Included Variables and Indices for Research
As the geocoding process becomes more refined and as additional variables and
indices from the ACS are incorporated with clinical data, clinical researchers will have
access to extra-EHR data shown to have a major impact on health outcomes.
Development of novel as well as refinement of existing socioeconomic indices will be
facilitated. A better understanding of elements impacting a patient’s clinical outcomes
may be developed. With the ability to query a plethora of variables in a de-identified
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database, the variables with the greatest clinical relevance may be identified. These data
may direct data collection within the clinical environment to describe a patients
socioeconomic status and the potential for interventions. In this way, data on a patient’s
neighborhood extracted from the census may be supplemented by a subset of data
offered by the patient.

Conclusions
The data and methods presented in this dissertation represent a step toward
facilitating replication in clinical research. I have presented both an approach for
evaluating a study and a data set for replication efforts as well as laid the groundwork for
filling in commonly missing elements. Further research is needed in many areas to build
on the conclusions drawn and to fully develop a computable phenotype for pregnancy
status. The approach to replicability evaluation as well as the pipeline for incorporating
socioeconomic data into a de-identified data warehouse may be shared and employed at
novel sites and across distributed research networks. With the incorporation of extraEHR data in a queryable fashion along with an approach to using EHR data for
replication of risk models and observational studies, additional studies may be validated
and extended to novel populations. In this way, the data driving clinical guidelines and
practices may be used with greater confidence, hopefully leading to improved patient
care.
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APPENDIX A - LOCAL INSTRUCTIONS FOR RUNNING
FEDERATED SAS QUERIES FROM PCORNET

SAS Based Queries
1. Create trac ticket:
o Attach zipped query package
o Assign to Respond to Queries milestone
o Paste name of query and description into trac ticket
o Assign to honest broker to run SAS
2. Load query package into SAS:
o Download and extract zipped query package
o Load file structure into DEID /d02/queries/BJG/PopMedNet_Queries
▪ This may be done manually in SAS Studio, OR,
▪ This may be done with WinSCP
3. Update the SAS script:
o In SAS Studio, in the query package > sasprograms folder, open the
master.sas file
o d02 folder is popmednet work
o Update user inputs:
▪ DMID = C4
▪ SiteID = UN
▪ Threshold = 11
▪ Attrition Table = Y
▪ All data tables in lowercase
▪ indata = '/d02/queries/data/' (Most current, approved CDM
datasets (Instructions to build SAS datasets)
▪ infolder =
/d02/queries/BJG/PopMedNet_Queries/QUERY_FOLDER/infolder
/
▪ drnoc =
/d02/queries/BJG/PopMedNet_Queries/QUERY_FOLDER/drnoc/
▪ dmlocal =
/d02/queries/BJG/PopMedNet_Queries/QUERY_FOLDER/dmlocal
/
▪ sasmacr=
/d02/queries/BJG/PopMedNet_Queries/QUERY_FOLDER/infolder
/macros/
▪ May be more or less user inputs to define
o Save changes to master.sas
4. Run query:
o With master.sas open, hit run button (running man icon at top of
screen)
o When complete, review the log to check for errors or warnings
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o

Review the workplan and ensure the dmlocal and drnoc folders have
all expected files created

5. Share results:
o Either manually or using WinSCP, extract all files from the drnoc folder
for the query
o Zip files in folder with the query name and attach to the trac ticket
o Assign trac ticket to jmcclay with next task for data oversight
committee review
o Once data oversight committee has approved the request, results may
be submitted via PopMedNet adn the trac ticket closed
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APPENDIX B – HEART FAILURE RISK MODEL SAMPLE I2B2
QUERY
insert into BlueHeronData.QUERY_GLOBAL_TEMP (encounter_num, patient_num,
panel_count)
with t as (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.encounter_num,
f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like '\i2b2\Demographics\Marital Status\%')
group by f.encounter_num , f.patient_num
)
select t.encounter_num, t.patient_num, 0 as panel_count from t
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =1 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 0 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.encounter_num,
f.patient_num
from BlueHeronData.observation_fact f
where
f.CONCEPT_CD IN (select CONCEPT_CD from
BlueHeronData.CONCEPT_DIMENSION where CONCEPT_PATH LIKE
'\i2b2\Procedures\cpt?_codes\99201-99499\99221-99239\99221-99223\%' {ESCAPE '?'}
)
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2016 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.encounter_num , f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num and
BlueHeronData.QUERY_GLOBAL_TEMP.encounter_num = t.encounter_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =1 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 0 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.encounter_num,
f.patient_num
from BlueHeronData.observation_fact f
where
f.CONCEPT_CD IN (select CONCEPT_CD from
BlueHeronData.CONCEPT_DIMENSION where CONCEPT_PATH LIKE
'\i2b2\Procedures\cpt?_codes\99201-99499\99221-99239\99231-99239\%' {ESCAPE '?'}
)
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2016 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.encounter_num , f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num and
BlueHeronData.QUERY_GLOBAL_TEMP.encounter_num = t.encounter_num )
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<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A8342219\A8345316\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A8342219\A8345316\402.
11\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A8342219\A8345317\402.
91\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
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'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A10863171\4
04.01\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A10863171\4
04.03\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8345328\40
4.11\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8345328\40
4.13\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
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update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8359867\40
4.91\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8359867\40
4.93\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\A19383986\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.4\%')
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AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.5\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.7\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.8\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where

139

f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.9\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 1 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339687\%')
AND ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS')
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )
group by f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count = -1 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 2 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.encounter_num,
f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path LIKE '\ICD10CM?_2015AA\(Z00-Z99) Fact~rmj9\(Z40-Z53)
Enco~eivf\(Z53) Persons~y7wq\(Z53.2) Proced~esd4\(Z53.21) Proce~0aof\%' {ESCAPE
'?'} )
group by f.encounter_num , f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num and
BlueHeronData.QUERY_GLOBAL_TEMP.encounter_num = t.encounter_num )
<*>
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count = -1 where
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count = 2 and exists ( select 1 from (
select /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.encounter_num,
f.patient_num
from BlueHeronData.observation_fact f
where
f.concept_cd IN (select concept_cd from BlueHeronData.concept_dimension where
concept_path like '\i2b2\DRG\SURG\Orthopedics\BILATERAL OR MULTIPLE MAJOR
JOINT PROCS OF LOWER EXTREMITY W MCC\%')
group by f.encounter_num , f.patient_num ) t where
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num and
BlueHeronData.QUERY_GLOBAL_TEMP.encounter_num = t.encounter_num )
<*>
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insert into BlueHeronData.DX ( patient_num , encounter_num ) select * from ( select
distinct patient_num , encounter_num from BlueHeronData.QUERY_GLOBAL_TEMP
where panel_count = 2 ) q

141

APPENDIX C – READMISSION RISK MODEL SQL SCRIPT
CREATE OR REPLACE PROCEDURE "JGARDNER"."TABAK_SCORING_PROC"
AS
my_date date;
rec_count int;
i int;
sql_string varchar2(32767);
table_name varchar2(100);
lab_mapping_table varchar2(100):='LAB_LOINC_MAPPING'; --change cursor if
changing table name
missing_value_threshold integer:=30; --Number of missing lab values allowed to
have Tabak score calculated
lab_count_variable integer;
percent_of_encs number(10,7);
total_encs integer;
cursor sel_cur is
select distinct(LAB_LABEL)
from JGARDNER.LAB_LOINC_MAPPING;
sel_rec sel_cur%ROWTYPE;

BEGIN
select sysdate into my_date from dual;
DBMS_OUTPUT.PUT_LINE('***Start of TABAK_SCORING_PROC');
dbms_output.PUT_LINE('***Creating '||lab_mapping_table||' table at ' ||
my_date);
/* Ensure table is created prior to running procedure.
--CREATE LAB_LOINC_MAPPING TABLE:
sql_string := q'[
CREATE TABLE JGARDNER.]'||lab_mapping_table||q'[
(
LAB_LABEL VARCHAR2(150),
LAB_LOINC VARCHAR2(13),
REFERENCE_LOW NUMBER(6,2),
REFERENCE_HIGH NUMBER(6,2))
]';
DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
sql_string:=q'[CREATE TABLE JGARDNER.TABAK_SUMMARY
(LAB_LABEL VARCHAR2(50),
ENCOUNTERS INTEGER,
PERCENT_OF_ENCOUNTERS NUMBER(10,7))];
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
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*/
--TRUNCATE TABAK_SUMMARY TABLE:
execute immediate 'TRUNCATE TABLE JGARDNER.TABAK_SUMMARY';
--TRUNCATE LAB_MAPPING_TABLE:
execute immediate 'TRUNCATE TABLE JGARDNER.'||lab_mapping_table;
--INSERT VALUES INTO LAB_LOINC_MAPPING TABLE:
sql_string := q'[INSERT ALL
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('ALBUMIN', 'LOINC:1751-7', 3.3, NULL)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('ALBUMIN', 'LOINC:2862-1', 3.3, NULL)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('AST', 'LOINC:1920-8', NULL, 30)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('AST', 'LOINC:88112-8', NULL, 30)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('AST', 'LOINC:30239-8', NULL, 30)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('TOTAL_BILIRUBIN', 'LOINC:1975-2', NULL, 1.4)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('TOTAL_BILIRUBIN', 'LOINC:42719-5', NULL, 1.4)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CALCIUM', 'LOINC:17861-6', 8.5, 10.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CALCIUM', 'LOINC:17863-2', 8.5, 10.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CALCIUM','LOINC:17864-0', 8.5, 10.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CALCIUM','LOINC:42567-8', 8.5, 10.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CALCIUM', 'LOINC:57333-7', 8.5, 10.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CALCIUM', 'LOINC:34907-6', 8.5, 10.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CREATININE', 'LOINC:2160-0', NULL, 2)
INTO JGARDNER.]'||lab_mapping_table||q'[
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(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PRO_BNP', 'LOINC:71425-3', NULL, 8000)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PRO_BNP', 'LOINC:33762-6', NULL, 8000)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PRO_BNP', 'LOINC:83107-3', NULL, 8000)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BNP', 'LOINC:42637-9', NULL, 1200)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BNP', 'LOINC:30934-4', NULL, 1200)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:2339-0', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:2340-8', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:2345-7', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:14749-6', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:1558-6', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:14771-0', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:15074-8', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:32016-8', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:1556-0', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('GLUCOSE', 'LOINC:27353-2', 71, 135)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('POTASSIUM', 'LOINC:75940-7', 3.3, 4.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('POTASSIUM', 'LOINC:22760-3', 3.3, 4.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('POTASSIUM', 'LOINC:42569-4', 3.3, 4.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
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(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('POTASSIUM', 'LOINC:77142-8', 3.3, 4.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('POTASSIUM', 'LOINC:51618-7', 3.3, 4.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('POTASSIUM', 'LOINC:2823-3', 3.3, 4.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('POTASSIUM', 'LOINC:6298-4', 3.3, 4.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('SODIUM', 'LOINC:2951-2', 136, 143)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('SODIUM','LOINC:2947-0', 136, 143)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('SODIUM','LOINC:42570-2', 136, 143)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('SODIUM','LOINC:77139-4', 136, 143)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('ALKALINE_PHOS','LOINC:1783-0', NULL, 115)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('ALKALINE_PHOS','LOINC:15148-0', NULL, 115)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('ALKALINE_PHOS','LOINC:6768-6', NULL, 115)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BUN','LOINC:3094-0', NULL, 25)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BUN','LOINC:6299-2', NULL, 25)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BUN','LOINC:12964-3', NULL, 25)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BUN','LOINC:35234-4', NULL, 25)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PH_ARTERIAL','LOINC:2744-1', 7.36, 7.48)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PH_ARTERIAL','LOINC:33254-4', 7.36, 7.48)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PO2_ARTERIAL','LOINC:2703-7', 55.1, 140)
INTO JGARDNER.]'||lab_mapping_table||q'[
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(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PO2_ARTERIAL','LOINC:19255-9', 55.1, 140)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PCO2_ARTERIAL','LOINC:2019-8', 36, 50)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PCO2_ARTERIAL','LOINC:32771-8', 36, 50)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PTT','LOINC:3173-2', 23, 45)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PTT','LOINC:14979-9', 23, 45)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PTT','LOINC:40100-0', 23, 45)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PT_INR','LOINC:6301-6', NULL, 1.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PT_INR', 'LOINC:34714-6', NULL, 1.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PT_INR', 'LOINC:38875-1', NULL, 1.1)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BANDS', 'LOINC:26508-2', NULL, 6)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BANDS', 'LOINC:13354-6', NULL, 6)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BANDS', 'LOINC:26510-8', NULL, 6)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BANDS', 'LOINC:764-1', NULL, 6)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('BANDS', 'LOINC:35332-6', NULL, 6)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('HB', 'LOINC:718-7', 11, 18)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('HB', 'LOINC:721-1', 11, 18)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PLATELETS', 'LOINC:26515-7', 150.1, 420)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('PLATELETS', 'LOINC:777-3', 150.1, 420)
INTO JGARDNER.]'||lab_mapping_table||q'[
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(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('WBC', 'LOINC:6690-2', 4.4, 10.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('WBC', 'LOINC:26464-8', 4.4, 10.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('WBC', 'LOINC:751-8', 4.4, 10.9)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('TROPONIN_1', 'LOINC:16255-2', NULL, 0.04)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('TROPONIN_1', 'LOINC:42757-5', NULL, 0.04)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('TROPONIN_1', 'LOINC:10839-9', NULL, 0.04)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('TROPONIN_1', 'LOINC:49563-0', NULL, 0.04)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CPK_MB', 'LOINC:13969-1', NULL, 2)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CPK_MB', 'LOINC:83092-7', NULL, 2)
INTO JGARDNER.]'||lab_mapping_table||q'[
(LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH)
VALUES ('CPK_MB', 'LOINC:49551-5', NULL, 2)
SELECT * FROM DUAL
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;

--Create potential encounter table:
table_name:='TEMP_POTENTIAL_ENCS';
dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date);
drop_table(table_name);
sql_string := q'[
CREATE TABLE JGARDNER.]'||table_name||q'[ AS
SELECT VD.PATIENT_NUM, VD.ENCOUNTER_NUM, VD.START_DATE,
VD.DISCHARGE_DISPOSITION, VD.DISCHARGE_STATUS,
VD.END_DATE - VD.START_DATE AS LOS
FROM BLUEHERONDATA.VISIT_DIMENSION VD
WHERE VD.ENC_TYPE IN ('IP','EI')
AND VD.DISCHARGE_DISPOSITION IS NOT NULL
AND VD.DISCHARGE_STATUS IS NOT NULL
AND VD.DISCHARGE_STATUS != 'OT'
AND VD.DISCHARGE_DISPOSITION IN ('A','E')
AND VD.END_DATE BETWEEN
TO_DATE('1/1/2013','mm/dd/yyyy') AND
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TO_DATE('12/31/2017','mm/dd/yyyy')
--AND (END_DATE - START_DATE) > 1
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
--Count encounters
sql_string:=q'[select count(*)
from JGARDNER.TEMP_POTENTIAL_ENCS]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string into total_encs;

--Variables:
--1 Age (at start of encounter encounter)
--Create potential encounter table:
table_name:='TEMP_AGE_AT_ENCOUNTER';
dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date);
drop_table(table_name);
sql_string := q'[
CREATE TABLE JGARDNER.]'||table_name||q'[ AS
select PE.PATIENT_NUM, PE.ENCOUNTER_NUM,
round((PE.start_date - PD.birth_date)/365.25,1) AGE_AT_ENC
FROM BLUEHERONDATA.PATIENT_DIMENSION PD
JOIN JGARDNER.TEMP_POTENTIAL_ENCS PE
ON PD.PATIENT_NUM = PE.PATIENT_NUM
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;

--2 Gender:
table_name:='TEMP_PATIENT_GENDER';
dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date);
drop_table(table_name);
sql_string := q'[
CREATE TABLE JGARDNER.]'||table_name||q'[ AS
SELECT PE.PATIENT_NUM, PD.SEX_CD GENDER
FROM BLUEHERONDATA.PATIENT_DIMENSION PD
JOIN JGARDNER.TEMP_POTENTIAL_ENCS PE
ON PD.PATIENT_NUM = PE.PATIENT_NUM
WHERE PD.SEX_CD IN ('Female','Male')
GROUP BY PE.PATIENT_NUM, PD.SEX_CD
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
--LAB VALUES:
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open sel_cur;
loop
fetch sel_cur into sel_rec;
exit when sel_cur%NOTFOUND; -- no more items, all done
dbms_output.PUT_LINE('***Creating
JGARDNER.TEMP_'||sel_rec.LAB_LABEL||' table at ' || my_date);
table_name:='JGARDNER.TEMP_'||sel_rec.LAB_LABEL;
drop_table(table_name);
sql_string := q'[CREATE TABLE JGARDNER.TEMP_]'||sel_rec.LAB_LABEL||q'[
as
SELECT PATIENT_NUM, ENCOUNTER_NUM, START_DATE, CONCEPT_CD,
NVAL_NUM, UNITS_CD, LAB_LABEL
FROM
(SELECT PE.PATIENT_NUM, PE.ENCOUNTER_NUM, O.START_DATE,
O.CONCEPT_CD,
O.NVAL_NUM, O.UNITS_CD,
']'||sel_rec.LAB_LABEL||q'[' AS LAB_LABEL,
ROW_NUMBER() OVER (PARTITION BY O.ENCOUNTER_NUM
ORDER BY O.START_DATE ASC) R_NUM
FROM JGARDNER.TEMP_POTENTIAL_ENCS PE
LEFT JOIN BLUEHERONDATA.OBSERVATION_FACT O
ON PE.ENCOUNTER_NUM = O.ENCOUNTER_NUM
WHERE PE.LOS > 1 --Eliminate outpatient surgical
procedures
and CONCEPT_CD IN (select LAB_LOINC from
JGARDNER.]'||lab_mapping_table||q'[
where LAB_LABEL = ']'||sel_rec.LAB_LABEL||q'['))
WHERE R_NUM = 1
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
--Count table
sql_string:=q'[select count(*)
from JGARDNER.TEMP_]'||sel_rec.LAB_LABEL;
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string into lab_count_variable;
sql_string:=q'[select round((]'||to_char(lab_count_variable)||q'[/
]'||to_char(total_encs)||q'[)*100,7)
from dual]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string into percent_of_encs;
--Populate summary table
sql_string := q'[INSERT INTO JGARDNER.TABAK_SUMMARY
(LAB_LABEL, ENCOUNTERS, PERCENT_OF_ENCOUNTERS)
VALUES (']'||sel_rec.LAB_LABEL||q'[',
]'||to_char(lab_count_variable)||q'[,
]'||to_char(percent_of_encs)||q'[)
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
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end loop;
close sel_cur;
-- raw scoring:
table_name:='TEMP_TABAK_RAW_SCORE';
dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date);
drop_table(table_name);
sql_string := q'[
CREATE TABLE JGARDNER.]'||table_name||q'[ AS
SELECT PE.PATIENT_NUM, PE.ENCOUNTER_NUM, PE.START_DATE,
PE.DISCHARGE_DISPOSITION, PE.DISCHARGE_STATUS,
PE.LOS,
AAE.AGE_AT_ENC,
PG.GENDER,
TEMP_ALBUMIN.CONCEPT_CD ALBUMIN_CONCEPT_CD,
TEMP_ALBUMIN.NVAL_NUM ALBUMIN_NVAL_NUM,
TEMP_ALBUMIN.UNITS_CD ALBUMIN_UNITS_CD,
TEMP_AST.CONCEPT_CD AST_CONCEPT_CD,
TEMP_AST.NVAL_NUM AST_NVAL_NUM,
TEMP_AST.UNITS_CD AST_UNITS_CD,
TEMP_TOTAL_BILIRUBIN.CONCEPT_CD TOTAL_BILIRUBIN_CONCEPT_CD,
TEMP_TOTAL_BILIRUBIN.NVAL_NUM TOTAL_BILIRUBIN_NVAL_NUM,
TEMP_TOTAL_BILIRUBIN.UNITS_CD TOTAL_BILIRUBIN_UNITS_CD,
TEMP_CALCIUM.CONCEPT_CD CALCIUM_CONCEPT_CD,
TEMP_CALCIUM.NVAL_NUM CALCIUM_NVAL_NUM,
TEMP_CALCIUM.UNITS_CD CALCIUM_UNITS_CD,
TEMP_CREATININE.CONCEPT_CD CREATININE_CONCEPT_CD,
TEMP_CREATININE.NVAL_NUM CREATININE_NVAL_NUM,
TEMP_CREATININE.UNITS_CD CREATININE_UNITS_CD,
TEMP_PRO_BNP.CONCEPT_CD PRO_BNP_CONCEPT_CD,
TEMP_PRO_BNP.NVAL_NUM PRO_BNP_NVAL_NUM,
TEMP_PRO_BNP.UNITS_CD PRO_BNP_UNITS_CD,
TEMP_BNP.CONCEPT_CD BNP_CONCEPT_CD,
TEMP_BNP.NVAL_NUM BNP_NVAL_NUM,
TEMP_BNP.UNITS_CD BNP_UNITS_CD,
TEMP_GLUCOSE.CONCEPT_CD GLUCOSE_CONCEPT_CD,
TEMP_GLUCOSE.NVAL_NUM GLUCOSE_NVAL_NUM,
TEMP_GLUCOSE.UNITS_CD GLUCOSE_UNITS_CD,
TEMP_POTASSIUM.CONCEPT_CD POTASSIUM_CONCEPT_CD,
TEMP_POTASSIUM.NVAL_NUM POTASSIUM_NVAL_NUM,
TEMP_POTASSIUM.UNITS_CD POTASSIUM_UNITS_CD,
TEMP_SODIUM.CONCEPT_CD SODIUM_CONCEPT_CD,
TEMP_SODIUM.NVAL_NUM SODIUM_NVAL_NUM,
TEMP_SODIUM.UNITS_CD SODIUM_UNITS_CD,
TEMP_ALKALINE_PHOS.CONCEPT_CD ALKALINE_PHOS_CONCEPT_CD,
TEMP_ALKALINE_PHOS.NVAL_NUM ALKALINE_PHOS_NVAL_NUM,
TEMP_ALKALINE_PHOS.UNITS_CD ALKALINE_PHOS_UNITS_CD,
TEMP_BUN.CONCEPT_CD BUN_CONCEPT_CD,
TEMP_BUN.NVAL_NUM BUN_NVAL_NUM,
TEMP_BUN.UNITS_CD BUN_UNITS_CD,
TEMP_PH_ARTERIAL.CONCEPT_CD PH_ARTERIAL_CONCEPT_CD,
TEMP_PH_ARTERIAL.NVAL_NUM PH_ARTERIAL_NVAL_NUM,
TEMP_PH_ARTERIAL.UNITS_CD PH_ARTERIAL_UNITS_CD,
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TEMP_PO2_ARTERIAL.CONCEPT_CD PO2_ARTERIAL_CONCEPT_CD,
TEMP_PO2_ARTERIAL.NVAL_NUM PO2_ARTERIAL_NVAL_NUM,
TEMP_PO2_ARTERIAL.UNITS_CD PO2_ARTERIAL_UNITS_CD,
TEMP_PCO2_ARTERIAL.CONCEPT_CD PCO2_ARTERIAL_CONCEPT_CD,
TEMP_PCO2_ARTERIAL.NVAL_NUM PCO2_ARTERIAL_NVAL_NUM,
TEMP_PCO2_ARTERIAL.UNITS_CD PCO2_ARTERIAL_UNITS_CD,
TEMP_PTT.CONCEPT_CD PTT_CONCEPT_CD,
TEMP_PTT.NVAL_NUM PTT_NVAL_NUM,
TEMP_PTT.UNITS_CD PTT_UNITS_CD,
TEMP_PT_INR.CONCEPT_CD PT_INR_CONCEPT_CD,
TEMP_PT_INR.NVAL_NUM PT_INR_NVAL_NUM,
TEMP_PT_INR.UNITS_CD PT_INR_UNITS_CD,
TEMP_BANDS.CONCEPT_CD BANDS_CONCEPT_CD,
TEMP_BANDS.NVAL_NUM BANDS_NVAL_NUM,
TEMP_BANDS.UNITS_CD BANDS_UNITS_CD,
TEMP_HB.CONCEPT_CD HB_CONCEPT_CD,
TEMP_HB.NVAL_NUM HB_NVAL_NUM,
TEMP_HB.UNITS_CD HB_UNITS_CD,
TEMP_PLATELETS.CONCEPT_CD PLATELETS_CONCEPT_CD,
TEMP_PLATELETS.NVAL_NUM PLATELETS_NVAL_NUM,
TEMP_PLATELETS.UNITS_CD PLATELETS_UNITS_CD,
TEMP_WBC.CONCEPT_CD WBC_CONCEPT_CD,
TEMP_WBC.NVAL_NUM WBC_NVAL_NUM,
TEMP_WBC.UNITS_CD WBC_UNITS_CD,
COALESCE(TEMP_TROPONIN_1.CONCEPT_CD,TEMP_CPK_MB.CONCEPT_CD) AS
TROP_CPK_CONCEPT_CD,
COALESCE(TEMP_TROPONIN_1.NVAL_NUM,TEMP_CPK_MB.NVAL_NUM) AS
TROP_CPK_NVAL_NUM,
COALESCE(TEMP_TROPONIN_1.UNITS_CD,TEMP_CPK_MB.UNITS_CD) AS
TROP_CPK_UNITS_CD,
COALESCE(TEMP_TROPONIN_1.LAB_LABEL,TEMP_CPK_MB.LAB_LABEL) AS
TROP_CPK_LAB_LABEL,
30 AS TOTAL_LABS,
999 AS TOTAL_SCORE
FROM JGARDNER.TEMP_POTENTIAL_ENCS PE
LEFT JOIN TEMP_ALBUMIN
ON PE.ENCOUNTER_NUM = TEMP_ALBUMIN.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_ALBUMIN.PATIENT_NUM
LEFT JOIN TEMP_AST
ON PE.ENCOUNTER_NUM = TEMP_AST.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_AST.PATIENT_NUM
LEFT JOIN TEMP_TOTAL_BILIRUBIN
ON PE.ENCOUNTER_NUM = TEMP_TOTAL_BILIRUBIN.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_TOTAL_BILIRUBIN.PATIENT_NUM
LEFT JOIN TEMP_CALCIUM
ON PE.ENCOUNTER_NUM = TEMP_CALCIUM.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_CALCIUM.PATIENT_NUM
LEFT JOIN TEMP_CREATININE
ON PE.ENCOUNTER_NUM = TEMP_CREATININE.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_CREATININE.PATIENT_NUM
LEFT JOIN TEMP_PRO_BNP
ON PE.ENCOUNTER_NUM = TEMP_PRO_BNP.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_PRO_BNP.PATIENT_NUM
LEFT JOIN TEMP_BNP
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ON PE.ENCOUNTER_NUM = TEMP_BNP.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_BNP.PATIENT_NUM
LEFT JOIN TEMP_GLUCOSE
ON PE.ENCOUNTER_NUM = TEMP_GLUCOSE.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_GLUCOSE.PATIENT_NUM
LEFT JOIN TEMP_POTASSIUM
ON PE.ENCOUNTER_NUM = TEMP_POTASSIUM.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_POTASSIUM.PATIENT_NUM
LEFT JOIN TEMP_SODIUM
ON PE.ENCOUNTER_NUM = TEMP_SODIUM.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_SODIUM.PATIENT_NUM
LEFT JOIN TEMP_ALKALINE_PHOS
ON PE.ENCOUNTER_NUM = TEMP_ALKALINE_PHOS.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_ALKALINE_PHOS.PATIENT_NUM
LEFT JOIN TEMP_BUN
ON PE.ENCOUNTER_NUM = TEMP_BUN.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_BUN.PATIENT_NUM
LEFT JOIN TEMP_PH_ARTERIAL
ON PE.ENCOUNTER_NUM = TEMP_PH_ARTERIAL.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_PH_ARTERIAL.PATIENT_NUM
LEFT JOIN TEMP_PO2_ARTERIAL
ON PE.ENCOUNTER_NUM = TEMP_PO2_ARTERIAL.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_PO2_ARTERIAL.PATIENT_NUM
LEFT JOIN TEMP_PCO2_ARTERIAL
ON PE.ENCOUNTER_NUM = TEMP_PCO2_ARTERIAL.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_PCO2_ARTERIAL.PATIENT_NUM
LEFT JOIN TEMP_PTT
ON PE.ENCOUNTER_NUM = TEMP_PTT.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_PTT.PATIENT_NUM
LEFT JOIN TEMP_PT_INR
ON PE.ENCOUNTER_NUM = TEMP_PT_INR.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_PT_INR.PATIENT_NUM
LEFT JOIN TEMP_BANDS
ON PE.ENCOUNTER_NUM = TEMP_BANDS.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_BANDS.PATIENT_NUM
LEFT JOIN TEMP_HB
ON PE.ENCOUNTER_NUM = TEMP_HB.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_HB.PATIENT_NUM
LEFT JOIN TEMP_PLATELETS
ON PE.ENCOUNTER_NUM = TEMP_PLATELETS.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_PLATELETS.PATIENT_NUM
LEFT JOIN TEMP_WBC
ON PE.ENCOUNTER_NUM = TEMP_WBC.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_WBC.PATIENT_NUM
LEFT JOIN TEMP_TROPONIN_1
ON PE.ENCOUNTER_NUM = TEMP_TROPONIN_1.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_TROPONIN_1.PATIENT_NUM
LEFT JOIN TEMP_CPK_MB
ON PE.ENCOUNTER_NUM = TEMP_CPK_MB.ENCOUNTER_NUM
AND PE.PATIENT_NUM = TEMP_CPK_MB.PATIENT_NUM
JOIN TEMP_AGE_AT_ENCOUNTER AAE
ON PE.PATIENT_NUM = AAE.PATIENT_NUM
AND PE.ENCOUNTER_NUM = AAE.ENCOUNTER_NUM
LEFT JOIN TEMP_PATIENT_GENDER PG
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ON PE.PATIENT_NUM = PG.PATIENT_NUM
WHERE AAE.AGE_AT_ENC >= 18
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;

--Actual Tabak score
table_name:='TABAK_SCORE';
dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date);
drop_table(table_name);
sql_string := q'[
CREATE TABLE JGARDNER.]'||table_name||q'[ AS
SELECT --RS.PATIENT_NUM,
RS.ENCOUNTER_NUM, RS.DISCHARGE_DISPOSITION,
RS.DISCHARGE_STATUS, round(RS.LOS,2) LENGTH_OF_STAY,
trunc(RS.AGE_AT_ENC) AGE, RS.GENDER,
999 AS TABAK_TOTAL_SCORE,
CASE WHEN RS.ALBUMIN_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.AST_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.TOTAL_BILIRUBIN_NVAL_NUM IS NULL THEN 1 ELSE 0
END +
CASE WHEN RS.CALCIUM_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.CREATININE_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.PRO_BNP_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.BNP_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.GLUCOSE_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.POTASSIUM_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.SODIUM_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.ALKALINE_PHOS_NVAL_NUM IS NULL THEN 1 ELSE 0 END
+
CASE WHEN RS.BUN_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.PH_ARTERIAL_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.PO2_ARTERIAL_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.PCO2_ARTERIAL_NVAL_NUM IS NULL THEN 1 ELSE 0 END
+
CASE WHEN RS.PTT_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.PT_INR_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.BANDS_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.HB_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.PLATELETS_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.WBC_NVAL_NUM IS NULL THEN 1 ELSE 0 END +
CASE WHEN RS.TROP_CPK_NVAL_NUM IS NULL THEN 1 ELSE 0 END
NumberOfNullFields,
CASE WHEN RS.AGE_AT_ENC BETWEEN 18 AND 29 THEN 0
WHEN RS.AGE_AT_ENC BETWEEN 30 AND 34.9 THEN 3
WHEN RS.AGE_AT_ENC BETWEEN 35 AND 39.9 THEN 10
WHEN RS.AGE_AT_ENC BETWEEN 40 AND 44.9 THEN 13
WHEN RS.AGE_AT_ENC BETWEEN 45 AND 49.9 THEN 17
WHEN RS.AGE_AT_ENC BETWEEN 50 AND 54.9 THEN 20
WHEN RS.AGE_AT_ENC BETWEEN 55 AND 59.9 THEN 23
WHEN RS.AGE_AT_ENC BETWEEN 60 AND 64.9 THEN 25
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WHEN RS.AGE_AT_ENC BETWEEN 65 AND 69.9 THEN 27
WHEN RS.AGE_AT_ENC BETWEEN 70 AND 74.9 THEN 30
WHEN RS.AGE_AT_ENC BETWEEN 75 AND 79.9 THEN 32
WHEN RS.AGE_AT_ENC BETWEEN 80 AND 84.9 THEN 35
WHEN RS.AGE_AT_ENC BETWEEN 85 AND 89.9 THEN 38
WHEN RS.AGE_AT_ENC > 89.9 THEN 42
ELSE 0
END AGE_SCORE,
CASE WHEN RS.GENDER = 'Male' THEN 2
WHEN RS.GENDER = 'Female' THEN 0
ELSE 0
END GENDER_SCORE,
CASE WHEN ALBUMIN_NVAL_NUM <= 2.4 THEN 14
WHEN ALBUMIN_NVAL_NUM BETWEEN 2.5 AND 2.7 THEN 7
WHEN ALBUMIN_NVAL_NUM BETWEEN 2.8 AND 3 THEN 4
WHEN ALBUMIN_NVAL_NUM BETWEEN 3.1 AND 3.3 THEN 1
WHEN ALBUMIN_NVAL_NUM > 3.3 THEN 0
ELSE 0
END AS ALBUMIN_SCORE,
RS.ALBUMIN_NVAL_NUM,
CASE WHEN AST_NVAL_NUM <= 30 THEN 0
WHEN AST_NVAL_NUM BETWEEN 31 AND 40 THEN 2
WHEN AST_NVAL_NUM BETWEEN 41 AND 60 THEN 4
WHEN AST_NVAL_NUM BETWEEN 61 AND 100 THEN 6
WHEN AST_NVAL_NUM > 100 THEN 9
ELSE 0
END AS AST_SCORE,
RS.AST_NVAL_NUM,
CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM <= 1.4 THEN 0
WHEN TOTAL_BILIRUBIN_NVAL_NUM BETWEEN 1.5 AND 2 THEN 1
WHEN TOTAL_BILIRUBIN_NVAL_NUM > 2 THEN 4
ELSE 0
END AS TOTAL_BILIRUBIN_SCORE,
RS.TOTAL_BILIRUBIN_NVAL_NUM,
CASE WHEN CALCIUM_NVAL_NUM <= 7.9 THEN 4
WHEN CALCIUM_NVAL_NUM BETWEEN 8 AND 8.4 THEN 1
WHEN CALCIUM_NVAL_NUM BETWEEN 8.5 AND 10.1 THEN 0
WHEN CALCIUM_NVAL_NUM > 10.1 THEN 3
ELSE 0
END AS CALCIUM_SCORE,
RS.CALCIUM_NVAL_NUM,
CASE WHEN CREATININE_NVAL_NUM <=2 THEN 0
WHEN CREATININE_NVAL_NUM > 2 THEN 1
ELSE 0
END AS CREATININE_SCORE,
RS.CREATININE_NVAL_NUM,
CASE WHEN PRO_BNP_NVAL_NUM <= 8000 THEN 0
WHEN PRO_BNP_NVAL_NUM BETWEEN 8001 AND 18000 THEN 5
WHEN PRO_BNP_NVAL_NUM > 18000 THEN 10
ELSE 0
END AS PRO_BNP_SCORE,
RS.PRO_BNP_NVAL_NUM,
CASE WHEN BNP_NVAL_NUM <= 1200 THEN 0
WHEN BNP_NVAL_NUM BETWEEN 1201 AND 2400 THEN 2
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WHEN BNP_NVAL_NUM > 2400 THEN 4
ELSE 0
END AS BNP_SCORE,
RS.BNP_NVAL_NUM,
CASE WHEN GLUCOSE_NVAL_NUM <=70 THEN 7
WHEN GLUCOSE_NVAL_NUM BETWEEN 71 AND 135 THEN 0
WHEN GLUCOSE_NVAL_NUM BETWEEN 136 AND 165 THEN 2
WHEN GLUCOSE_NVAL_NUM > 165 THEN 5
ELSE 0
END AS GLUCOSE_SCORE,
RS.GLUCOSE_NVAL_NUM,
CASE WHEN POTASSIUM_NVAL_NUM <= 3.2 THEN 3
WHEN POTASSIUM_NVAL_NUM BETWEEN 3.3 AND 4.9 THEN 0
WHEN POTASSIUM_NVAL_NUM BETWEEN 5 AND 5.3 THEN 2
WHEN POTASSIUM_NVAL_NUM >5.3 THEN 3
ELSE 0
END AS POTASSIUM_SCORE,
RS.POTASSIUM_NVAL_NUM,
CASE WHEN SODIUM_NVAL_NUM <= 130
THEN 4
WHEN SODIUM_NVAL_NUM BETWEEN 131 AND 135 THEN 1
WHEN SODIUM_NVAL_NUM BETWEEN 136 AND 143 THEN 0
WHEN SODIUM_NVAL_NUM BETWEEN 144 AND 145 THEN 4
WHEN SODIUM_NVAL_NUM > 145 THEN 9
ELSE 0
END AS SODIUM_SCORE,
RS.SODIUM_NVAL_NUM,
CASE WHEN ALKALINE_PHOS_NVAL_NUM <= 115 THEN 0
WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 116 AND 220 THEN 2
WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 221 AND 630 THEN 5
WHEN ALKALINE_PHOS_NVAL_NUM >630 THEN 8
ELSE 0
END AS ALKALINE_PHOS_SCORE,
RS.ALKALINE_PHOS_NVAL_NUM,
CASE WHEN BUN_NVAL_NUM <= 25 THEN 0
WHEN BUN_NVAL_NUM BETWEEN 26 AND 30 THEN 4
WHEN BUN_NVAL_NUM BETWEEN 31 AND 40 THEN 6
WHEN BUN_NVAL_NUM BETWEEN 41 AND 55 THEN 8
WHEN BUN_NVAL_NUM >55 THEN 10
ELSE 0
END AS BUN_SCORE,
RS.BUN_NVAL_NUM,
CASE WHEN PH_ARTERIAL_NVAL_NUM <= 7.2 THEN 21
WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.21 AND 7.3 THEN 13
WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.31 AND 7.35 THEN 10
WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.36 AND 7.48 THEN 0
WHEN PH_ARTERIAL_NVAL_NUM >7.48 THEN 8
ELSE 0
END AS PH_ARTERIAL_SCORE,
RS.PH_ARTERIAL_NVAL_NUM,
CASE WHEN PO2_ARTERIAL_NVAL_NUM <= 50 THEN 12
WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 50.1 AND 55 THEN 9
WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 55.1 AND 140 THEN 0
WHEN PO2_ARTERIAL_NVAL_NUM > 140 THEN 12
ELSE 0

155

END AS PO2_ARTERIAL_SCORE,
RS.PO2_ARTERIAL_NVAL_NUM,
CASE WHEN PCO2_ARTERIAL_NVAL_NUM <=35 THEN 9
WHEN PCO2_ARTERIAL_NVAL_NUM BETWEEN 36 AND 50 THEN 0
WHEN PCO2_ARTERIAL_NVAL_NUM > 50 THEN 7
ELSE 0
END AS PCO2_ARTERIAL_SCORE,
RS.PCO2_ARTERIAL_NVAL_NUM,
CASE WHEN PTT_NVAL_NUM <= 22
THEN 3
WHEN PTT_NVAL_NUM BETWEEN 23 AND 45 THEN 0
WHEN PTT_NVAL_NUM BETWEEN 45.1 AND 55 THEN 3
WHEN PTT_NVAL_NUM > 55 THEN 4
ELSE 0
END AS PTT_SCORE,
RS.PTT_NVAL_NUM,
CASE WHEN PT_INR_NVAL_NUM <=1.1 THEN 0
WHEN PT_INR_NVAL_NUM BETWEEN 1.11 AND 1.4 THEN 4
WHEN PT_INR_NVAL_NUM BETWEEN 1.41 AND 2 THEN 7
WHEN PT_INR_NVAL_NUM BETWEEN 2.1 AND 5 THEN 5
WHEN PT_INR_NVAL_NUM > 5 THEN 8
ELSE 0
END AS PT_INR_SCORE,
RS.PT_INR_NVAL_NUM,
CASE WHEN BANDS_NVAL_NUM <=6 THEN 0
WHEN BANDS_NVAL_NUM BETWEEN 7 AND 13 THEN 6
WHEN BANDS_NVAL_NUM BETWEEN 14 AND 32 THEN 9
WHEN BANDS_NVAL_NUM > 32 THEN 12
ELSE 0
END AS BANDS_SCORE,
RS.BANDS_NVAL_NUM,
CASE WHEN HB_NVAL_NUM <=10 THEN 2
WHEN HB_NVAL_NUM BETWEEN 11 AND 18 THEN 0
WHEN HB_NVAL_NUM > 18 THEN 4
ELSE 0
END AS HB_SCORE,
RS.HB_NVAL_NUM,
CASE WHEN PLATELETS_NVAL_NUM <=115 THEN 10
WHEN PLATELETS_NVAL_NUM BETWEEN 115.1 AND 150 THEN 2
WHEN PLATELETS_NVAL_NUM BETWEEN 150.1 AND 420 THEN 0
WHEN PLATELETS_NVAL_NUM > 420 THEN 2
ELSE 0
END AS PLATELETS_SCORE,
RS.PLATELETS_NVAL_NUM,
CASE WHEN WBC_NVAL_NUM <=4.3 THEN 4
WHEN WBC_NVAL_NUM BETWEEN 4.4 AND 10.9 THEN 0
WHEN WBC_NVAL_NUM BETWEEN 11 AND 14.1 THEN 4
WHEN WBC_NVAL_NUM BETWEEN 14.2 AND 19.8 THEN 7
WHEN WBC_NVAL_NUM > 19.8 THEN 12
ELSE 0
END AS WBC_SCORE,
RS.WBC_NVAL_NUM,
CASE WHEN TROP_CPK_LAB_LABEL = 'TROPONIN_1'
AND TROP_CPK_NVAL_NUM <= 0.04 THEN 0
WHEN TROP_CPK_LAB_LABEL = 'TROPONIN_1'
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AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
WHEN TROP_CPK_LAB_LABEL =
AND TROP_CPK_NVAL_NUM
ELSE 0
END AS TROP_CPK_SCORE,
RS.TROP_CPK_NVAL_NUM,
RS.TROP_CPK_LAB_LABEL
FROM TEMP_TABAK_RAW_SCORE RS

BETWEEN 0.05 AND 0.1 THEN 2
'TROPONIN_1'
BETWEEN 0.11 AND 0.2 THEN 4
'TROPONIN_1'
BETWEEN 0.21 AND 0.3 THEN 8
'TROPONIN_1'
>0.3 THEN 13
'CPK_MB'
<= 2 THEN 0
'CPK_MB'
BETWEEN 3 AND 5 THEN 2
'CPK_MB'
BETWEEN 6 AND 10 THEN 4
'CPK_MB'
BETWEEN 11 AND 34 THEN 8
'CPK_MB'
> 34 THEN 13

]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted.');
sql_string:=q'[UPDATE JGARDNER.TABAK_SCORE
SET TABAK_TOTAL_SCORE = ALBUMIN_SCORE +
AST_SCORE +
TOTAL_BILIRUBIN_SCORE +
CALCIUM_SCORE +
CREATININE_SCORE +
PRO_BNP_SCORE +
BNP_SCORE +
GLUCOSE_SCORE +
POTASSIUM_SCORE +
SODIUM_SCORE +
ALKALINE_PHOS_SCORE +
BUN_SCORE +
PH_ARTERIAL_SCORE +
PO2_ARTERIAL_SCORE +
PCO2_ARTERIAL_SCORE +
PTT_SCORE +
PT_INR_SCORE +
BANDS_SCORE +
HB_SCORE +
PLATELETS_SCORE +
WBC_SCORE +
TROP_CPK_SCORE +
GENDER_SCORE +
AGE_SCORE
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]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;

--Add columns for binning with 1 = yes and 0 = no:
table_name:='TABAK_SCORE_BINS';
dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date);
drop_table(table_name);
sql_string := q'[
CREATE TABLE JGARDNER.]'||table_name||q'[ AS
SELECT TS.*,
CASE WHEN AGE BETWEEN 18 AND 29.9 THEN 1 ELSE 0 END AS AGE_LT_30,
CASE WHEN AGE BETWEEN 30 AND 34.9 THEN 1 ELSE 0 END AS AGE_30_34,
CASE WHEN AGE BETWEEN 35 AND 39.9 THEN 1 ELSE 0 END AS AGE_35_39,
CASE WHEN AGE BETWEEN 40 AND 44.9 THEN 1 ELSE 0 END AS AGE_40_44,
CASE WHEN AGE BETWEEN 45 AND 49.9 THEN 1 ELSE 0 END AS AGE_45_49,
CASE WHEN AGE BETWEEN 50 AND 54.9 THEN 1 ELSE 0 END AS AGE_50_54,
CASE WHEN AGE BETWEEN 55 AND 59.9 THEN 1 ELSE 0 END AS AGE_55_59,
CASE WHEN AGE BETWEEN 60 AND 64.9 THEN 1 ELSE 0 END AS AGE_60_64,
CASE WHEN AGE BETWEEN 65 AND 69.9 THEN 1 ELSE 0 END AS AGE_65_69,
CASE WHEN AGE BETWEEN 70 AND 74.9 THEN 1 ELSE 0 END AS AGE_70_74,
CASE WHEN AGE BETWEEN 75 AND 79.9 THEN 1 ELSE 0 END AS AGE_75_79,
CASE WHEN AGE BETWEEN 80 AND 84.9 THEN 1 ELSE 0 END AS AGE_80_84,
CASE WHEN AGE BETWEEN 85 AND 89.9 THEN 1 ELSE 0 END AS AGE_85_89,
CASE WHEN AGE > 89 THEN 1 ELSE 0 END AS AGE_GT_89,
CASE WHEN GENDER = 'Male' THEN 1 ELSE 0 END AS GENDER_M,
CASE WHEN GENDER = 'Female' THEN 1 ELSE 0 END AS GENDER_F,
CASE WHEN ALBUMIN_NVAL_NUM <= 2.4 THEN 1 ELSE 0 END AS
ALBUMIN_LE_24,
CASE WHEN ALBUMIN_NVAL_NUM BETWEEN 2.5 AND 2.7 THEN 1 ELSE 0 END
AS ALBUMIN_25_27,
CASE WHEN ALBUMIN_NVAL_NUM BETWEEN 2.8 AND 3 THEN 1 ELSE 0 END AS
ALBUMIN_28_3,
CASE WHEN ALBUMIN_NVAL_NUM BETWEEN 3.1 AND 3.3 THEN 1 ELSE 0 END
AS ALBUMIN_31_33,
CASE WHEN ALBUMIN_NVAL_NUM > 3.3 THEN 1 ELSE 0 END AS
ALBUMIN_GT_33,
CASE WHEN AST_NVAL_NUM <= 30 THEN 1 ELSE 0 END AS AST_LE_30,
CASE WHEN AST_NVAL_NUM BETWEEN 31 AND 40 THEN 1 ELSE 0 END AS
AST_31_40,
CASE WHEN AST_NVAL_NUM BETWEEN 41 AND 60 THEN 1 ELSE 0 END AS
AST_41_60,
CASE WHEN AST_NVAL_NUM BETWEEN 61 AND 100 THEN 1 ELSE 0 END AS
AST_61_100,
CASE WHEN AST_NVAL_NUM > 100 THEN 1 ELSE 0 END AS AST_GT_100,
CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM <= 1.4 THEN 1 ELSE 0 END AS
TOT_BIL_LE_14,
CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM BETWEEN 1.5 AND 2 THEN 1 ELSE 0
END AS TOT_BIL_15_2,
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CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM > 2 THEN 1 ELSE 0 END AS
TOT_BIL_GT_2,
CASE WHEN CALCIUM_NVAL_NUM <= 7.9 THEN 1 ELSE 0 END AS
CALCIUM_LE_79,
CASE WHEN CALCIUM_NVAL_NUM BETWEEN 8 AND 8.4 THEN 1 ELSE 0 END AS
CALCIUM_8_84,
CASE WHEN CALCIUM_NVAL_NUM BETWEEN 8.5 AND 10.1 THEN 1 ELSE 0 END
AS CALCIUM_85_101,
CASE WHEN CALCIUM_NVAL_NUM > 10.1 THEN 1 ELSE 0 END AS
CALCIUM_GT_101,
CASE WHEN CREATININE_NVAL_NUM <=2 THEN 1 ELSE 0 END AS
CREATININE_LE_2,
CASE WHEN CREATININE_NVAL_NUM > 2 THEN 1 ELSE 0 END AS
CREATININE_GT_2,
CASE WHEN PRO_BNP_NVAL_NUM <= 8000 THEN 1 ELSE 0 END AS
PRO_BNP_LE_8000,
CASE WHEN PRO_BNP_NVAL_NUM BETWEEN 8001 AND 18000 THEN 1 ELSE 0
END AS PRO_BNP_8_18,
CASE WHEN PRO_BNP_NVAL_NUM > 18000 THEN 1 ELSE 0 END AS
PRO_BNP_GT_18,
CASE WHEN BNP_NVAL_NUM <= 1200 THEN 1 ELSE 0 END AS BNP_LE12,
CASE WHEN BNP_NVAL_NUM BETWEEN 1201 AND 2400 THEN 1 ELSE 0 END AS
BNP_12_24,
CASE WHEN BNP_NVAL_NUM > 2400 THEN 1 ELSE 0 END AS BNP_GT24,
CASE WHEN GLUCOSE_NVAL_NUM <=70 THEN 1 ELSE 0 END AS
GLUCOSE_LE_70,
CASE WHEN GLUCOSE_NVAL_NUM BETWEEN 71 AND 135 THEN 1 ELSE 0 END AS
GLUCOSE_71_135,
CASE WHEN GLUCOSE_NVAL_NUM BETWEEN 136 AND 165 THEN 1 ELSE 0 END
AS GLUCOSE_136_165,
CASE WHEN GLUCOSE_NVAL_NUM > 165 THEN 1 ELSE 0 END AS
GLUCOSE_GT_165,
CASE WHEN POTASSIUM_NVAL_NUM <= 3.2 THEN 1 ELSE 0 END AS
POTASSIUM_LE_32,
CASE WHEN POTASSIUM_NVAL_NUM BETWEEN 3.3 AND 4.9 THEN 1 ELSE 0 END
AS POTASSIUM_33_49,
CASE WHEN POTASSIUM_NVAL_NUM BETWEEN 5 AND 5.3 THEN 1 ELSE 0 END
AS POTASSIUM_5_53,
CASE WHEN POTASSIUM_NVAL_NUM >5.3 THEN 1 ELSE 0 END AS
POTASSIUM_GT_53,
CASE WHEN SODIUM_NVAL_NUM <= 130 THEN 1 ELSE 0 END AS
SODIUM_LE_130,
CASE WHEN SODIUM_NVAL_NUM BETWEEN 131 AND 135 THEN 1 ELSE 0 END AS
SODIUM_131_135,
CASE WHEN SODIUM_NVAL_NUM BETWEEN 136 AND 143 THEN 1 ELSE 0 END AS
SODIUM_136_143,
CASE WHEN SODIUM_NVAL_NUM BETWEEN 144 AND 145 THEN 1 ELSE 0 END AS
SODIUM_144_145,
CASE WHEN SODIUM_NVAL_NUM > 145 THEN 1 ELSE 0 END AS
SODIUM_GT_145,
CASE WHEN ALKALINE_PHOS_NVAL_NUM <= 115 THEN 1 ELSE 0 END AS
ALKALINE_PHOS_LE_115,
CASE WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 116 AND 220 THEN 1 ELSE 0
END AS ALKALINE_PHOS_116_220,
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CASE WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 221 AND 630 THEN 1 ELSE 0
END AS ALKALINE_PHOS_221_630,
CASE WHEN ALKALINE_PHOS_NVAL_NUM >630 THEN 1 ELSE 0 END AS
ALKALINE_PHOS_GT_630,
CASE WHEN BUN_NVAL_NUM <= 25 THEN 1 ELSE 0 END AS BUN_LE_25,
CASE WHEN BUN_NVAL_NUM BETWEEN 26 AND 30 THEN 1 ELSE 0 END AS
BUN_26_30,
CASE WHEN BUN_NVAL_NUM BETWEEN 31 AND 40 THEN 1 ELSE 0 END AS
BUN_31_40,
CASE WHEN BUN_NVAL_NUM BETWEEN 41 AND 55 THEN 1 ELSE 0 END AS
BUN_41_55,
CASE WHEN BUN_NVAL_NUM >55 THEN 1 ELSE 0 END AS BUN_GT_55,
CASE WHEN PH_ARTERIAL_NVAL_NUM <= 7.2 THEN 1 ELSE 0 END AS
PH_ARTERIAL_LE_72,
CASE WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.21 AND 7.3 THEN 1 ELSE 0
END AS PH_ARTERIAL_721_73,
CASE WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.31 AND 7.35 THEN 1 ELSE 0
END AS PH_ARTERIAL_731_735,
CASE WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.36 AND 7.48 THEN 1 ELSE 0
END AS PH_ARTERIAL_736_748,
CASE WHEN PH_ARTERIAL_NVAL_NUM >7.48 THEN 1 ELSE 0 END AS
PH_ARTERIAL_GT_748,
CASE WHEN PO2_ARTERIAL_NVAL_NUM <= 50 THEN 1 ELSE 0 END AS
PO2_ARTERIAL_LE_50,
CASE WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 50.1 AND 55 THEN 1 ELSE 0
END AS PO2_ARTERIAL_501_55,
CASE WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 55.1 AND 140 THEN 1 ELSE 0
END AS PO2_ARTERIAL_551_140,
CASE WHEN PO2_ARTERIAL_NVAL_NUM > 140 THEN 1 ELSE 0 END AS
PO2_ARTERIAL_GT_140,
CASE WHEN PCO2_ARTERIAL_NVAL_NUM <=35 THEN 1 ELSE 0 END AS
PCO2_ARTERIAL_LE_35,
CASE WHEN PCO2_ARTERIAL_NVAL_NUM BETWEEN 36 AND 50 THEN 1 ELSE 0
END AS PCO2_ARTERIAL_36_50,
CASE WHEN PCO2_ARTERIAL_NVAL_NUM > 50 THEN 1 ELSE 0 END AS
PCO2_ARTERIAL_GT_50,
CASE WHEN PTT_NVAL_NUM <= 22 THEN 1 ELSE 0 END AS PTT_LE_22,
CASE WHEN PTT_NVAL_NUM BETWEEN 23 AND 45 THEN 1 ELSE 0 END AS
PTT_23_45,
CASE WHEN PTT_NVAL_NUM BETWEEN 45.1 AND 55 THEN 1 ELSE 0 END AS
PTT_451_55,
CASE WHEN PTT_NVAL_NUM > 55 THEN 1 ELSE 0 END AS PTT_GT_55,
CASE WHEN PT_INR_NVAL_NUM <=1.1 THEN 1 ELSE 0 END AS PT_INR_LE_11,
CASE WHEN PT_INR_NVAL_NUM BETWEEN 1.11 AND 1.4 THEN 1 ELSE 0 END
AS PT_INR_111_14,
CASE WHEN PT_INR_NVAL_NUM BETWEEN 1.41 AND 2 THEN 1 ELSE 0 END AS
PT_INR_141_2,
CASE WHEN PT_INR_NVAL_NUM BETWEEN 2.1 AND 5 THEN 1 ELSE 0 END AS
PT_INR_21_5,
CASE WHEN PT_INR_NVAL_NUM > 5 THEN 1 ELSE 0 END AS PT_INR_GT_5,
CASE WHEN BANDS_NVAL_NUM <=6 THEN 1 ELSE 0 END AS BANDS_LE_6,
CASE WHEN BANDS_NVAL_NUM BETWEEN 7 AND 13 THEN 1 ELSE 0 END AS
BANDS_7_13,
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CASE WHEN BANDS_NVAL_NUM BETWEEN 14 AND 32 THEN 1 ELSE 0 END AS
BANDS_14_32,
CASE WHEN BANDS_NVAL_NUM > 32 THEN 1 ELSE 0 END AS BANDS_GT_32,
CASE WHEN HB_NVAL_NUM <=10 THEN 1 ELSE 0 END AS HB_LE_10,
CASE WHEN HB_NVAL_NUM BETWEEN 11 AND 18 THEN 1 ELSE 0 END AS
HB_11_18,
CASE WHEN HB_NVAL_NUM > 18 THEN 1 ELSE 0 END AS HB_GT_18,
CASE WHEN PLATELETS_NVAL_NUM <=115 THEN 1 ELSE 0 END AS
PLATELETS_LE_115,
CASE WHEN PLATELETS_NVAL_NUM BETWEEN 115.1 AND 150 THEN 1 ELSE 0
END AS PLATELETS_115_150,
CASE WHEN PLATELETS_NVAL_NUM BETWEEN 150.1 AND 420 THEN 1 ELSE 0
END AS PLATELETS_150_420,
CASE WHEN PLATELETS_NVAL_NUM > 420 THEN 1 ELSE 0 END AS
PLATELETS_GT_420,
CASE WHEN WBC_NVAL_NUM <=4.3 THEN 1 ELSE 0 END AS WBC_LE_43,
CASE WHEN WBC_NVAL_NUM BETWEEN 4.4 AND 10.9 THEN 1 ELSE 0 END AS
WBC_44_109,
CASE WHEN WBC_NVAL_NUM BETWEEN 11 AND 14.1 THEN 1 ELSE 0 END AS
WBC_11_141,
CASE WHEN WBC_NVAL_NUM BETWEEN 14.2 AND 19.8 THEN 1 ELSE 0 END AS
WBC_142_198,
CASE WHEN WBC_NVAL_NUM > 19.8 THEN 1 ELSE 0 END AS WBC_GT_198,
CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1'
AND TROP_CPK_NVAL_NUM <= 0.04)
OR
(TROP_CPK_LAB_LABEL = 'CPK_MB'
AND TROP_CPK_NVAL_NUM <= 2)
THEN 1 ELSE 0
END AS TROP_CPK_0,
CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1'
AND TROP_CPK_NVAL_NUM BETWEEN 0.05 AND 0.1)
OR
(TROP_CPK_LAB_LABEL = 'CPK_MB'
AND TROP_CPK_NVAL_NUM BETWEEN 3 AND 5)
THEN 1 ELSE 0
END AS TROP_CPK_2,
CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1'
AND TROP_CPK_NVAL_NUM BETWEEN 0.11 AND 0.2)
OR
(TROP_CPK_LAB_LABEL = 'CPK_MB'
AND TROP_CPK_NVAL_NUM BETWEEN 6 AND 10)
THEN 1 ELSE 0
END AS TROP_CPK_4,
CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1'
AND TROP_CPK_NVAL_NUM BETWEEN 0.21 AND 0.3)
OR
(TROP_CPK_LAB_LABEL = 'CPK_MB'
AND TROP_CPK_NVAL_NUM BETWEEN 11 AND 34)
THEN 1 ELSE 0
END AS TROP_CPK_8,
CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1'
AND TROP_CPK_NVAL_NUM >0.3)
OR
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(TROP_CPK_LAB_LABEL = 'CPK_MB'
AND TROP_CPK_NVAL_NUM > 34)
THEN 1 ELSE 0
END AS TROP_CPK_13
FROM JGARDNER.TABAK_SCORE TS
]';
--DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted.');
commit;
END;
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APPENDIX D – SQL SCRIPTS TO IDENTIFY PREGNANT
POPULATION AND ASSOCIATED VARIABLES
CREATE OR REPLACE PROCEDURE "JGARDNER"."PREG_FACT_TABLE_PROC_DEID"
AS
--nightherondata.visit_dimension_2 is date shifted
--heronloader.visit_dimension is NOT date shifted
--nightherondata.patient_dimension is NOT date shifted
--heronloader.patient_dimension is NOT date shifted
my_date date;
rec_count int;
i int;
sql_string varchar2(32767);
table_name varchar2(100);
temp_table varchar2(100);
window_start_date date;
window_end_date date;
BEGIN
DBMS_OUTPUT.put_line('Start of PREG_FACT_TABLE_PROC_DEID');
window_start_date:= to_date('2015/11/01', 'yyyy/mm/dd');
window_end_date:= to_date('2016/12/31', 'yyyy/mm/dd');
DBMS_OUTPUT.put_line('window_start_date = '|| window_start_date);
DBMS_OUTPUT.put_line('window_end_date = '|| window_end_date);
--DBMS_OUTPUT.put_line('window_start_date - 280 = '|| (window_start_date 270));
table_name:='JGARDNER.PREGNANCY_PROJECT_FACT_TABLE';
select sysdate into my_date from dual;
dbms_output.put_line('Creating '||table_name||' table at ' || my_date);
drop_table(table_name);

--Create table of PREGNANCY_PROJECT_FACT_TABLE:
temp_table:='JGARDNER.PREGNANCY_PROJECT_FACT_TABLE';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'# AS
WITH
VARIABLES(VARIABLE_CD, TAG) AS
--1. SUPERVISION OF PREGNANCY
(select concept_cd VARIABLE_CD, 'SUPERVISION OF PREGNANCY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(Z00-Z99) Fact~rmj9\(Z30Z39) Pers~awcc\(Z33) Pregnant state\'
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UNION
select concept_cd VARIABLE_CD, 'SUPERVISION OF PREGNANCY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(Z00-Z99) Fact~rmj9\(Z30Z39) Pers~awcc\(Z34) Encounte~f8zh\'
--2. COMPLICATIONS OF DELIVERY
UNION
select concept_cd VARIABLE_CD, 'COMPLICATIONS OF DELIVERY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O60O77) Comp~zbt1\'
union
select concept_cd VARIABLE_CD, 'COMPLICATIONS OF DELIVERY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O80O82) Enco~1n2b\'
union
select concept_cd VARIABLE_CD, 'COMPLICATIONS OF DELIVERY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O85O92) Comp~cvwo\'
--3. DISORDERS DURING PREGNANCY
union
select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O09O09) Supe~n4q2\'
union
select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O10O16) Edem~7xf2\'
union
select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O20O29) Othe~2ok2\'
union
select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O94O9A) Othe~id4e\(O98) Maternal~73qv\'
union
select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG
from BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O94O9A) Othe~id4e\(O99) Other ma~dyic\'
--4.

'PREGNANCY COMPLICATIONS'
union
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select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O31) Complica~dv5r\'
union
select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O32) Maternal~2pdg\'
union
select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O33) Maternal~17i3\'
union
select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O34) Maternal~3tra\'
union
select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O35) Maternal~zs1x\'
union
select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O36) Maternal~kssm\'
union
select concept_cd, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O40) Polyhydramnios\'
union
select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A)
Preg~a433\(O30-O48) Mate~b9yp\(O41) Other di~8hg3\'
--5.

'OBSTETRIC ULTRASOUND'
union
select CONCEPT_CD VARIABLE_CD, 'OBSTETRIC ULTRASOUND' TAG from
BlueHeronData.CONCEPT_DIMENSION
where CONCEPT_PATH LIKE
'\UNMC\Procedures\cpt?_codes\70000-79999\76500-76999\76801-76857\7680176828\%' ESCAPE '?'
--6.

'ABO AND RH GROUP'
union
select concept_cd VARIABLE_CD, 'ABO AND RH GROUP' TAG
from BlueHeronData.concept_dimension
where concept_path LIKE '\UNMC\Laboratory Results\Blood and body
fluids\Blood typing and transfusion\882-1\%'
or concept_cd in ('LOINC:882-1','LOINC:884-7','LOINC:773978','LOINC:972-0',
'LOINC:34961-3','LOINC:978-7','LOINC:10331-7','LOINC:13052')
--7.

'HCG IN SERUM EIA'
union
select concept_cd VARIABLE_CD, 'HCG IN SERUM EIA' TAG
from BlueHeronData.concept_dimension

165

where concept_path LIKE '\HH\LP29693-6\LP7786-9\20415-6\%'
or concept_cd in ('LOINC:20415-6','LOINC:80384-1','LOINC:80385-8')
group by concept_cd, 'HCG IN SERUM EIA'
--8.

'HCG IN URINE'
union
select concept_cd VARIABLE_CD, 'HCG IN URINE' TAG
from BlueHeronData.concept_dimension
where concept_path LIKE '\HH\LP29693-6\LP7786-9\2106-3\%'
or concept_cd in ('LOINC:2112-1','LOINC:2106-3','LOINC:21139','LOINC:2107-1','LOINC:2114-7',
'LOINC:25372-4')
group by concept_cd, 'HCG IN URINE'
--9.

'HCG IN SERUM_PLASMA'
union
select concept_cd VARIABLE_CD, 'HCG IN SERUM_PLASMA' TAG
from BlueHeronData.concept_dimension
where concept_path LIKE '\HH\LP29693-6\LP7786-9\2118-8\%'
or concept_cd in ('LOINC:19080-1','LOINC:19180-9','LOINC:21154','LOINC:2110-5','LOINC:2111-3',
'LOINC:2118-8','LOINC:2119-6','LOINC:211987','LOINC:20994-0','LOINC:25373-2',
'LOINC:34670-0','LOINC:45194-8','LOINC:558692','LOINC:56497-1')
group by concept_cd, 'HCG IN SERUM_PLASMA'
--10. 'DISORDER OF PREGNANCY'
union
select concept_cd VARIABLE_CD, 'DISORDER OF PREGNANCY' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME =
'\UNMCDIAG\SNOMEDCT\404684003\250171008\248982007\118185001\77386006\'
--11. 'PATIENT CURRENTLY PREGNANT'
union
select concept_cd VARIABLE_CD, 'PATIENT CURRENTLY PREGNANT' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME =
'\UNMCDIAG\SNOMEDCT\404684003\250171008\248982007\118185001\77386006\'
--12. 'MULTIPLE PREGNANCY'
union
select concept_cd VARIABLE_CD, 'MULTIPLE PREGNANCY' TAG from
BlueHeronData.ITCP_DIAGNOSIS
where C_FULLNAME =
'\UNMCDIAG\SNOMEDCT\404684003\250171008\248982007\118185001\173300003\10600700
6\106008001\16356006\'
--13. 'VISIT OBSTETRIC CLINIC'
union
select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601054\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601073\%'
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UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601030\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601051\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10801042\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601028\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10604005\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10701043\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10701044\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601052\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601053\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10801019\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10801009\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10801018\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601035\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10701045\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601072\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10801034\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601034\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10801017\%'

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from
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UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10801015\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\10\10601031\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101054\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101073\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101030\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20104007\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101051\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20103003\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101028\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20104005\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101052\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101055\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101053\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20501019\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20501009\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20501018\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101035\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101072\%'

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

168

UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20501034\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101034\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20501017\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20501015\%'
UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC
BlueHeronData.concept_dimension
where concept_path like
'\i2b2\Encounters\Service Areas\20\20101031\%'

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

CLINIC' TAG from

--14. 'UTERUS FUNDAL HEIGHT'
union
select concept_cd VARIABLE_CD, 'UTERUS FUNDAL HEIGHT' TAG
from BlueHeronData.concept_dimension
where concept_path LIKE '\HH\LP29694-4\LP29717-3\LP7830-5\118810\%'
--15. 'FETAL HEART RATE'
union
select concept_cd VARIABLE_CD, 'FETAL HEART RATE' TAG
from BlueHeronData.concept_dimension
where concept_path LIKE '\HH\LP29694-4\LP29711-6\LP7800-8\552836\%'
--16. 'FETAL MOVEMENT'
union
select concept_cd VARIABLE_CD, 'FETAL MOVEMENT' TAG
from BlueHeronData.concept_dimension
where concept_path LIKE '\HH\LP29694-4\LP29711-6\LP7800-8\570887\%'
),
PROVIDERS(PROVIDER_ID, PROVIDER_NAME, PROVIDER_PATH) AS
(SELECT PROVIDER_ID, NAME_CHAR, PROVIDER_PATH
FROM BLUEHERONDATA.PROVIDER_DIMENSION PD
WHERE REGEXP_LIKE(PD.NAME_CHAR, '*[^ 0123456789 ]')),
PATIENTS_WITHIN_50_MILES(PATIENT_NUM) AS
(SELECT DISTINCT PATIENT_NUM
FROM BLUEHERONDATA.OBSERVATION_FACT
WHERE CONCEPT_CD IN ('DEM|GEO|UNMC:50mi',
'DEM|GEO|UNMC:10mi',
'DEM|GEO|UNMC:15mi',
'DEM|GEO|UNMC:20mi',
'DEM|GEO|UNMC:5mi')
)
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SELECT ENCOUNTER_NUM,
O.PATIENT_NUM,
O.CONCEPT_CD,
--PROVIDER_ID,
P.PROVIDER_NAME,
P.PROVIDER_PATH,
O.START_DATE,
O.MODIFIER_CD,
O.INSTANCE_NUM,
O.VALTYPE_CD,
O.TVAL_CHAR,
O.NVAL_NUM,
O.VALUEFLAG_CD,
O.QUANTITY_NUM,
O.UNITS_CD,
O.END_DATE,
--LOCATION_CD,
LD.NAME_CHAR AS ENC_LOCATION,
O.UPLOAD_ID,
V.VARIABLE_CD,
V.TAG,
P50.PATIENT_NUM AS MILES
FROM BLUEHERONDATA.OBSERVATION_FACT O
LEFT JOIN BLUEHERONDATA.LOCATION_DIMENSION LD
ON O.LOCATION_CD = LD.LOCATION_CD
LEFT JOIN PROVIDERS P
ON O.PROVIDER_ID = P.PROVIDER_ID
JOIN VARIABLES V
ON O.CONCEPT_CD = V.VARIABLE_CD
LEFT JOIN PATIENTS_WITHIN_50_MILES P50
ON O.PATIENT_NUM = P50.PATIENT_NUM
#';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE POSITIVE HCG URINE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN URINE - POS'
WHERE
TAG = 'HCG IN URINE'
AND modifier_cd = '@'
AND valtype_cd = 'T'
AND tval_char IN
('POSITIVE','P','pos','Pos','POS','pos.','POS.','posative','POSATIVE','posatvi
e','POSISTIVE','positive','Positive','POSITIVE','POSITIVEx2','positivie','posi
tve','POSITVE','positvie','postitive','Postitive','postive','POSTIVE','preg','
+')
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
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DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);
--PREG_FACT_TABLE_PROC_DEID UPDATE NEGATIVE HCG URINE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN URINE - NEG/UNK'
WHERE
TAG = 'HCG IN URINE'
AND modifier_cd = '@'
AND valtype_cd = 'T'
AND TVAL_CHAR IN
('n','N','nagative','NAGATIVE','neagative','NEAGATIVE','neagtive','Neagtive','
neg','Neg','NEG','neg.','Neg.','NEG.','negaative','NEGAATIVE','negaavie','NEGA
GIVE','negaitve','negaive','Negaive','negarive','negartive','negataive','NEGAT
IAVE','negatie','NEGATIE','Negativ','negative','negaTIVE','nEGATIVE','Negative
','NEGATIVE','-NEGATIVE','negative.','negative`','Negative at
1:20','negativer','negativew','negativr','negatve','negatvie','NEGATVIE','nega
vtive','neggative','NEGGATIVE','negitive','Negitive','NEGITIVE','negitve','neg
native','negstive','negtaive','NEGTAIVE','NEGTAIVEX1','negtive','Negtive','NEG
TIVE','neg x 1','ng','NG','ngative','nrgative','Normal','No Specimen
Received','NO SPECIMEN RECEIVED, SEE SERUM PREG REPORT.','Not Done','See
text','See Text','SEE TEXT','unsure','weak posit','WRONG ORDER','PARTIAL
+','<SEE TEXT>','CANCELED BY HIS','CHANGED','Clear','Cloudy','CONTROL
OK','DELETED','E','Faint pos','false
+','inconclusi','Indeterminate','INDETERMINATE','intermedia','INTERMEDIA','low
positi','Moderate')
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE POSITIVE HCG URINE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN URINE - POS'
WHERE
TAG = 'HCG IN URINE'
AND modifier_cd = '@'
AND valtype_cd = 'N'
AND NVAL_NUM > 5
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);
--PREG_FACT_TABLE_PROC_DEID UPDATE NEGATIVE HCG URINE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN URINE - NEG/UNK'
WHERE
TAG = 'HCG IN URINE'
AND modifier_cd = '@'
AND valtype_cd = 'N'
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AND NVAL_NUM <= 5
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - POSTIVE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN SERUM/PLASMA -POS'
WHERE
TAG = 'HCG IN SERUM_PLASMA'
AND modifier_cd = '@'
AND valtype_cd = 'T'
AND tval_char IN ('pos','Positive','POSITIVE')
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - NEGATIVE/UNKNOWN:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN SERUM/PLASMA -NEG/U'
WHERE
TAG = 'HCG IN SERUM_PLASMA'
AND modifier_cd = '@'
AND valtype_cd = 'T'
AND TVAL_CHAR IN ('neg','negative','Negative','<SEE
TEXT>','E',
'Equicical, suggest repeating.','Incorrect
Order','PENDING',
'See note','See Text','SEE TEXT', 'NEGATIVE')
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - POSTIVE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN SERUM/PLASMA -POS'
WHERE
TAG = 'HCG IN SERUM_PLASMA'
AND modifier_cd = '@'
AND valtype_cd = 'N'
AND NVAL_NUM > 5
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
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DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);
--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - NEGATIVE/UNKNOWN:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN SERUM/PLASMA -NEG/U'
WHERE
TAG = 'HCG IN SERUM_PLASMA'
AND modifier_cd = '@'
AND valtype_cd = 'N'
AND NVAL_NUM <= 5
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - POSITIVE:
sql_string := q'[
UPDATE ]'||temp_table||q'#
SET TAG = 'FETAL HEART RATE - POS'
WHERE
TAG = 'FETAL HEART RATE'
AND modifier_cd = '@'
AND valtype_cd = 'T'
AND (upper(TVAL_CHAR) IN ('PRESENT', 'POS', 'PRESENT ',
'PRSENT', 'PRES', 'PRESENT/PRESEMT','PRESE',
'PRESETN', 'PRESEMT', 'PRESENT ON US', 'PRESNT',
'PRESENT ON ULTRASOUND', 'PRESNET',
'PREENT', 'PRESEENT', 'PRESESNT', 'PRESENET',
'PRESENTS', 'PRESET')
OR TVAL_CHAR LIKE '%+%'
OR UPPER(TVAL_CHAR) LIKE '%POS%'
OR REGEXP_LIKE(TVAL_CHAR, '*[1-9]'))
#';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - NEGATIVE:
sql_string := q'[
UPDATE ]'||temp_table||q'#
SET TAG = 'FETAL HEART RATE - N/U'
WHERE
TAG = 'FETAL HEART RATE'
AND modifier_cd = '@'
AND valtype_cd = 'T'
AND upper(TVAL_CHAR) IN ('ABSENT', 'NEG', 'NOT
HEARD','NONE', 'NEGATIVE', 'NO', 'NOT SEEN',
'NOT PRESENT')
#';
--dbms_output.put_line(sql_string);
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execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - POSITIVE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'FETAL HEART RATE - POS'
WHERE
TAG = 'FETAL HEART RATE'
AND modifier_cd = '@'
AND VALTYPE_CD = 'N'
AND NVAL_NUM > 0
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - NEGATIVE/UNKNOWN:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'FETAL HEART RATE - N/U'
WHERE
TAG = 'FETAL HEART RATE'
AND modifier_cd = '@'
AND VALTYPE_CD = 'N'
AND NVAL_NUM = 0
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL MOVEMENT - POSITIVE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'FETAL MOVEMENT - POS'
WHERE
TAG = 'FETAL MOVEMENT'
AND modifier_cd = '@'
AND VALTYPE_CD = 'T'
AND TVAL_CHAR IN ('Increased','Present')
]';
--'Absent','Decreased' are tval_char not included in this logic. Tag from
earlier in procedure remains unchanged.
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM EIA
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN SERUM EIA - POS'
WHERE
TAG = 'HCG IN SERUM EIA'
AND modifier_cd = '@'

POSITIVE:
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AND VALTYPE_CD = 'N'
AND NVAL_NUM > 5
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM EIA NEGATIVE:
sql_string := q'[
UPDATE ]'||temp_table||q'[
SET TAG = 'HCG IN SERUM EIA - N/U'
WHERE
TAG = 'HCG IN SERUM EIA'
AND modifier_cd = '@'
AND VALTYPE_CD = 'N'
AND NVAL_NUM <= 5
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--Create PREG_HEALTH_MAIN
temp_table:='JGARDNER.PREG_HEALTH_MAIN';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'# AS
WITH
PROVIDERS(PROVIDER_ID, PROVIDER_NAME, PROVIDER_PATH) AS
(SELECT PROVIDER_ID, NAME_CHAR, PROVIDER_PATH
FROM BLUEHERONDATA.PROVIDER_DIMENSION PD
WHERE REGEXP_LIKE(PD.NAME_CHAR, '*[^ 0123456789 ]'))
SELECT O.ENCOUNTER_NUM,
O.PATIENT_NUM,
O.CONCEPT_CD,
P.PROVIDER_NAME,
P.PROVIDER_PATH,
VD.START_DATE,
O.MODIFIER_CD,
O.INSTANCE_NUM,
O.VALTYPE_CD,
O.TVAL_CHAR,
O.NVAL_NUM,
VD.END_DATE,
LD.NAME_CHAR AS ENC_LOCATION
FROM BLUEHERONDATA.OBSERVATION_FACT O
JOIN JGARDNER.PREGNANCY_PROJECT_FACT_TABLE P
ON O.PATIENT_NUM = P.PATIENT_NUM
LEFT JOIN BLUEHERONDATA.LOCATION_DIMENSION LD
ON O.LOCATION_CD = LD.LOCATION_CD
LEFT JOIN PROVIDERS P
ON O.PROVIDER_ID = P.PROVIDER_ID
JOIN BLUEHERONDATA.VISIT_DIMENSION VD
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ON O.ENCOUNTER_NUM = VD.ENCOUNTER_NUM
WHERE O.CONCEPT_CD IN
('CPT4:99381','CPT4:99382','CPT4:99383','CPT4:99384','CPT4:99385','CPT4:99386'
,
'CPT4:99387','CPT4:99391','CPT4:99392','CPT4:99393','CPT4:99394','CPT4:99395',
'CPT4:99396','CPT4:99397')
AND VD.ENC_TYPE IN ('AV', 'IP', 'EI', 'ED', 'IS')
GROUP BY O.ENCOUNTER_NUM,
O.PATIENT_NUM,
O.CONCEPT_CD,
P.PROVIDER_NAME,
P.PROVIDER_PATH,
VD.START_DATE,
O.MODIFIER_CD,
O.INSTANCE_NUM,
O.VALTYPE_CD,
O.TVAL_CHAR,
O.NVAL_NUM,
VD.END_DATE,
LD.NAME_CHAR
#';
-- DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||table_name||'.');
commit;

/*
drop temporary tables:
temp_table:='JGARDNER.PREGNANCY_PROJECT_PATIENTS';
drop_table(temp_table);
temp_table:='JGARDNER.PREGNANCY_PROJECT_RACE';
drop_table(temp_table);
temp_table:='JGARDNER.PREGNANCY_PROJECT_RESIDENCE';
drop_table(temp_table);
temp_table:='JGARDNER.PREGNANCY_PROJECT_DEMOGRAPHICS';
drop_table(temp_table);
*/
commit;
END;

CREATE OR REPLACE PROCEDURE "JGARDNER"."PREG_FACT_TABLE_PROC"
AS
--nightherondata.visit_dimension_2 is date shifted

176

--heronloader.visit_dimension is NOT date shifted
--nightherondata.patient_dimension is NOT date shifted
--heronloader.patient_dimension is NOT date shifted
my_date date;
rec_count int;
i int;
sql_string varchar2(32767);
table_name varchar2(100);
temp_table varchar2(100);
window_start_date date;
window_end_date date;
BEGIN
DBMS_OUTPUT.put_line('Start of PREG_FACT_TABLE_PROC');
window_start_date:= to_date('2015/11/01', 'yyyy/mm/dd');
window_end_date:= to_date('2016/12/31', 'yyyy/mm/dd');
DBMS_OUTPUT.put_line('window_start_date = '|| window_start_date);
DBMS_OUTPUT.put_line('window_end_date = '|| window_end_date);
--DBMS_OUTPUT.put_line('window_start_date - 280 = '|| (window_start_date 270));
table_name:='JGARDNER.PREGNANCY_PROJECT_FACT_TABLE';
select sysdate into my_date from dual;
dbms_output.put_line('Creating '||table_name||' table at ' || my_date);
drop_table(table_name);

--Create table of PREG_FACT_TABLE:
temp_table:='JGARDNER.PREG_FACT_TABLE';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'[ AS
SELECT ENCOUNTER_NUM,
PATIENT_NUM,
CONCEPT_CD,
PROVIDER_NAME,
PROVIDER_PATH,
START_DATE,
MODIFIER_CD,
INSTANCE_NUM,
VALTYPE_CD,
TVAL_CHAR,
NVAL_NUM,
VALUEFLAG_CD,
QUANTITY_NUM,
UNITS_CD,
END_DATE,
ENC_LOCATION,
UPLOAD_ID,
VARIABLE_CD,
TAG,
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MILES
FROM JGARDNER.PREGNANCY_PROJECT_FACT_TABLE@DEID
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREG_FACT_TABLE_DATES:
--Limit facts to date range +/- 90 days
temp_table:='JGARDNER.PREG_FACT_TABLE_DATES';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'[ AS
SELECT PM.PATIENT_IDE,
PFT.ENCOUNTER_NUM,
PFT.PATIENT_NUM,
PFT.CONCEPT_CD,
PFT.PROVIDER_NAME,
PFT.PROVIDER_PATH,
(PFT.START_DATE - PD.DATE_SHIFT) START_DATE,
PFT.MODIFIER_CD,
PFT.INSTANCE_NUM,
PFT.VALTYPE_CD,
PFT.TVAL_CHAR,
PFT.NVAL_NUM,
PFT.VALUEFLAG_CD,
PFT.QUANTITY_NUM,
PFT.UNITS_CD,
(PFT.END_DATE - PD.DATE_SHIFT) END_DATE,
PFT.ENC_LOCATION,
PFT.UPLOAD_ID,
PFT.VARIABLE_CD,
PFT.TAG,
PFT.MILES
FROM JGARDNER.PREG_FACT_TABLE PFT
JOIN NIGHTHERONDATA.PATIENT_DIMENSION PD
ON PFT.PATIENT_NUM = PD.PATIENT_NUM
JOIN NIGHTHERONDATA.PATIENT_MAPPING PM
ON PFT.PATIENT_NUM = PM.PATIENT_NUM
WHERE (PFT.START_DATE - PD.DATE_SHIFT)
BETWEEN
(TO_DATE(']' ||window_start_date|| q'[','dd-MON-yy') - 90)
AND (TO_DATE(']' ||window_end_date|| q'[','dd-MON-yy') + 90)
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--PREGNANCY_PROJECT_FACT_TABLE_PATIENTS:
temp_table:='JGARDNER.PREG_FACT_TABLE_PATIENTS';
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drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'[ AS
SELECT COALESCE(P.PAT_MRN_ID, P2.PAT_MRN_ID) MRN,
PPD.PATIENT_IDE ELIGIBLE_PATIENT_IDE,
PPD.PATIENT_NUM ELIGIBLE_PATIENT_NUM,
CASE
WHEN PPF.PAT_ID IS NOT NULL THEN 'IDENTIFIED'
ELSE NULL
END AS EPISODE_DATA,
PPD.AGE,
PPD.RACE,
PPD.RESIDENCE,
PPF.PREG_START_DATE,
PPF.PREG_END_DATE,
PPF.PREG_LENGTH,
PPF.PREG_OUTCOME,
PPF.GESTATIONAL_AGE,
PPF.PREG_EPISODE_ID PREGNANCY_EPISODE_ID,
PPF.DEL_EPISODE_ID DELIVERY_EPISODE_ID,
EM.ENCOUNTER_IDE,
PFTD.*
FROM JGARDNER.PREG_FACT_TABLE_DATES PFTD
FULL JOIN JGARDNER.PREGNANCY_PROJECT_DEMOGRAPHICS PPD
ON PFTD.PATIENT_NUM = PPD.PATIENT_NUM
FULL JOIN JGARDNER.PREGNANCY_PROJECT_FINAL_FILTER PPF
ON PFTD.PATIENT_IDE = PPF.PAT_ID
LEFT JOIN NIGHTHERONDATA.ENCOUNTER_MAPPING EM
ON PFTD.ENCOUNTER_NUM = EM.ENCOUNTER_NUM
LEFT JOIN PATIENT@VCLARITY P
ON PFTD.PATIENT_IDE = P.PAT_ID
LEFT JOIN PATIENT@VCLARITY P2
ON PPD.PATIENT_IDE = P2.PAT_ID
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);
/*Certain elements have been redacted from this procedure as they contain
proprietary content. Further details available via request to author and
demonstration of authorization to view Clarity content.
*/
--PREG_FACT_TABLE_ENROLL:
--Limit to patients seeking consistent care at UNMC
temp_table:='JGARDNER.PREG_FACT_TABLE_ENROLL';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'[ AS
SELECT ENCOUNTER_NUM,
PATIENT_NUM,
CONCEPT_CD,
PROVIDER_NAME,
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PROVIDER_PATH,
START_DATE,
MODIFIER_CD,
INSTANCE_NUM,
VALTYPE_CD,
TVAL_CHAR,
NVAL_NUM,
END_DATE,
ENC_LOCATION
FROM JGARDNER.PREG_HEALTH_MAIN@DEID
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);
--PREG_FACT_TABLE_ENROLL_DATES:
--Limit to patients seen 2x in 2015-2016 OR have health maintenance visit in
this range
temp_table:='JGARDNER.PREG_FACT_TABLE_ENROLL_DATES';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'[ AS
SELECT PM.PATIENT_IDE,
PFT.ENCOUNTER_NUM,
PFT.PATIENT_NUM,
PFT.CONCEPT_CD,
PFT.PROVIDER_NAME,
PFT.PROVIDER_PATH,
(PFT.START_DATE - PD.DATE_SHIFT) START_DATE,
PFT.MODIFIER_CD,
PFT.INSTANCE_NUM,
PFT.VALTYPE_CD,
PFT.TVAL_CHAR,
PFT.NVAL_NUM,
(PFT.END_DATE - PD.DATE_SHIFT) END_DATE,
PFT.ENC_LOCATION
FROM JGARDNER.PREG_FACT_TABLE_ENROLL PFT
JOIN NIGHTHERONDATA.PATIENT_DIMENSION PD
ON PFT.PATIENT_NUM = PD.PATIENT_NUM
JOIN NIGHTHERONDATA.PATIENT_MAPPING PM
ON PFT.PATIENT_NUM = PM.PATIENT_NUM
WHERE (PFT.START_DATE - PD.DATE_SHIFT)
BETWEEN
TO_DATE('2015/01/01', 'yyyy/mm/dd')
AND TO_DATE(']' ||window_end_date|| q'[','dd-MON-yy')
]';
--dbms_output.put_line(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table);

--Create PREG_ENROLLED_PATIENT_TABLE
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temp_table:='JGARDNER.PREG_ENROLLED_PATIENT_TABLE';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'[ AS
WITH
PATIENTS_SEEN_2X_IN_WINDOW(PATIENT_NUM, FIRST_ADMIT_DATE, LAST_ADMIT_DATE)
AS
(SELECT
VD.PATIENT_NUM,
MIN(VD.ADMIT_DATE) AS FIRST_ADMIT_DATE,
MAX(VD.ADMIT_DATE) AS LAST_ADMIT_DATE
FROM
NIGHTHERONDATA.VISIT_DIMENSION_2 VD
JOIN NIGHTHERONDATA.ENCOUNTER_MAPPING EM
ON VD.ENCOUNTER_NUM = EM.ENCOUNTER_NUM
JOIN NIGHTHERONDATA.PATIENT_MAPPING PM
ON VD.PATIENT_NUM = PM.PATIENT_NUM
JOIN NIGHTHERONDATA.PATIENT_DIMENSION PD
ON VD.PATIENT_NUM = PD.PATIENT_NUM
JOIN JGARDNER.PREG_FACT_TABLE_PATIENTS_D PFTD
ON PM.PATIENT_IDE = PFTD.ELIGIBLE_PATIENT_IDE
WHERE
VD.ADMIT_DATE BETWEEN
TO_DATE('2015/01/01', 'yyyy/mm/dd')
AND TO_DATE('2016/12/31', 'yyyy/mm/dd')
AND VD.ENC_TYPE IN ('AV', 'IP', 'EI', 'ED', 'IS')
GROUP BY
VD.PATIENT_NUM
HAVING
MAX(VD.ADMIT_DATE) - MIN(VD.ADMIT_DATE) > 30),
PATIENTS_HEALTH_MAINTENANCE(PATIENT_NUM, FIRST_ADMIT_DATE, LAST_ADMIT_DATE)
AS
(SELECT
P.PATIENT_NUM,
CASE WHEN MAX(P.START_DATE) - MIN(P.START_DATE) < 365
THEN MAX(P.START_DATE) -365
ELSE MIN(P.START_DATE) END
AS FIRST_ADMIT_DATE,
MAX(P.START_DATE) AS LAST_ADMIT_DATE
FROM
JGARDNER.PREG_FACT_TABLE_ENROLL_DATES P
JOIN NIGHTHERONDATA.VISIT_DIMENSION_2 VD
ON P.PATIENT_NUM = VD.PATIENT_NUM
WHERE
P.START_DATE BETWEEN
TO_DATE('2015/01/01', 'yyyy/mm/dd')
AND TO_DATE('2016/12/31', 'yyyy/mm/dd')
AND VD.ENC_TYPE IN ('AV', 'IP', 'EI', 'ED', 'IS')
AND P.CONCEPT_CD IN
('CPT4:99381','CPT4:99382','CPT4:99383','CPT4:99384','CPT4:99385','CPT4:99386'
,
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'CPT4:99387','CPT4:99391','CPT4:99392','CPT4:99393','CPT4:99394','CPT4:99395',
'CPT4:99396','CPT4:99397')
GROUP BY
P.PATIENT_NUM),
ALL_ENROLLED_PATIENTS(PATIENT_NUM, FIRST_ADMIT_DATE, LAST_ADMIT_DATE) AS
(SELECT
COALESCE(A.PATIENT_NUM, B.PATIENT_NUM),
CASE WHEN A.FIRST_ADMIT_DATE IS NOT NULL
AND B.FIRST_ADMIT_DATE IS NOT NULL THEN
LEAST(A.FIRST_ADMIT_DATE, B.FIRST_ADMIT_DATE)
ELSE COALESCE(A.FIRST_ADMIT_DATE, B.FIRST_ADMIT_DATE)
END
AS FIRST_ADMIT_DATE,
CASE WHEN A.LAST_ADMIT_DATE IS NOT NULL
AND B.LAST_ADMIT_DATE IS NOT NULL THEN
GREATEST(A.LAST_ADMIT_DATE, B.LAST_ADMIT_DATE)
ELSE COALESCE(A.LAST_ADMIT_DATE, B.LAST_ADMIT_DATE)
END
AS LAST_ADMIT_DATE
FROM
PATIENTS_SEEN_2X_IN_WINDOW A
FULL OUTER JOIN PATIENTS_HEALTH_MAINTENANCE B
ON A.PATIENT_NUM = B.PATIENT_NUM)
SELECT
PATIENT_NUM,
FIRST_ADMIT_DATE AS ENR_START_DATE,
LAST_ADMIT_DATE AS ENR_END_DATE
FROM
ALL_ENROLLED_PATIENTS
]';
-- DBMS_OUTPUT.PUT_LINE(sql_string);
execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||table_name||'.');
commit;

--Create PREG_FACT_TABLE_PATIENTS_E
temp_table:='JGARDNER.PREG_FACT_TABLE_PATIENTS_E';
drop_table(temp_table);
sql_string := q'[
CREATE TABLE ]'||temp_table||q'[ AS
SELECT A.*, B.PATIENT_NUM PATIENT_NUM_ENROLL, B.ENR_START_DATE,
B.ENR_END_DATE
FROM JGARDNER.PREG_FACT_TABLE_PATIENTS_D A
LEFT JOIN JGARDNER.PREG_ENROLLED_PATIENT_TABLE B
ON A.PATIENT_NUM = B.PATIENT_NUM
]';
-- DBMS_OUTPUT.PUT_LINE(sql_string);
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execute immediate sql_string;
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into
'||table_name||'.');
commit;
/*
drop temporary tables:
temp_table:='JGARDNER.PREG_PATIENTS';
drop_table(temp_table);
temp_table:='JGARDNER.PREGNANCY_PROJECT_RACE';
drop_table(temp_table);
temp_table:='JGARDNER.PREGNANCY_PROJECT_RESIDENCE';
drop_table(temp_table);
temp_table:='JGARDNER.PREGNANCY_PROJECT_DEMOGRAPHICS';
drop_table(temp_table);
*/
commit;
END;

